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Abstract 
 
Substituted maleimide fluorophores have been extensively used to study 
polymeric systems, as their optical properties are responsive to polymer 
environment and assembly. They are particularity effective as a result of their 
small size, and ease of functionalization. Furthermore, this makes them well-
suited for peptide-based applications too, where fluorescence labelling is essential 
for tracking peptide therapeutics and disease diagnostics. 
Initially in this work, the conjugation of maleimide precursors to enzymes 
is investigated as a turn-on fluorescence conjugation technique. However, despite 
the successful effective conjugation, the fluorescence of the conjugates was poor 
from solvent quenching interactions. Further work focused on improving aqueous 
fluorescence. Firstly, the dye imide substitution was investigated in an effort to 
prevent protic solvent quenching events, which led to insights into the 
fluorescence mechanism including improved solid-state fluorescence through 
preventing pi-pi interactions. Secondly, the synthesis of fluorescent amino acids 
was successfully undertook for incorporation deeper into enzymes, where solvent 
quenching should be minimal. In addition, the synthesis of alkyne functionalized 
probes for the tagging and trapping of enzyme intermediates was completed and 
the subsequent compatibility of such dyes with cellular incubation conditions was 
proven.   
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Thesis overview 
 
The general concepts of the thesis and background literature are introduced 
in Chapter 1. This has been split into two broad categories: macromolecules with 
a focus on biological peptide-based entities and fluorescence and its applications 
in macromolecules.  
Chapter 2 covers the investigation of maleimide fluorophores for the 
tagging of enzymes. Its starts with exploring established dithiomaleimide-based 
conjugations and goes onto develop a new fluorescence conjugation technique 
through the formation of aminomaleimides. The efficiency of conjugation, 
conjugate fluorescence and the effect on enzyme integrity are all quantified.  
The poor fluorescence of maleimides in water affected the applicability of 
work in Chapter 2, therefore, Chapter 3 investigates how chemical modifications 
to the maleimide fluorophore may improve fluorescence characteristics such as 
fluorescence in polar environments. Research led to observations of novel solid 
and solution state fluorescence behaviour and mechanistic insights into this 
phenomenon. 
Chapter 4 focuses on the development and synthesis of a fluorescent 
maleimide-based amino acid for genetic incorporation into enzymes. Firstly, this 
would allow the incorporation of the dye deep into the enzyme structure, 
preventing quenching effects seen in Chapter 2. Secondly, this would have other 
applications such as active site monitoring and for the study of protein-protein 
interactions. Synthesis of four variants was completed and subsequent 
incorporation tests, by collaborators, have been successful for one activated amino 
acid. 
In Chapter 5 the synthesis of maleimide based probes for studying enzyme 
mechanisms and intermediates in polyketide synthesis and non-ribosomal peptide 
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synthesis is completed, and their stability in enzyme expression media is 
established.  
Finally, Chapter 6 covers a side-project which involved the synthesis of 
peptide-based monomers and chain transfer agents (CTA) for the templation of 
polymer assembly during aqueous polymerization induced self-assembly. Peptide 
CTAs universally led to aggregated assemblies however, this was used to 
synthesize peptide monomers which underwent PISA.  
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1.1 Biological macromolecules  
1.1.1 Macromolecules 
Originally coined by Hermann Staudinger as ‘high molecular compounds (in 
excess of 1,000 atoms)’, macromolecules are these days regarded broadly as 
molecules of high molecular weight, made up from multiple lower molecular 
weight units.2 They can be either of natural origins for example, biological 
macromolecules like proteins, carbohydrates and DNA; or synthetic, for example, 
synthetic polymers like plastics and rubbers. 
Biology has relied upon macromolecules since the formation of 
microorganisms, initially relying upon RNA for information storage and catalysis, 
and lipids for protocell formation.3 Contemporarily, biological macromolecules 
include proteins and enzymes comprised of amino acid subunits; DNA and RNA 
comprised of nucleic acid units; polysaccharides, polymers of sugars; and 
phospholipids derived from fatty acids (Figure 1.1).  Proteins are highly functional 
Figure 1.1: Make-up and classification of biological macromolecules and their 
respective monomers. 
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biological molecules performing a broad range of functions such as catalysis, 
stimuli response, molecule transportation and even providing structure. As such, 
they provide a major target for research into fields such as therapeutics and also 
materials for biological applications such as drug delivery vectors and tissue 
scaffolds.4,5 
1.1.2 Proteins 
 Protein primary structure 
Proteins are able to exhibit such a wide array of functionality as a result of 
their complex structural features. The determinant for this is the range of over 20 
amino acids that comprise the sequence of units that makes up polypeptide 
chains. This sequence of units is defined as the proteins primary structure and is 
the first level of four generally agreed levels of organisation, the others being 
secondary, tertiary and quaternary.6 
These amino acids contain a side chain pendant to a chiral carbon that lies 
between the peptidic bonds (Figure 1.2). In nature, this carbon is near universally 
the (S) or L- isomer, excluding glycine which is non-chiral. The side chain is highly 
viable and can contain a range of functionality and properties from hydrophilicity 
to aromaticity, large to small, and acidic to basic (Figure 1.2). The precise 
sequence of these is controlled during their synthesis in vivo from mRNA 
translation, and the sequence determines all higher levels of protein structure.  
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Figure 1.2: The structure of the twenty natural amino acids. 
 
 Protein secondary structure 
The primary structure determines the three-dimensional shape preference 
of the chain in solution, which is mostly governed by hydrogen bonding between 
the peptidic bonds.7 This shape preference leads to two main secondary structure 
features: α-helices and β-sheets.  
The α-helix is a right handed helix, in which the backbone amide proton 
hydrogen bonds to a carbonyl C=O located 3 or 4 residues along the chain.8 
Despite being the most prevalent secondary structure in proteins, oligomeric 
polypeptide chains rarely exhibit strong helical character in solution, as a result of 
the entropic penalty associated with folding.9 Even in large proteins, helix 
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backbone hydrogen bonds are weaker than those found in beta sheets and are 
readily attacked by water molecules.10 However, when shielded from these 
interactions oligopeptides can readily adopt a strong helical character, for example 
in more hydrophobic environments such as membranes, or with the addition of 
cosolvents like trifluoroethanol.11,12  
In an α-helix, the amino acid side chains (R) point outwards and this R group 
character greatly influences the tendency of a chain to form a helix. Residues such 
as proline and glycine have very poor helix forming tendencies, proline because it 
cannot donate a backbone hydrogen and glycine because its conformational 
flexibility disfavours helix formation.10 On the other end of the scale, alanine is the 
residue which most favours helix formation.  
β-sheets are formed of multiple β-strands which are linearly aligned, in 
either parallel or anti-parallel directions. These strands are aligned through 
hydrogen bonding interactions, again between backbone amide groups, however, 
in β-sheets these are inter-strand bonding interactions.13 These strands can either 
be aligned in the same direction, parallel (i.e. both C to N), or in opposite 
directions, anti-parallel. The hydrogen bonding interaction between parallel sheets 
is distorted from ideal geometries, however, the energetics of sheet formation are 
 
Figure 1.3: Cartoon representation of α-helix structure in manganin II 
(PDB:1PEF).  
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indistinguishable between the two.14 Often anti-parallel sheets are formed as a 
result of β-turns, or β-hairpins, which induce strand interactions within a 
continuous chain.15,16 Hydrophobic residues can also provide favourable 
interactions between strands, increasing the stability of β-sheet and β-hairpin 
structures.17,18  
In addition to these two main categories of structure many rarer structural 
elements exist, for example 310 helices and π-helices are observed in a small 
number of proteins.19 These helices are rare as they are inherently destabilizing 
and therefore when they occur they are typically integral to the functionality of a 
peptide.20 The more common alternative structures are β-turns and random coils 
(Figure 1.5). β-turns are particularly unique as they provide a 180⁰ turn in a 
peptide chain, often inducing anti-parallel β-sheet formation. Random coils are 
commonly observed in proteins, however, the term just defines a lack of preferred 








Figure 1.4:  Cartoon representation of antiparallel -helix structure in 
peptidyl-prolyl cis/trans isomerase (PDB:PIN1). 
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 Protein tertiary structure 
The tertiary structure of a protein describes the three-dimensional assembly 
of a complete peptide chain.22 The interactions of side chains from different 
secondary structures will dictate the tertiary assembly. While residues in the final 
structure may be close together spatially, because of the complex nature of 
tertiary folding they may well be far apart in the peptide primary structure. 
Hydrophobic residues will drive core-based assembly, while charged polar residues 
will favour surface regions of the structure. Along with hydrophobicity driving 
forces, assembly is dictated by other R chain interactions such as ionic 
interactions, hydrogen bonding and even covalent bonds through disulfide 
linkages.23 These driving forces mean that the native folded peptide structure has 
a lower Gibbs free energy than the unfolded peptide chain.23 As a result, folding 
occurs spontaneously and a thermodynamically favoured state is reached, referred 
to as the protein’s native configuration. While this state is near universally reached 
in biology, a systematic study for the lowest energy conformation would exceed 







Figure 1.5: -turn type-II (top) in globin (PDB:2BK9), and random coil 
(bottom) in indolicin (PDB:1G89). 
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through multiple pathways that generally all lead to the lowest energy minima 
(Figure 1.6).24,25 
 
 Protein quaternary structure 
Protein quaternary structure defines the arrangement of multiple peptide 
chains or units that form a functional complex. The simplest form of this is the 
dimer, where 2 protein units come together to form an active complex.26 One 
common example, is the immunoglobulin A antibody, used for immune response 
in mucosal tissue.27 The quaternary structure can also include the complexation 
of peptides with cofactors such as the heme group for oxygen binding in 
haemoglobin, or magnesium ions in DNA polymerase.28 The quaternary structure 
and co-factors are essential for unique functions in many enzymes and even 
fluorescent proteins. For example, DsRed is a large barrel-shaped protein isolated 
 
Figure 1.6: Example of protein folding pathways, from folding@home [CC 
BY-SA 3.0].   
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from Discosoma coral, in which the barrel-like assembly of β-sheets arranges into 
tetramers (Figure 1.7).29,30 
1.1.3 Peptide biosynthesis  
With protein structure and activity so dependent on amino acid sequence, 
the ability of cells to reliably and accurately synthesise peptide chains through in 
vivo peptide synthesis is essential for life. This sequence is determined by specific 
sequences of single strands of DNA known as template strands. The copying of 
this information from the template strand to a new RNA strand then occurs, a 
process known as transcription. Occurring in the cell nucleus, the duplexed DNA 
is ‘unzipped’ into its comprising strands via a helicase enzyme.31 RNA polymerase 
then attaches to the template strands and reads from the 3’ to 5’ direction along 
the strand. As it reads, the synthesis of a complementary messenger RNA (mRNA) 
strand is completed from its 5’ to 3’ end. For eukaryotes, this mRNA can be 
recognised by the nuclear membrane and selectively released into the 
cytoplasm.32 Here it can attach to a ribosome to undergo the second stage of 
protein biosynthesis, translation.  
 
Figure 1.7: Cartoon representation of the tetrameric assmebly of DsRed. 
From PDB: 1G7K.30 
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In translation the mRNA chain is read from the 5’ end, which in turn initiates 
the synthesis of a chain of amino acids from the peptide N-terminus.32  The 
synthesis requires the pre-activation of transfer RNAs (tRNA), in which an tRNA is 
acylated with the amino acid, facilitated by aminoacyl tRNA synthetases. These 
activated tRNAs, which code for triplets of RNA bases (known as codons), can bind 
to the ribosome when the decoding centre of the small ribosomal subunit reaches 
the corresponding complementary mRNA codon.33 Upon binding, a peptide bond 
formation is catalyzed between the existing amino acid chain and the new tRNA 
bound amino acid, simultaneously releasing the tRNA (Figure 1.8). This process 
repeats until the ribosome comes across a stop codon (either UAA, UAG, or UGA). 
This stop codon causes binding of a release factor protein which terminates 
peptide synthesis, including complete disassembly of the tRNA/ribosome complex, 
and facilitates the release of the final peptide.34 
While in vivo peptide synthesis is used in research,35 the preparation of 
peptides at large scale is generally accepted to be easier through microwave-
  
Figure 1.8: Illustration of mRNA translation in peptide biosynthesis. 
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assisted solid-phase peptide synthesis (SPPS). This is introduced further in 
Chapter 6, where SPPS is used to synthesize peptide macro-CTAs for 
polymerisation induced self-assembly (PISA). 
1.1.4 Enzymes 
Broadly, enzymes are biological catalysts that facilitate chemical reactions. 
While generally regarded as peptides, enzymes can be RNA based, known as 
ribozymes. Ribozymes are increasingly regarded as the original enzyme, as 
researchers have shown they can catalyse their own synthesis which is an 
important step in the evolution of early pre-biotic systems.36,37 In regards to 
peptide-based enzymes, they catalyse almost all known chemical processes in 
cells, most of which would otherwise be too slow to sustain life.38 While the activity 
of an enzyme is usually based upon the functionality in the primary structure, or 
associated cofactor, it is the aforementioned folding into functional structures 
which activates the enzyme and facilitates catalysis. The classic example found in 
many enzymes is the catalytic triad, in which distant residues in the primary chain, 
when brought close together by folding, act as a catalytic unit. The classic example 
is the activity of proteases which are catalyzed by a trimer of aspartate (acid), 
histidine (base) and serine (nucleophile).39 Significant research is focused on 
synthesizing artificial enzymes, to improve upon the rate achieved in nature. Such 
scaffolds that have been developed to achieve this include micellular polymers,40-42 
functionalized macrocycles,43 and even artificial peptidic enzymes.44 
 Mechanistically, the active site of an enzyme catalyses the transformation 
of a substrate into a product. The way a substrate binds to the active site is loosely 
described by an induced fit approximation where, upon approaching the active 
site, a substrate induces structural changes in the enzyme until the substrate can 
be considered bound. Once bound, the energy level for the intermediate of the 
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reaction is lowered significantly, thus accelerating the reaction.38 Measuring the 
rate of this process, or enzyme activity, is approximated by several kinetic models. 
The most widely used is the Michaelis-Menten approximation, which is suitable for 
diffusion-controlled pathways in which product formation is irreversible.45  
1.1.5 Synthetic macromolecules  
 For chemists, the goal of replicating biology’s functionality and control of 
assembly is a formidable challenge. Synthetic materials that can efficiently 
replicate the shapes and functions of biologics could help develop novel 
therapeutics with reduced costs and the ability to introduce a greater range of 
functionality.46 Synthetic macromolecules are diverse in chemical make-up, size 
and shape. Inorganic materials alone can be wide in nature ranging from metallic 
nanoparticles (such as iron and gold-based therapeutic conjugates,47,48 and 
optically interesting quantum dots)49,50 to inorganic polymers such as silicones51 
and sulfur-based polymers.52,53 Arguably, more has been realized with organic-
based chemistries, with plastics and polymers being well-established areas of 
research with large commercial sectors. In addition, new areas are developing 
from carbon nanotubes54 to complex molecular machines pioneered by Nobel 
laureates Stoddart, Sauvage and Feringa, based upon assemblies such as 
rotaxanes and catenanes.55–57 In regards to polymers in particular, the field of 
controlled radical polymerisation (CRP), with methods such as atom transfer 
radical polymerization (ATRP) and reversible activation fragmentation chain 
transfer polymerization (RAFT), has revolutionized macromolecular synthesis, 
allowing a much greater degree in control of organic nanoparticle synthesis.58  
1.1.6 Self-assembly of polymer objects 
CRP has made steps towards replicating the assemblies seen in nature, 
through facilitating greater control of molecular weight and dispersity of synthetic 
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macromolecules, as well as the ability to create multi-block copolymers with a 
wide array of compatible functionality. The ability to precisely control the 
polymerization method has allowed a wide array of polymer architectures to be 
realized, from the simple chain block-copolymers (from gradient to statistical) to 
branched architectures like star-like assemblies and brush-like polymers (Figure 
1.9).59  
 
In a process analogous to peptide tertiary structure formation, block 
copolymers with sufficiently different blocks can phase separate, and assemble 
into structures through a process known as self-assembly. While this can occur in 
the bulk phase, it is more commonly utilized in a selective solvent (i.e. a solvent 
which is miscible with one block and immiscible with the other) where self-
assembly still occurs, and the interfacial area between the solvophobic block and 
the solvent is minimized. The assembled morphology (for example spheres, 
cylinders or vesicles, Figure 1.10) depends primarily upon the relative volume 
fractions of each block, which in itself is affected by the solvent.60,61 This can be 
 
Figure 1.9: Examples of some common polymer compositions (left) and 
architectures (right) achievable through RAFT. 
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approximated by a parameter known as the packing parameter, p, developed by 
Ninham and co-workers.62,63 This parameter relates the volume of the solvophobic 
tail (v) to the solvophobic chain length (lc) and the surface area of the solvophilic 
chain at the particle-solvent interface (ao). Polymer chains with a low p (p < 1/3) 
form highly curved structures such as spherical nanoparticles (Figure 1.10), while 
values of p approaching 1 form near-linear assemblies such as vesicles and 
bilayers. In practical applications, v, lc and ao are difficult to calculate absolutely 
and therefore weight fractions of the blocks are often used as approximates.61  
 
1.1.7 Peptide-polymer complexation 
While peptides are highly complex, monodisperse, functional therapeutics, 
synthesis of them on large scale is complex and economically challenging. They 
are also susceptible to degradation in vivo such as through proteolysis and 
 
Figure 1.10: The equation describing packing parameter, p and an 
illustration of its effect on the morphology of assembled diblock 
copolymers.  
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denaturing. Combining peptides with synthetic polymers can alleviate some of 
these issues; for example, polymers are far cheaper to synthesize and can add 
additional properties such as peptide stabilization and lowering 
immunogenicity,64,65 or introduce a stimuli-response, such as to pH or light.66–68  
These benefits can be combined without covalent attachment, for instance 
polymer additives are often added to enzyme solutions to enhance stability (such 
as sugar-based polymers and ionic polymers which can stabilize the half-life of 
many enzymes through preventing protein-protein interactions).69–71 The two 
main methods for forming polymer-peptide complexes is through covalent 
conjugation or encapsulation of the peptide therapeutic.  
1.1.8 Peptide encapsulation in polymer nanoparticles 
 One of these approaches is to encapsulate the peptide within a polymer 
vesicle. By encapsulating the therapeutic within a nanoparticle, similar effects of 
proteolytic and immunogenic protection can be achieved without reducing the 
activity of the encapsulated peptide.72 Importantly, for encapsulated therapeutics 
to be effective, the substrates and products must diffuse through the polymer 
vesicle, or the therapeutic must be released in a controlled manner.73–75 Some 
developed polymersome release triggers include pH,76 pressure,77 and chemical 
triggers, for example through disulfide cleavage78 or sugar-binding by boronic acid 
functionalized polymers.79 
 Combination of multiple enzymes within separate vesicles can create 
nanoreactor cascades, in which the enzymes are prevented from interacting with 
each other thus retaining optimal activity and stability, in a process similar to 
cellular compartmentalization. This is a well-studied area and recent work has 
demonstrated: peptide incorporation into vesicle lumen, membrane and 
surface;80,81 controlled disassembly of loaded vesicles;82 three component enzyme 
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cascades;80 and  the precise control of vesicle permeability for substrate specificity 
(Figure 1.11).72,83 
 
1.1.9 Peptide-polymer conjugates 
 Covalent conjugation of polymers to peptides is a commonly undertaken, 
well understood procedure, which effectively creates hybrid materials overcoming 
the shortcomings of either component alone.84,85 The most successful area of this 
is peptide PEGylation, in which the covalent attachment of polyethylene glycol 
(PEG) to peptides can improve various in vivo properties of the peptide, for 
example stability, immunogenicity and blood circulation time.86,87 PEGylation will 
be discussed further in Chapter 2, but it is noteworthy that recent polymer 
research has focused on broadening the array of polymers for peptide conjugation 
resulting in the introduction of new properties and increased functionality.88 This 
field has relied heavily upon the development of controlled radical polymerization 
techniques such as ATRP and RAFT to create realistic alternatives to PEG. This has 
also allowed the broadening of conjugation techniques from grafting to, to grafting 
 
Figure 1.11: Tuning the membrane permeability of PISA synthesized 
vesicles by varying crosslinking chemistry (right), to give different dye 
release measured by ΔA (left), reported by Varlas et al.83 
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through and from.89 Grafting to is the traditional modification of a peptide handle 
(such as lysine residues) or macromolecule with a reactive polymer (Figure 1.12). 
Handles and chemistries used to achieve this are discussed further in Chapter 2.  
Grafting through utilizes peptide or macromolecule which has been modified 
with polymerizable functionality, such as acrylates or norbornenes.85 Subsequent 
polymerization of these monomeric units leads to the formation of brush-like 
polymers, in which a polymer backbone is functionalized with arms of peptide 
(Figure 1.12). This process is commonly utilized to create novel materials such as 
thermoresponsive conjugates using elastin-like peptides,90,91 enzyme degradable 
conjugates,92–94 and materials with enhanced cellular uptake.95,96 
 Finally, grafting from is the process of growing a polymer chain off a pre-
functionalized macromolecule or peptide (Figure 1.12). Notably, there are a few 
advantages to this technique, in particular it does not require the tricky separation 
 
Figure 1.12: Illustration of grafting through, grafting from and grafting to 
a macromolecule, for example polymer or protein (light blue), using 
monomers or polymers (dark blue).  
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of unreacted polymer from the conjugate, it does not require the large excess of 
reagents needed for grafting to, and it allows the synthesis of more hydrophobic 
polymeric conjugates, as monomers are typically more hydrophilic than their 
respective polymer units.97 RAFT and single electron transfer living radical 
polymerization (SET-LRP) have been particularly successful in this area as they 
allow the utilization of peptide-based chain transfer agents under aqueous 
conditions.89,98 In particular, it has been used for: the creation of cyclic peptide 
conjugates which exhibit unique stacking interactions;99 the synthesis of active, 
more stable enzyme conjugates;100 and temperature responsive bioactive peptide 
conjugates.98,101 
1.1.10 Peptide directed assembly 
 The ability of peptides to assemble into unique secondary and tertiary 
structures, as a result of their sequence specific nature, has been utilized in 
macromolecular chemistry to create novel and interesting architectures. The 
Perrier group have recently widely explored cyclic peptides as a powerful motif 
that assembles into stacked supramolecular nanotubes (Figure 1.13).102 Their 
work  has shown how nanotube length and functionality can be controlled;103,104  
how tubes can be responsive to pH, reducing conditions and host-guest 
interactions;103,105,106 and how tubes can be used as drug delivery vectors.107,108 
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Other novel assemblies commonly encountered with peptide conjugates are 
ribbons/lamella. Often these can be reached with a β-sheet forming domain, which 
dictates linear assemblies based upon hydrogen bonding and hydrophobic 
interactions. Such assemblies allow the creation of fibres,109 nanotubes,110 and 
self-healing hydrogels.111 One field that has grown out of this area is peptide 
amphiphiles, which are short peptide units conjugated to alkyl chains, or aromatic 
moieties which aggregate under aqueous conditions to form long tubular 
structures (Figure 1.14).112,113 Originally developed by the Stupp group, their work 
has shown how beta-sheet peptide domains dictate long range assembly, 
favouring the formation of nanotubes up to 0.1 mm in length.114–116 These 
assemblies have been used as antimicrobial materials,117,118 as scaffolds for cell 
support and even stem cell differentiation.119–121 
 
 
Figure 1.13: Cyclic peptide-polymer based nanotubes, which assemble 
thorugh a combination of hydrophobivity and hydrogen bonding, developed 
by Perrier and co-workers. Reproduced from ref.102 [CC BY 4.0].  







Figure 1.14: Top: example structure of a peptide amphiphile developed by 
the Stupp group.122 Bottom: giant nanotubes, visualized by AFM, assembled 
from a peptide amphiphile.114 
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1.2 Fluorescence  
1.2.1 Overview 
 Fluorescence has become an indispensable tool for the detection and 
analysis of a wide range of analytes. Commonly used in both the biological 
sciences and materials sciences, fluorescence is useful as a result of its 
unparalleled sensitivity; with fairly simple detection methods available, which are 
non-invasive and non-destructive.  
 Specifically, fluorescence is the emission of a photon occurring when a 
molecule relaxes from an excited singlet state to the ground state. This higher 
energy state is reached through the absorption of a photon that matches the 
energy difference between the states. Often this is illustrated through a Jablonski 
diagram (Figure 1.15) which shows how a photon is absorbed from a ground 
energy state (S0) to an excited singlet state (Sn). The molecule can then relax to 
a lower vibrational level within this singlet energy state through non-radiative 
 
Figure 1.15: Jablonski diagram showing absorption and emission events in 
fluorescence and phosphorescence. 
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relaxation, followed by emission of a photon, as it relaxes to the S0 state. This 
emitted photon is lower in energy than the excited photon, and the time the 
molecule spends in the excited state before returning to the ground state is known 
as the fluorescence lifetime (). In most molecules, the energy gap between S1 
and S0 is so small that relaxation can occur by non-radiative processes such as 
collision, and therefore emission does not oc#cur. In rare cases the excited singlet 
state can transform into a triplet state, e.g. T1, through intersystem crossing.123 
Once in this state, relaxation to the ground state can take orders of magnitude 
longer so that the emission, known as phosphorescence, occurs significantly later 
than absorption (from milliseconds to hours in phosphorescence compared to 
nanoseconds in fluorescence).124 When emission of a photon follows other 
excitation processes it can be referred to by other terminology, for example, 
emission following chemical excitation is known as chemiluminescence.125  
1.2.2 Fluorescence labelling of biomolecules 
 Fluorescence provides a unique way of imaging biomolecules in vivo. It is 
able to overcome limitations of other labelling techniques, such as radiolabelling 
or staining, as fluorescence is responsive to environmental conditions and dyes 
also tend to be easily synthesized or attached to targets.126 There are several 
types of fluorophore that can be utilized in bioimaging, including fluorescent 
proteins that can be expressed with the target biomolecule, organic dyes that are 
comparatively small and more photostable,127 as well as metal based fluorophores, 
for example europium (III) based complexes,128 and newer quantum dot based 
imaging agents.129 Each of these has its own advantages and disadvantages for 
particular applications and all are commonly used in biological research. The two 
types relied upon most for protein and DNA imaging are organic dyes and 
fluorescent proteins.127  
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A significant number of biology researchers rely upon fluorescent proteins. 
For biologists, the synthesis of fluorescent proteins is advantageous as they can 
easily be attached to any expressed peptide through expanding the genetic vector 
to express the fluorescent protein along with the target protein.127,130 The original 
and most ubiquitous fluorescent protein is green fluorescent protein (GFP).29,131 
GFP is a 238 amino acid, 26.8 kDa protein, which has a characteristic barrel-like 
structure which includes the photoactive moiety (see section 1.1.2.4, Figure 
1.7).30 In water, GFP exhibits λmax for excitation at 395 nm and 475 nm, and for 
emission at 509 nm, with a quantum yield* of 79%. Since the expression of GFP 
a range of fluorescent proteins have been isolated (such as DsRed - Discosoma 
red fluorescent protein and Aequorea green fluorescent protein)132 or developed 
through rationally introduced mutations or directed evolution (for example ultra-
red fluorescent protein, mOrange and enhanced GFP (EGFP) – Figure 1.16).133,134 
All fluorescent proteins, while easy to synthesize, are very large molecules which 
may affect target properties,134 and are generally prone to photobleaching in 
comparison to modern small molecule dyes.127  
 
*Quantum yield (f) is the ratio of absorbed photons to emitted photons, for example a f 
= 50% signifies half of absorbed photons being re-emitted.   
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Organic, small molecule dyes are much more numerous and have 
experienced a significant growth of use in research as of recent.127 In particular, 
dye lifetime, photostability and spectral window have been optimized for a great 
number of dyes;135 many of which are commercially available and are easily 
conjugatable to the target of interest (the chemistries used to achieve this are 
discussed further in Chapter 2). This is particularly important for achieving good 
spatial and temporal monitoring of targets which requires increasingly large 
photostability of dyes, especially for techniques such as single-molecule 
imaging.136,137 Classes of dye which have recently been developed towards these 
aims include Si-rhodamines,136 as well as commercially available Alexa Fluor® and 
CyDyes® (Figure 1.17).138,139 With this variety, a large range of optical properties 
and spectral windows are available to researchers for imaging.  Notably, all these 
dyes are large, aromatic compounds; usually either hydrophobic in nature or 
 
Figure 1.16: Illustration of selected GFP variants in their respective 
emission shades, showing the range of emissions achivable [CC BY-SA 3.0].   
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charged to allow water solubility, which has known consequences for the 
localization of the target.140  
 
Figure 1.17: Selected recently developed commercial small-molecule 
fluorophores commonly used for fluorescence imaging.   
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1.3 Maleimide based fluorophores 
1.3.1 Maleimide chemistry 
Maleimides are unsaturated four carbon cyclic imides, which have been 
extensively researched as a tool for chain-end functionalization handles in polymer 
synthesis, and for protein modification. They undergo two highly efficient 
reactions: Michael addition with thiols, and Diels-Alder cycloadditions with 
dienophiles.141,142 Recently, it has been shown that halogen substituted 
maleimides, such as monobromomaleimide (MBM) and dibromomaleimide (DBM), 
also undergo efficient reactions with thiols.143 However, in these molecules the 
reaction proceeds via an addition elimination; retaining the double bond of the 
maleimide. Moreover, DBM can undergo a reaction with two equivalents of thiol to 
form a dithiomaleimide (DTM).144  Halogenated maleimides are known to react with 
other nucleophiles, such as amines and alcohols (Figure 1.18).145–147 Our group 
has pioneered the investigation of such substituted maleimides as efficient charge 
transfer fluorophores. Since originally reporting the fluorescence of DTMs as 
polymer tagging moieties,148 our group has gone onto report the fluorescence 
properties of amino and alcohol substituted maleimides.149,150 
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1.3.2 Substituted maleimide fluorophores 
Exhibiting a low lying π* state, maleimides have historically been utilized as 
quenchers of fluorescence.151–153 However, in 2013 Robin et al.148 showed that 
substituted DTMs are a class of highly emissive fluorophore. It was discovered that 
DTM solubility and further functionalization could be easily varied through the 
selection of N- and S- substituents. Generally, the fluorophore has bright, solvent 
dependent emission around 500 nm and is quenched by aromatic thiol substitution 
(e.g. dithiophenolmaleimide).148  
Following this, our group also showed that monoaminomaleimides (MAMs), 
and aminobromomaleimides (ABMs) - synthesized by addition–elimination 
reactions with monobromomaleimides and dibromomaleimides respectively- were 
also highly emissive.149 These moieties have large Stokes shifts (~100 nm) and 
show solvent-dependent emission wavelengths and intensities, with polar protic 
 
Figure 1.18: Reported reactions of dihalogenated maleimides. 
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solvents causing a red shift and large reduction in emission intensity. This is 
explored further in the introduction to Chapter 3. In parallel to DTMs, ABMs and 
MAMs are also quenched by direct conjugation of aromatic amines to the 
maleimide ring.149 
Most recently, our group completed a thorough study into the effect various 
substituents impart on the fluorescence of maleimide compounds (Figure 1.19).150 
In particular, it was shown that alcohol mono-functionalized chloromaleimides 
(OCMs) showed blue-shifted emission, and mixed di-substituted amino-thiol 
maleimides (ATMs) exhibit weaker red-shifted emission (~560 nm in diethyl ether 
versus ~480 nm for ABMs).150 These developments allow the use of different 
functionalities and chemistries for labelling, while broadening the window of dye 
excitation and emission. The exchange of halogens was also investigated, shown 
to be directly related to quantum yield where chlorine and hydrogen substitution 
led to highest f (Figure 1.19).  
 
 
Figure 1.19: Approximate trends in fluorescence of substituted maleimides 
(with abbreviations) studied by Xie et al.146 
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1.3.3 Solvent dependent fluorescence 
 The fluorescence properties of a fluorophore are partially dependant on it’s 
environment, but the degree to which this is true varies depending on the 
fluorophore in question.154 For example, the temperature of a fluorophore normally 
directly relates to the fluorescence emission of a dye. This is because non-radiative 
processes that affect fluorescence are due to thermally dependent events (e.g. 
collisions, vibrations and rotations) and scale with thermal energy in a system, 
thus leading to a typical decrease in emission at higher temperature.154 Note, 
delayed fluorescence in thermally activated delayed fluorophores can exhibit the 
reverse property due to reverse intersystem crossing being an energy activated 
process.155 
 Another environmental factor that effects fluorescence is the solvent, and 
probes in which emission wavelength is highly dependent upon solvent effects are 
termed solvatochromic. In general, the stabilization of the ground and excited 
state of a dye are going to be affected by interactions with the dipoles of the 
solvent, as the dipole of a molecule is different in its ground and excited state. 
Therefore, following an excitation event, the nearby solvent must reorganise to 
stabilize the new dipole. Depending on the polarity of the solvent this may be 
more or less effective, leading to differences in the stabilization of these excited 
states. Generally, more polar solvents lead to an increase in the stabilization of 
the excited state, and therefore dyes tend to exhibit a red-shifted emission in polar 
solvents.154,156 Probes that undergo photoinduced charge transfer (PCT) are 
exceptional candidates as polarity probes. Such probes exhibit an electron-
donating and electron-withdrawing group in conjugation. In such systems the 
dipole moment change upon excitation is usually relatively large.154,156 
Consequently, the solvent molecules must undergo a significantly larger amount 
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of reorganisation to relax the excited state, leading to large solvatochromic 
effects. The effects of solvent on maleimide dyes, in particular, will be discussed 
in the introduction to Chapter 3.  
In addition to the solvent response, dyes can be designed to be responsive 
to other stimuli, for example, pH responsive probes are commonly found. Most 
probes are somewhat pH dependant, for example, fluorescein and rhodamine 
derivatives,157,158 however types of fluorophores have been developed to exhibit 
extreme responses for pH, for example dyes which rely upon protonation or 
deprotonation to become fluorescent.159,160 
1.3.4 Fluorescence applications of substituted 
maleimides 
Due to their promising fluorescent properties and uniquely small size, DTMs, 
MAMs, and ABMs have been researched extensively as polymer functionalization 
moieties in the O’Reilly group.144,148,161–164 After originally reporting the use of DBM 
as a radical polymerisation compatible functionalization handle, which could be 
functionalized post-polymerization to form dithiomaleimdie functionalized 
polymers,144 Robin et al. subsequently, reported the fluorescence of DTM 
polymers. They showed how the fluorescence intensity, wavelength and lifetime 
of these polymers is dependent upon supramolecular assembly of the polymer.161 
The authors attributed this effect to the polymeric scaffold preventing both solvent 
and collisional quenching effects. The dye was applied to in-tissue studies in rat 
hippocampal tissue. In the region of a blood clot (Figure 1.20), micellar polymer 
could be differentiated from non-micellar polymer using fluorescence lifetime 
imaging microscopy (FLIM),161 as the unimers exhibited much shorter fluorescence 
lifetimes.  
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The presence of the DTM dye also allows detection of guest molecules by 
Förster resonance energy transfer (FRET). Robin et al. synthesized 
poly(triethylene glycol acrylate)-b-poly(tert-butyl acrylate) block co-polymer 
micelles which were labelled with a fluorescent DTM group in either the micelle 
core or shell.164 Self-assembly of both shell and core labelled micelles could be 
identified by an increase in emission intensity, as a result of shielding of the DTM 
units from solvent quenching interactions. The unimer to micelle transition of the 
core-labelled micelles could also be distinguished through fluorescence lifetime 
measurements. By treating the core labelled micelles with a hydrophobic dye (Nile 
Red), FRET could be used to measure the uptake of dye into the micelle core as 
FRET occurs between the maleimide (donor) and Nile Red (acceptor). A hydrophilic 
dye (Rhodamine B), which was not taken up into the core, showed no FRET with 
the DTM micelles (Figure 1.21).164  
 
Figure 1.20: FLIM of DTM labelled micelles in rat hippocampal tissue with 
fast-FLIM lifetime extractions for A) blood clot B) vascular tissue and C) red 
blood cells reported by Robin et al.161  
 Chapter 1    33 
Maleimide fluorophores have also shown compatibility with ring-opening 
polymerisation (ROP),165,166 ring-opening metathesis polymerisation (ROMP),167 
and SET-LRP.168,169 Using DTMs and ABMs in these techniques has led to 
interesting functions and novel responsive materials. For example, DTM labelled 
polycaprolactone (PCL) polymers have been shown to exhibit mechanochemical 
responsive fluorescence, where fluorescence is responsive to sonication induced 
mechanical stress,170 and ABM tagged micelles can show pH and CO2 responsive 
fluorescence.166 Despite containing sulfur atoms, DTMs have been shown to be 
stable to reducing conditions, leading DTM dyes to being used for labelling in pH171 
and glutathione172 responsive drug delivery applications.  
Other unique applications of maleimide dyes include monitoring 
crystallization driven self-assembly (CDSA), where the alternating incorporation 
of labelled and non-labelled polymer can create striking fluorescent crystals 
(Figure 1.22). They have also been used for labelling of silica nanoparticles for the 
 
Figure 1.21: Schematic representation showing the interaction between 
micelles and fluorescent dyes Nile Red and Rhodamine B. CLMs = core-
labelled micelles, NLMs = non-labelled micelles. Figure reproduced from 
Robin et. al. with permission.164  
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detection of copper ions,173 and the surface labelling of thiol-terminated, emulsion 
templated, porous polymers.169 
 
1.3.5 Biomolecule based applications of substituted 
maleimides 
 Maleimides are well-known conjugation agents, often used in thiol-Michael 
additions, a class of click reaction. They are particularly reactive for this application 
as the highly electron withdrawn C=C bond is also under ring strain.175 As a 
consequence, they have been heavily used in applications that require highly 
efficient chemistry, such as macromolecule labelling/conjugation.176 This 
chemistry however, is susceptible to retro-Michael reaction; as the addition is 
reversible, and also prone to thiol exchange with biological thiols.177,178 Many 
attempts have been made to overcome this which rely on the hydrolysis of the 
formed Michael product. This hydrolysed maleic amide is not susceptible to thiol-
Michael pathways and thus traps the product, preventing retro-Michael thiol 
exchange (Figure 1.23).176 
 
Figure 1.22: Confocal microscopy images of ABM tagged particles with (a) 
one ABM unimer addition with one fluorescent ring and (b) two ABM unimer 
additions with two fluoresent rings, illustating how seperate polymer blocks 
can be synthesized by CDSA and then visualized. Scale bar = 1000 nm. 
Reproduced from reference with permission.174 
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 Recently, Caddick and co-workers have pioneered the use of halogenated 
maleimides, as next-generation maleimides for thiol based conjugations.143,179,180 
These substituted maleimides have been shown to be highly specific for cysteine, 
and can also be hydrolysed to prevent thiol exchange, a process that has been 
shown to cleave conjugates in blood serum (Scheme 1.23).181,182 The group, 
however, has utilized the efficient thiol exchange of these substituted maleimides 
to enable targeted cleavage of conjugates in vivo, including for fluorophore and 
drug release.153 Along with the Baker group, their research has focused 
extensively on the use of such dyes as antibody conjugation reagents, through 
reaction with reduced disulfide bonds, forming maleimide bridged 
conjugates.179,183 In particular, by using this technique, up to four molecules of 
anti-cancer drug doxorubicin could be conjugated to a  HER2 breast cancer 
targeting antibody trastuzumab.179 Further work showed how different drugs could 
be conjugated, that conjugates were stable in blood serum conditions were 
selective and potent against HER2 expressing cell lines.183  
 
 
Figure 1.23: Maleimide (left) and bromomaleimide (right) thiol conjugation 
pathways, including post conjugation hydrolysis.  
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Other biological applications for halogenated maleimides have been 
reported by other groups. One promising use is as a peptide stapling agent. 
Peptide stapling agents are alpha-helical peptides that are held 
together/constrained by a bridge between two residues, helping the helix achieve 
greater helical character.184 Using dibromomaleimide, Wilson and co-workers 
showed the efficient bridging of two cysteine residues (Figure 1.24), creating 
helical peptides with increased bioactivity in two examples: BID a protein-protein 
interaction inhibitor, and RNAse S a hydrolase.185 Through stapling, the peptides 
were also shown to be drastically more resistant to proteolysis. Also, Chen et al. 
have shown how bromomaleimide disulfide bridging of virus-like particles can be 
used to create blood serum stable, fluorescently tagged particles.186  
 
 
Figure 1.23: Illustration of DBM based stapling of α-helical BID.181 
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1.4 Summary 
 
This introductory Chapter covers the general concepts behind the topics 
within this thesis. Firstly, an introduction into peptides and biological 
macromolecules was presented, as the structure of peptides and their functions 
underpins the work completed in Chapter 2 and Chapter 5, and the rules for 
peptide assembly form the basis for Chapter 6 which investigates peptides for 
dictating polymer assembly. State of the art research into peptide-based assembly 
for macromolecular applications was also introduced, for example, cyclic peptide 
driven assembly of nanotubes by the Perrier group102 and peptide amphiphiles 
driving the assembly of nanofibers by the Stupp and Hamley groups.115-117 
Secondly, the principles of fluorescence and its applications to labelling of 
macromolecules was introduced as Chapters 2 to 5 focus on developing maleimide 
fluorophores for peptide labelling and monitoring. To help give context, commonly 
used fluorescence proteins and small molecule probes are introduced, familiarizing 
the reader with current technology and the advantages and disadvantages of 
these, highlighting how these can be improved, work which will underpin this 
thesis.  
As the potential solution to these issues, maleimides are finally introduced, 
covering their structure; current applications in peptides, including conjugation 
and peptide stapling;176,181 and fluorescence properties, highlighting the expansive 
and high impact previous work in the group on polymer labelling.161-164 This work 
has enabled the collection of unparalleled information from nanoparticles through 
fluorescence of maleimides, including in vivo assembly, polymer morphology and 
co-encapsulation of other dyes. Work in Chapters 2, 4 and 5 all relate to using 
these fluorophores in peptides as smaller and more appropriate dyes compared to 
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those currently used. In addition, Chapter 3 covers the bottom-up development of 
these dyes for these applications which relies heavily on the structure and 
functions introduced herein. Further explanation of the fluorescence quenching in 
aqueous conditions, as well as aggregation induced emission (AIE) that is 
serendipitously observed, is introduced in the Chapter itself.  
The first work covered in this thesis is the conjugation of maleimide 
precursors to enzymes through a turn-on fluorescence conjugation. However, 
despite successful conjugation, the fluorescence of the conjugates was poor from 
quenching interactions with water, limiting applications compared to current 
labelling techniques presented here in the introduction. Further work, outlined in 
Chapter 3, focused on improving aqueous fluorescence which led to insights into 
the fluorescence mechanism including improved solid-state fluorescence through 
preventing pi-pi interactions. This AIE-like behaviour shows promise for improved 
performance in solid-state applications. In Chapter 4, the synthesis of fluorescent 
amino acids was successfully undertaken for incorporation deeper into enzymes 
through artificial expression techniques, where solvent quenching should be 
minimal and properties of the enzyme should be unaffected, unlike traditional 
labelling techniques presented in this introduction. In Chapter 5, the synthesis of 
alkyne functionalized probes for the tagging and trapping of enzyme intermediates 
was completed and the subsequent compatibility of such dyes with cellular 
incubation conditions was proven. And finally, Chapter 6, provides a novel method 
for dictating polymer assembly through peptide mediate interactions, introduced 
in this introduction.  
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1.6 Abstract 
 
Two efficient enzyme conjugation techniques have been explored by 
exploiting the reactions of bromomaleimides. The conjugations utilize 
monobromo- and dibromo-maleimides which have been reacted with reduced 
disulfide bonds or terminal amines in α-chymotrypsin and human lysozyme. These 
reactions allow the formation of dithio- (DTM), monoamino- (MAM), and 
aminobromo- (ABM) maleimides, which are bright, solvent-dependent 
fluorophores that have a handle for further functionalization.  The efficiency of the 
maleimide conjugation was monitored and the fluorescence of the resulting 
conjugates examined. The quantum yields of the maleimide conjugates have been 
calculated but are low due to solvent quenching effects. Catalytic activities of the 
conjugate enzymes have been compared to their respective native enzyme and 
no discernible effect of the conjugation on enzymatic activity or room temperature 
stability was observed. Additionally, one step PEGylation and fluorescent labelling 
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1.7 Introduction 
1.7.1 Enzyme conjugation via lysine and cysteine 
residues 
Conjugation to amino acids in proteins is a widespread practice. It is used 
for many applications, including fluorophore incorporation,1,2 biotinylation,3 drug 
conjugates,4 and radiolabelling.5 The two most commonly accessed sites for 
conjugation are lysine residues and reduced cysteine residues. Among amine-
reactive techniques, most commonly N-hydroxysuccinimide (NHS) activated 
esters are used for conjugation.6,7 The technique requires activation of an acid 
group prior to conjugation, and due to the large number of lysine residues usually 
present in proteins, it is commonly difficult to control the location and number of 
modifications.  Other lysine conjugation techniques include 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC) coupling, and isocyanate and imidoester 
chemistries (Figure 2.1). 
In order to facilitate a cysteine coupling, a reduced cysteine residue is 
required for functionalization. Cysteine is regarded as the most nucleophilic amino 
acid, towards soft electrophiles, in the majority of proteins and therefore is 
commonly regarded as the easiest to modify in a selective manner.6,8 The most 
Figure 2.1: Commonly utilized protein conjugation techniques for lysine and 
cysteine targeting. 
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widely used cysteine modification technique is maleimide conjugation, in which 
cysteine will undergo highly selective addition to the maleimide double bond.9  
Other cysteine conjugation methods include iodoacetamide chemistry, as well as 
utilizing disulfide exchange with, 2-dithiopyridine derivatives (Figure 2.1).10,11 
1.7.2 PEGylation of enzymes and biomolecules 
PEGylation is the process of chemically attaching polyethylene glycol (PEG) 
to molecules, such as drugs and therapeutic proteins. PEG can enhance the 
therapeutic properties of a molecule which can include better physical and thermal 
stability;12 protection against degradation;13 increased solubility;14 longer half-life 
in vivo;15 and even increased potency.16 As of 2015, there were ten PEGylated 
proteins approved by the FDA for pharmaceutical use.17 All of these are conjugated 
via lysine residues, the N-terminus or a cysteine residue.18  
The effects of PEGylation on protein pharmacokinetics and 
pharmacodynamics can be difficult to predict. In fact, the amount of PEG and its 
location can negatively affect many properties of the therapeutic activity, including 
elimination and absorption.19 Another major disadvantage of PEG is that it is non-
biodegradable. Indeed, medium molecular weight PEG (40-60 kDa) can cause 
renal clearance problems and accumulation in the liver.20 It should be noted that 
some degradable, or partially degradable PEG analogues, have been developed in 
the literature, which are expected to be cleared through the renal filtration system. 
This has been achieved through multiple strategies, for example, synthesizing a 
copolymer of PEG with degradable units such as PLA-PEG copolymers,21 
introducing hemiacetals through use of hydrogen peroxide and FeCl3,22 or by 
developing fully degradable alternatives such as poly(ethylene oxide sulphide).23  
In addition to degradable alternatives, there are many recent reports of 
alternative stabilizing polymers for peptide conjugation. Some of these include 
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polyzwitterions such as poly(amino acids) which exhibit tuneable degradation in 
addition to other benefits such as low toxicity and tuneable thermal properties24 
and sugar based polymers like the trehalose polymers reported by the Maynard 
group, which are not only degradable but also provided increased thermal stability 
in comparison to PEG.25 Limitations of using alternatives includes a greater 
expense associate with controlled polymers and more challenges in getting FDA 
approval, as PEG has been classified to be Generally Regarded As Safe (GRAS) by 
the FDA.26 
It should be noted that enzymes have been previously PEGylated via 
disulfide bridging, in the literature.27-29 All reported methods have two steps in 
common: firstly, reduction of the disulfide to form two free cystine thiols; 
secondly, re-bridging of these thiols with a reagent. It used to be considered that 
an enzyme’s native disulfides could not be modified because they were believed 
to be crucial to the enzyme’s structure and function.28 However, Brocchini et al.27 
have shown that bridging can be achieved by bis-alkylation utilizing an α,β-









Figure 2.2: α,β-unsaturated-β’-mono-sulfone functionalized PEG bridging of 
disulfide bonds.27  
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1.7.3 Conjugation to α-chymotrypsin  
α-Chymotrypsin (α-CT) is a proteolysis enzyme, produced by the body in 
the pancreas and found in the duodenum. It has an activated serine residue, which 
helps it break down proteins and polypeptides, to aid with digestion.30 Proteases 
like chymotrypsin are often used in laundry formulations31 and chymotrypsin itself 
is used in cataract surgery.32  
Chymotrypsin is most active at cleaving bonds where the carboxyl side of 
the amide bond is a large hydrophobic residue (for example tyrosine or 
tryptophan), as the aromatic side-chain can interact with chymotrypsin’s 
‘hydrophobic pocket’. 33 Chymotrypsin contains such residues, and can, therefore, 
digest itself (autolysis), making it an interesting target for stabilization.34  
α-CT has fourteen lysine residues and five disulfide bonds which can act as 
handles for conjugation.35 Russell et al.34 developed an atom transfer radical 
polymerization (ATRP) initiator (Figure 2.3) which was successfully conjugated to 
twelve lysine residues. They then polymerized N,N-dimethylaminoethyl 
methacrylate (DMAEMA), among other polymers, from these sites. When stored 
at pH 7, the CT-DMAEMA protein-polymer conjugate retained over 90% activity 
over 6 hours, compared with native α-CT that retains only around 50% activity.34 
This was attributed to steric and electronic shielding and shows that conjugating 
certain polymers to α-CT can lead to increased stability.  
Figure 2.3: Polymerization of DMEMA by α-CT conjugated ATRP 
initiators.17 
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1.7.4 Lysozyme variant conjugations 
Human lysozyme is a glycoside hydrolase and it performs β-1-4 glycosidic 
bond cleavage. By cleaving these bonds between N-acetylmuramic acid and N-
acetyl-D-glucosamine residues in peptidoglycan bacterial cells walls, it can cause 
lysis and subsequent death of the cell.36 As a consequence, lysozyme is critical to 
immune systems, for example, it kills bacteria in tears.37  
Human lysozyme’s structure and function is well characterized;35 
furthermore,  the activity of the enzyme can be measured reliably by multiple 
assay methods making it a suitable target for this project.38–40 
Lysozyme – most commonly hen egg white lysozyme (HEWL) - has been a 
frequent target of conjugation chemistry. CRP techniques such as RAFT41 and SET-
LRP42 have been used to polymerize from lysozyme conjugated initiators. Both of 
these studies utilized succinimide-lysine coupling for the initial attachment. Lucius 
et al. showed that enzymatic activity was reduced as the conjugated polymer chain 
length increased.42 However, when the enzyme was used to lyse negatively 
charged M. lysodeikticus, HEWL conjugated to the cationic polymer PDMAEMA 
showed an increase in activity. This was attributed to the “electrostatic attraction 
between the negatively charged cell wall and the positively charged polymer-
conjugate.”42 The synthesis of PEGylated HEWL has also been reported.41 Mono-
PEGylated HEWL and mono-PEGylated human growth hormone were used to 
investigate the conformation of conjugated PEG in solution. The enzymes were 
analyzed by small-angle neutron scattering (SANS). The results showed that in 
this case, PEG behaves like a random coil adjacent to the protein, in contrast to 
the commonly assumed model of PEG encapsulating enzymes (Figure 2.4).44  
 
 






Figure 2.4: Topology of enzyme conjugated PEG (left) versus the incorrect, 
commonly assumed ‘shroud’ model (right). Figure reproduced from Pai et al.44  
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1.8 Results 
1.8.1 Initial investigations into DBM bridging of α-CT 
The first aim of this project was to investigate the bridging of disulfide bonds 
in α-CT. N-methyldibromomaleimide (M-DBM) was chosen as the initial 
conjugating molecule, due to its small size and reported resistance to hydrolysis.46 
In addition, tris(2-carboxyethyl)phosphine (TCEP) was used to reduce the 
disulfides prior to conjugation (Scheme 2.1). Unusually for disulfide based 
conjugations, reacting M-DBM under an optimized protocol produced a singular 
conjugate with three DTMs conjugated as observed by matrix-assisted laser 
desorption/ionization-time of flight mass spectroscopy (MALDI-ToF MS - Figure 
2.5). This result suggests that two of the disulfides are not solvent accessible and 
therefore, under such conditions, this conjugation technique allows for site-






Scheme 2.1 Scheme of DBM disulfide bridging conjugations. 
Figure 2.5: MALDI-ToF spectra of purified M-DBM α-CT conjugate (red) 
against native α-CT (black), showing formation of 3 DTM units. 
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A study into the progress of the conjugation with time, analyzed by MALDI-
ToF, showed reaction of the native protein in 10 minutes, and the appearance of 
a strong band at around 25840 m/z representative of three DTMs per enzyme. 
However, after 90 minutes there is a large broad mass peak observed at around 
+700 m/z which corresponds to a conjugate with an average of 6.4 DTMs (Figure 
2.6). It was thought that this may be caused by solvent or reagents becoming 
entrapped and desorbing with the enzyme. To test this hypothesis, the product 
enzyme was purified through a Bio-Spin® Column with Bio-Gel® P-30, which 
should allow removal of low molecular weight species (< 6000 Da) through 
centrifugation. The resultant purified enzyme was analyzed by MALDI-ToF (Figure 
2.5) and the > 5 DTM peak is no longer present, suggesting that it was indeed 
caused by small molecule interference. It is noted that this could also be caused 
by side-product conjugates, which crash out upon conjugation and are therefore 
filtered off during the purification.  
Figure 2.6: MALDI-ToF spectra of M-DBM α-CT conjugates, at 10 mins (red), 
90 mins (green) and after spin filtering (blue), against native α-CT (black). 
Species above 5 DTM are clearly visible in the 90 min spectrum (blue) 
however, are removed in the spin fitered sample (green). 























 90min + spin filter
3 DTMs
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In an effort to obtain a quantitative analysis of the reaction, as well as to 
isolate the maximally conjugated species, high-performance liquid 
chromatography (HPLC) analysis of the conjugation was undertaken. After 
optimization of the method, HPLC chromatograms (Figure 2.7) were obtained for 
the conjugation mixture and other mixtures of reaction components (-CT with 
TCEP and -CT with MDBM without TCEP).  Common to all chromatograms are 










 To identify these peaks, fractions were collected every minute and 
analyzed by MALDI-ToF MS. The results showed that no intact enzyme was 
observed until the 15-minute mark. The earlier peaks corresponded to smaller 
mass species (from 11-14 minutes), which could be attributed to digested and 
fragmented enzyme. HPLC analysis of the native enzyme that had been left in 
solution for several hours also showed an increase in signal intensities at 5-14 
minutes, confirming this hypothesis.  
 
Figure 2.7: HPLC chromatogram of α-CT under various reaction conditions, 
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Due to these impurities, it was decided to filter the samples and 
immediately HPLC the purified enzyme, using an optimized method (Figure 2.8). 
This did significantly reduce the signals that eluted before 14 minutes; however, 
separation of the unreacted native enzyme from the conjugated enzyme could still 
not be achieved. Positively, the conjugated enzyme produced a large fluorescence 
response in the fluorescence detector, making identification of conjugated species 
facile.  
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
analysis of the conjugation was attempted. However, after multiple attempts, no 
fluorescence under a UV transilluminator was observed in the conjugated 
fragments and mass differentiation was difficult due to the small mass change 
upon M-DBM conjugation (Figure 2.22). For these reasons, SDS-PAGE analysis 
was determined to be an unsuitable method for characterizing this conjugation.  
To ascertain whether the conjugation was residue-specific, analysis of the 
availability of the disulfides in α-CT was undertaken. Firstly, a Kyte-Dolittle plot 



































Figure 2.8: HPLC of the further optimized procedure with 220 nm and 
fluorescence detectors (λex: 382 nm, λem: 531 nm). 
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hydrophobic or hydrophilic location in the enzyme (Figure 2.9). However, all 
disulfides lay across a neutral value and no significant conclusions could be drawn. 
To gain further insight, the solvent-accessible surface area of the enzyme was 
calculated using a crystal structure of the enzyme (from the Protein Data Bank: 
4CHA)35 and PyMol® software.  It was clear that C1-C120 had the most solvent 
accessible surface area (Table 2.1) by this model, and C168-C182 and C191-220 
displayed minimal to no solvent accessible surface area. This suggests that the 
C1-C122 bond is very likely to be the most reactive disulfide and that the C168-
C182 and C191-220 bonds are the unmodified bonds. A trypsin digest was 
attempted to prove this hypothesis as this method would provide exact 
conjugation locations; however, as a consequence of α-CT autolysis, this was 
excessively complex and not informative. Another method that could be used to 
gather information on site-specificity is MS proteomics (i.e. MS/MS), however 

















Figure 2.9: Kyte-Dolittle plot of α-CT, showing aproximate hydrophillicty of 
residues, including locations of disulfide bridges. 
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The Baker and Caddick groups have preferentially used dithiomaleimdies 
for the majority of their recent disulfide conjugations.46–48 In some test reactions 
with TCEP they showed that both dibromomaleimides and dithiomaleimides react 
with TCEP, the reducing agent.48 However, DBM showed a marginally greater 
reactivity with TCEP than dithiophenolmaleimide, hence their recent use of 
dithiophenolmaleimides. Therefore, it was decided to also investigate methyl-
dithiophenolmaleimide as a conjugation agent. Using the same procedure as the 
M-DBM conjugation, no conjugation was observed with methyl-
dithiophenolmaleimide (2.1) by MALDI-ToF analysis. Upon addition of DTM, the 
solution immediately went cloudy, indicative of DTM precipitating out of solution. 
Subsequent testing showed that a minimum of 30% DMF was required to solubilize 
dithiophenolmaleimide for the conjugation. Conjugations under these conditions 
did not produce any conjugated enzyme product. As a result of the harsher 
conditions required and lack of initial success, investigations into this method were 
no longer pursued.     
1.8.2 Disulfide conjugations to human lysozyme 
To ascertain that the bromomaleimide conjugations are applicable to a 
range of enzymes, human lysozyme was chosen as a second target for 









Table 2.1: Approximate solvent accessible surface area of disulfide bonds 
calculated using PyMol (PDB: 4CHA). 
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attachment, is smaller than α-CT and does not perform autolysis.38 Disulfide 
bridging to HLZ using M-DBM was undertaken using the same conditions as for α-
CT. In contrast to α-CT, a distribution of 0-4 DTM species were observed by MALDI-
ToF MS after purification (Figure 2.10). Interestingly, up to four DTMs can be 
formed per enzyme suggesting that all are solvent accessible, this which may be 
a result of the more hydrophilic nature of HLZ. However, as often observed in 
multi-site conjugation techniques,49 only a distribution of differentially conjugated 
products was obtainable, indicating that the site-specific nature of this technique 
is limited. It should be noted that MALDI-ToF MS analysis of native HLZ showed a 
strong signal at around 14110 m/z, which does not match literature structures of 
HLZ, but has been observed by other groups.43 However, the secondary peak at 
14700 m/z correlates with published structures and therefore conjugation mass 










The retention of the tertiary structure of M-DTM HLZ was probed through 
circular dichroism (CD). α-chymotrypsin exhibits a very poor CD signal in the 
Figure 2.10: MALDI-ToF spectra of purified M-DTM HLZ conjugate (red) 
against native HLZ (black). 
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amide region for characterization,50 and therefore CD analysis was undertaken on 
HLZ and the DTM HLZ conjugate. By recording the molar ellipticity -Δ[Ɵ]m at 222 
nm, the α-helicity of the enzyme can be measured. A negligible change in [Ɵ]222 
was noted for the conjugate (97% of the native HLZ – Figure 2.11) and both CD 
spectra showed very similar structural features, indicating a minimal effect of 











For further characterization, the denaturing temperature (Tm) was 
measured for HLZ and the HLZ DTM conjugate, using differential scanning 
calorimetry (DSC). The Tm for the native enzyme was measured as 72.7 °C in pH 
6 buffer, which compares well to previous literature.50 For the HLZ DTM conjugate, 
multiple melts were observed (Figure 2.12), however, the major melt can be 
attributed to the singular DTM HLZ conjugate and was measured at 68.2 °C, 
suggesting a small loss in thermal stability upon DTM conjugation. The unresolved 
Figure 2.11: CD spectra of HLZ (black) and DTM-HLZ (red) in pH 6 phosphate 
buffer. 
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melts observed below 68.2 °C could be attributed to conjugates with more than 











1.8.3 PEGylation thorough disulfide bridging  
To establish the effect of PEGylation via this disulfide bridging method on 
enzyme integrity, PEG-dibromomaleimide, PEG-DBM (2.2) was synthesized as a 
conjugation agent through a Mitsunobu reaction of hydroxyl-PEG350 and DBM 
(Scheme 2.2).  
 
 
Scheme 2.2: Synthesis of PEG-DBM (2.2). 
Figure 2.12: DSC spectra of HLZ (black) and DTM HLZ (red) recorded in pH 6 
PB buffer at approximately 0.5 mg/ml. Recorded by Malin Suurkuusk (TA 
instruments). 
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PEGylation was attempted in pH 6 sodium phosphate buffer with a range of 
DMF concentrations from 0-33% v/v. MALDI-ToF MS analysis for the conjugation 
of both enzymes to PEG-DBM (2.2) showed that higher DMF concentration leads 
to higher degrees of PEG conjugation. For α-CT conjugation, 33% v/v DMF 
conditions gave a mean, measured by Gaussian fit, of 1.8 attached PEG-DTM 
molecules (Table 2.2). However, the HLZ conjugate was observed to have a 
broader MALDI-ToF mass spectra (see 2.5.4.10), where an average of 2.0 PEG-
DTMs per enzyme was observed (Table 2.2). It is hypothesized that the lower 
reactivity of the PEG-based conjugation can be attributed to the PEG chain 
providing steric hindrance to the conjugation through lowering chain end 






1.8.4 Amine targeted bromomaleimide conjugations  
Following the disulfide conjugations, conjugation utilizing lysine residues 
was investigated as a novel fluorogenic conjugation method. Using M-DBM the 
conditions of the conjugation were altered to mimic those in the synthesis of ABMs 
(Scheme 2.3). Conjugating to α-CT overnight, in pH 8.5 tris buffer, resulted in a 
distribution of products as seen at around 26,600 m/z by MALDI-ToF MS (Table 
2.3 and section 2.5.4.2). The conjugation appears relatively slower than the thiol 
conjugations, which mirrors reaction rates observed in small molecule synthesis. 
One could hypothesize the polarizability of thiols makes them more nucleophilic 
Enzyme Conjugate # Attached 
α-CT 
M-DTM 3/5* 
PEG-DTM 1.8/5 ± 1.5 
HLZ 
M-DTM 0-4/4* 
PEG-DTM 2.0/4 ± 1.8 
Table 2.2. Table showing number of attached units for disulfide conjugates 
observed by MALDI-ToF MS and standard deviation measured by Gaussian fit. 
*= Gaussian fit not possible, observed discrete conjugates listed.  
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for these electrophiles. By completing a Gaussian fit of this peak an average of 
6.2 ± 2.5 ABMs per enzyme was observed. Through exposing HLZ to the same 
conditions, conjugation was also observed by MALDI-ToF MS with an average of 
2.7 ± 2.3 ABMs formed per enzyme from 6 amine handles (Table 2.3).  
Our group has also shown the synthesis of MAMs under these conditions, 
producing a smaller more fluorescent dye. It was therefore decided to synthesize 
methyl-MBM (2.3), alkyne-MBM (2.4) and PEG-MBM (2.5) for conjugation. The 
alkyne substituent provides an opportunity for further functionalization, for 
example via copper-catalyzed azide-alkyne cycloaddition reactions (CuAAC).52 
Scheme 2.3: Synthesis of ABM and MAM conjugates using conjugating 
agents M-DBM, 2.3, 2.4 and 2.5. 
Figure 2.13: MALDI-ToF spectra of purified M-ABM HLZ conjugate (left, red) 
and alkyne-MAM conjugate (right, red) against native HLZ (black). 
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Conjugation of 2.3 and 2.4 was successful for both enzymes and subsequent 
MALDI-ToF MS analysis showed a distribution of products formed (Figure 2.13). 
Gaussian fits of the spectra are listed in Table 2.3, of note is the large distribution 
and deviation for conjugates, potentially due to trapped ions in the MALDI-ToF, 
but this highlights the poor site specificity and control in the conjugations. The 
reaction proved much more effective than the ABM reactions indicating 
conjugation of up to 12.1 ± 3.6 MAMs for the α-CT M-MAM conjugate. PEGylation 
using 2.4 was also successful; however, lower reactivity was again observed with 









To again help establish enzyme integrity the Tm of the MAM conjugate was 
investigated (Figure 2.14). For the M-MAM HLZ conjugate, a broad melt was 
observed as a consequence of many species being present. The average of these 
was measured at 64.8 °C, suggesting a greater reduction in thermal stability 
compared to the DTM conjugate (68.2 °C) as expected from a more modified 
conjugate. 
Enzyme Conjugate # Attached 
α-CT 
M-ABM 6.2/17 ± 2.5 
M-MAM 12.1/17 ± 3.6 
Alkyne-MAM 11.2/17 ± 1.8 
PEG-MAM 2.3/17 ± 1.5 
HLZ 
M-ABM 2.7/6 ± 2.3 
M-MAM 5.4/6 ± 3.1 
Alkyne-MAM 4.9/6 ± 2.5 
PEG-MAM 1.5/6 ± 1.8 
Table 2.3. Table showing number of attached units for lysine/amine conjugates 
observed by MALDI-ToF MS and standard deviation measured by Gaussian fit. 












DTM conjugates have been shown to undergo hydrolysis at pH 8.5, 
dependent on structure, with half-lives as short as 16.5 minutes reported.53 In 
order to ascertain the stability of MAM conjugates, the emission of alkyne-MAM 
HLZ was studied in pH 8.5 buffer. Under these conditions, no hydrolysis was 































Figure 2.15: Fluorescence emission of conjugates in pH 8.5 tris buffer. Left: 
alkyne-MAM HLZ conjugate (511 nm emission and 356 nm excitation), right: 
M-DTM HLZ conjugate (540 nm emission and 395 nm excitation).  
 
Figure 2.14: DSC spectra of HLZ (black) and MAM HLZ (red) recorded in pH 6 
PB buffer at approximately 0.5 mg/ml. Recorded by Malin Suurkuusk (TA 
instruments). 
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observed over 10 hours (Figure 2.15), whereas a significant reduction in emission 
was observed for an M-DTM HLZ conjugate control (Figure 2.15), this indicates 
greater resistance to hydrolysis in the MAM species and suggests no foreseeable 
hydrolysis under the conjugation conditions.  
1.8.5 Fluorescence analysis of conjugates  
To establish the fluorescence properties of conjugates, and therefore the 
turn-on nature of the conjugations, excitation/emission spectra were measured 
for all conjugates of both α-CT and HLZ (Table 2.4). All recorded wavelengths 
were similar to those observed in water for small molecule species,51 indicating 
retention of the maleimide motif.  
 
 
Small molecule MAMs have been shown to exhibit high (>59%) quantum 
yields in organic aprotic solvents; however, in water they are quenched 
significantly, exhibiting Φf<0.4%.54 Robin et al. have shown that by incorporating 
DTMs into nanostructures, shielding them from solvent quenching effects, the 
quantum yield can be restored (>30 %).55 To investigate whether the same effect 
would be observed in enzymes, the quantum yield of two conjugates was 
Enzyme Conjugate λex max(nm) λem max(nm) Φf(%) 
α-CT 
M-DTM 382 532 - 
M-ABM 368 521 - 
M-MAM 368 530 - 
Alkyne-MAM 348 518 - 
PEG-DTM 386 528 - 
PEG-MAM 347 496 - 
HLZ 
M-DTM 395 540 0.77 ± 0.07 
M-ABM 364 524 - 
M-MAM 364 521 - 
Alkyne-MAM 356 511 0.69 ± 0.04 
PEG-DTM 408 538 0.49 ± 0.05 
PEG-MAM 350 508 1.43 ± 0.24 
Table 2.4. All measured λex/λem maximum, and recorded Φf(%) for conjugates. 
 Chapter 2   68 
measured. The quantum yield of both MAM and DTM HLZ conjugates was 
measured in 18.2 MΩ.cm water, using a standard of quinine (Φquinine = 59%). As 
shown in Table 2.4, the alkyne-MAM HLZ conjugate exhibited a quantum yield of 
Φf(%)=0.7 ± 0.04 (λex=362 nm) and the M-DTM HLZ conjugate of Φf(%)=0.8 ± 0.07 
(λex=365 nm). The quantum yields for both conjugates have increased compared 
to the DTM and MAM small molecule analogues in water (all less than 0.4%);54 
however, the values were significantly lower than the fluorescent proteins 
currently used and would not meet the brightness requirements for applications 
such as fluorescence microscopy.56 The quantum yield of the PEGylated HLZ 
samples were also measured to compare to the small molecule analogues. The 
PEG-DTM HLZ conjugate exhibited a quantum yield of Φf(%)=0.5 ± 0.05 (λex=362 
nm), lower than the respective M-DTM conjugate. This could be attributed to the 
lower degree of conjugation observed for the polymer species. Theoretically, the 
most accessible and least shielded disulfide would be the most likely to undergo 
conjugation, leading to high solvent accessibly, and therefore fluorescence 
quenching, of the resulting maleimide moiety. In contrast, the PEG-MAM species 
exhibited a quantum yield of Φf(%)=1.4 ± 0.2 (λex=364 nm), double the quantum 
yield of the respective alkyne-MAM conjugate. In this case, despite exhibiting a 
lower degree of conjugation compared to the small molecule conjugate, it would 
appear the polymer chain provides a solvent shielding effect to the MAM dye.  
1.8.6 Activity analysis of conjugates 
To further establish the structural integrity of the conjugates and to check 
the catalytic activity of the DTM and MAM α-CT conjugates, their activity was 
measured using a p-nitroaniline hydrolysis assay (details in 2.5.5).57 The initial 
velocity was measured and compared to the native enzyme after periods of time 
in solution. Results indicated a drop-in activity after conjugation for all conjugates 
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(Figure 2.16A). Indeed, it is notable that the activity is comparable to that of the 
native enzyme left in solution for the same time period as the conjugation and 
purification (6 hours for the DTM conjugates and 24 hours for the MAM 
conjugates). This indicates that the chemical modification itself has negligible 
effect on enzyme activity, which corroborates with the CD analysis of the DTM HLZ 
conjugate. Positively, the stability of the enzyme over 4 days was unaffected 
(Figure 2.16B), suggesting the conjugates have similar stability and autolysis rate 
to the native α-CT.  
 
The HLZ conjugates were assayed by EnzChek® lysis to confirm their 
integrity. This assay relies on the lysis of fluorescein labelled micrococcus 
lysodeikticus cells, where upon cell lysis fluorescence signal increases.36 When 
stored at room temperature the conjugates show no discernible difference in 
activity compared to native HLZ (Figure 2.17A). To discern whether any 
differences in stability are observed in more extreme conditions, the conjugates 
were also examined at 50 °C and their activity was measured at various time 
Figure 2.16:  (A) Initial activity of α-CT at time points against purified conjugates 
at t= 0 hr and (B) residual activities of native α-CT and conjugates (black = native 
enzyme; red = M-DTM conjugate; blue = alkyne-MAM conjugate; green = PEG-
DTM conjugate; yellow = PEG-MAM conjugate). 
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intervals. It has been shown that under raised temperature storage the stability 
of native HLZ is negatively affected.58 Results showed that the MAM conjugates 
showed only a minor decrease in activity over 7 days, comparable to that of the 
native enzyme. On the other hand, the DTM conjugates exhibited a decrease in 
activity. Specifically, the M-DTM conjugate lost all activity over 9 days compared 
to the native enzyme which retained 44% activity (Figure 2.17B). This indicates 
that disulfide re-bridging negatively affected enzyme stability at raised 
temperature, with the M-DTM conjugate, having the most DTM bridged disulfides, 
being least stable. This suggests that the stability of future DTM bio-conjugates 
should be carefully considered.  
Figure 2.17:  The residual activity, by EnzChek® lysis assay, of native HLZ and 
conjugates when stored at (A) room temperature (B) 50 °C (black = native 
enzyme; red = M-DTM conjugate; blue = alkyne-MAM conjugate; green = PEG-DTM 
conjugate; yellow = PEG-MAM conjugate). 
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1.9 Conclusions 
 
In conclusion, enzyme conjugates have been synthesized by reacting 
dibromomaleimides and monobromomaleimides with reduced disulfides and free 
amines in human lysozyme and α-chymotrypsin. Reactions of dibromomaleimides 
with reduced disulfides produced dithiomaleimide bridged enzyme conjugates, 
which showed fluorescence upon formation. Both α-CT and HLZ DTM conjugates 
showed the same stability as the native enzyme when stored at room 
temperature, and exhibited negligible structural change by circular dichroism.  
However, at elevated temperature storage (50 °C) the HLZ DTM conjugates 
showed reduced stability, which corroborates with a decrease in the observed Tm, 
indicating this conjugation technique may have a destabilizing effect on some 
enzymes.  
Reactions of dibromo- and monobromomaleimides with free amines in both 
enzymes produced fluorescent aminobromo- and monoaminomaleimide 
conjugates respectively. Monoaminomaleimides are shown to react with higher 
efficiency in both enzymes and conjugates are shown to be as stable as native 
enzymes at room temperature and at 50 °C, however, a decrease in Tm was 
observed by DSC analysis. Fluorescence analysis of all conjugated enzymes 
showed excitation and emission profiles comparable to small molecule studies; 
however, fluorescence quantum yields were low because of solvent quenching 
effects.  
Both reactions were trialed as PEGylation methods using bromomaleimide 
functionalized PEG. Conjugation efficiency was detrimentally affected, attributed 
to the reduced availability of chain ends and steric hindrance. The PEG-MAM HLZ 
conjugate showed marginally increased fluorescence quantum yield attributed to 
solvent shielding effects of the short PEG chain.  
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1.10 Experimental 
1.10.1 Instrumentation 
NMR spectra were recorded on a Bruker Avance 300, a Bruker Avance III 
HD 400 or a Bruker Avance III HD 500 spectrometer at 298 K and at 300, 400 and 
500 MHz respectively. Shifts are quoted in δ in parts per million and quoted 
relative to the internal standard trimethylsilane (TMS) or the solvent peak. 
High-Resolution Mass Spectra (HR-MS) were conducted on a Bruker UHR-
Q-ToF MaXis spectrometer with electrospray ionization. MALDI-ToF MS was 
conducted on a Bruker Autoflex MALDI TOF/TOF spectrometer with a mass error 
of <5 ppm. Protein solution (2.0 mg/ml) was spotted on the MALDI plate followed 
by an equal volume of synaptic acid matrix (15 mg in 0.5 mL of water, 0.5 mL of 
acetonitrile and 1 μL of trifluoroacetic acid (TFA)). The solvent was evaporated 
before recording the spectra and analysis using flexControl software. Gaussian fits 
were completed on conjugates which could be successfully fitted and full width at 
half maximum (FWHM) analysis was used to determine the standard deviation 
(FWHM = 2.355*σ). It should be noted that MALDI-ToF MS analysis of native HLZ 
showed a strong signal at around 14110 m/z, which does not match literature 
structures of HLZ, but has been observed by other groups.40 However, the 
secondary peak at 14692 m/z correlates with published structures and therefore 
conjugation mass shifts were based on this value.  
Infrared spectra were recorded on neat samples using a Perkin Elmer 
Spectrum 100 FT-IR Spectrometer. 
UV-Vis spectroscopy was carried out on a Perkin Elmer Lambda 35 UV/vis 
spectrometer or an Agilent Cary 60 UV-Vis Spectrometer at room temperature.  
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Fluorescence spectra were recorded using an Agilent Cary Eclipse 
Fluorescence spectrophotometer. Quartz cells with four polished sides (Starna) 
were used for fluorescence and UV-vis measurements. 
Enzyme assays were conducted on a FLUOstar OPTIMA multi-well 
microplate reader according to the assay conditions for each individual enzyme. 
Human lysozyme room temperature activities were recorded on non-freeze-dried 
samples. Data was analyzed using OPTIMA analysis software. 
Differential scanning calorimetry (DSC) analysis was performed on a TA 
Instruments Nano DSC. Blank runs were made with a buffer in both the sample 
and reference side. Each protein sample was run with a buffer in the reference 
side. Scans were made between 20 and 100 °C at 1 ˚C/min and a 600 s 
equilibration time was applied prior to each scan. Data is buffer subtracted 
(measured in pH 6 buffer at 0.5 mg/ml) and converted to molar heat capacity. 
The midpoint of the transitions was used to get an average Tm for each enzyme.  
CD spectra were recorded on a J-720 CD spectrometer in 1 mM pH 6.0 
phosphate buffer using a quartz cuvette with a path length of 0.1 cm. All 
experiments were run with ten acquisitions and recorded at 20 nm/min. The molar 
ellipticity was based upon protein concentration measured at 280 nm.  
Reverse-phase high-performance liquid chromatography (RP-HPLC) was 
carried out using a 569223-U Discovery C18 column on a Varian 9250 with an 
autosampler. Sample detection was carried out using a photodiode array (PDA) 
detector and a fluorescence detector (382 nm excitation / 531 nm emission). The 
mobile phases used were (A) water with 0.04 % v/v TFA; B: MeCN (spectroscopy 
grade). A range of mobile phase gradients was investigated. The optimized 
gradient is shown below (Figure 2.18). 
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1.10.2 Materials and chemicals 
α-chymotrypsin (Type II from bovine pancreas, lyophilized powder) and 
human lysozyme (expressed in rice, lyophilized powder) were used as received 
from Sigma-Aldrich and stored in a freezer (at approximately -18 C). All other 
chemicals were obtained from either: Sigma Aldrich, Fisher Chemicals, Acros 
Chemicals, Alfa Aesar or IRIS biotech GmbH and used as received. Spin filters 




Figure 2.18: Elution gradient of water/acetonitrile used for enzyme 
analysis by HPLC.  
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1.10.3 Small molecule synthesis 





The synthesis of dithiophenolmaleimide (2.1) was based on a previously 
reported literature procedure.56 In summary, dibromomaleimide (0.2 g, 0.78 
mmol) and NaHCO3 was added to a round-bottom flask containing a stirrer bar 
and 15 mL of MeOH. To this thiophenol (0.19 g, 1.7 mmol) in 1 mL methanol was 
added, and an immediate yellow color formed. The reaction was stirred at room 
temperature for 20 mins. After which solvent was removed in vacuo, and the crude 
solid was purified by silica column by flash chromatography (8:2  petroleum ether 
40-60 °C: EtOAc) to yield a yellow solid 2.1 (177 mg, 57%). 
 
1H NMR (DMSO-d6, 400 MHz, ppm) δ = 7.30 – 7.18 (m, 10H, ArH). 
13C NMR (DMSO-d6, 101 MHz, ppm) δ = 168.03 (CO), 136.77 (CS), 131.23 (CH), 
129.86 (C), 129.48 (CH), 128.36 (CH). 
MS (ESI) - [M-H]-: observed: 312.1 calculated: 312.0 
Matches literature data.59  
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Triphenylphosphine (1.44 g, 5.5 mmol) was dissolved in dry 
tetrahydrofuran (100 mL) and cooled to -78 °C. Diisopropyl azodicarboxylate 
(1.14 mL, 5.5 mmol) was added dropwise and the solution was left to stir for 5 
minutes. Methoxypoly(ethylene glycol) (Mn= 350 g/mol, 1.75 g, 5.5 mmol) was 
added dropwise to the cooled solution and left to stir for a further 5 minutes. 
Neopentyl alcohol (0.22 g, 2.5 mmol) was added and the solution was left to stir 
for a further 10 minutes. 3,4-dibromomaleimide (1.39 g, 5.5 mmol) was added to 
the solution and left to stir at -78 °C for 1 hour. The solution was allowed to warm 
to room temperature and left to stir for 24 hours. The solvent was removed in 
vacuo, and the resultant oil purified by silica column by flash chromatography (2:1 
to 0:1 gradient of petroleum ether 40-60 °C : EtOAc) to yield a yellow oil 2.2 (287 
mg, 17%). Rf (2:1 petroleum ether 40-60 °C : EtOAc): 0.1 to 0.4. 
 
1H NMR (CDCl3, 300 MHz, ppm) δ = 3.82 (t, 3JH-H= 5.6Hz, 2H, NCH2), 3.71-3.53 
(br m, 31H, CH2-CH2), 3.38 (s, 3H, CH3-O). 
13C NMR (CDCl3, 125 MHz, ppm) δ = 163.8, 129.4, 71.9, 70.6-70.5, 70.1, 67.5, 
59.0, 38.9  
HR-MS (MaXis) - [M+Na]+ calculated m/z 688.0764, observed m/z 688.0768 
FTIR (cm-1) –2872 (υC-H), 1716 (υC=O), 1104 (υC-O) 
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Figure 2.19: 1H NMR spectrum of 2.2. 
 
Figure 2.19: 13C NMR spectrum of 2.2. 
 Chapter 2   78 




The synthesis was based on a previously reported literature procedure.57 To 
a solution of bromomaleic anhydride (1 g, 5.65 mmol) in acetic acid (20 mL) was 
added methyl amine in ethanol (695 µl, 5.65 mmol.) The solution was refluxed for 
3 hours after which the solvent was removed in vacuo. The resultant solid was 
purified by silica column chromatography and eluted with 10% ethyl acetate in 
petroleum ether 40-60 °C to give a cream colored solid 2.3 (190 mg, 15%). Rf : 
0.2. 
 
1H NMR (CDCl3, 500 MHz, ppm) δ = 6.88 (s, 1H, CHCBr), 4.33 (s, 3H, NCH3). 
MS (ESI) - [M+H]+: observed: 190.0 calculated: 189.9 
Matches literature data.60 
 
 Synthesis of 3-bromo-1-(prop-2-yn-1-yl)-1H-pyrrole-2,5-




The synthesis was based on a previously reported literature procedure.57 To 
a solution of bromomaleic anhydride (1.2 g, 6.9 mmol) in acetic acid (15 mL) was 
added propargyl amine (432 µl, 7.5 mmol.) The solution was refluxed for 6 hours 
after which the solvent was removed in vacuo. The resultant solid was purified by 
silica column chromatography and eluted with 100% dichloromethane (CH2Cl2) to 
give a cream colored solid 2.4 (1.1 g, 78%), Rf (100% CH2Cl2): 0.9. 
 Chapter 2   79 
 
1H NMR (CDCl3, 300 MHz, ppm) δ = 6.39 (s, 1H, CHCBr), 4.33 (d, 4JH-H= 2.5Hz, 
2H, NCH2) and 2.24 (t, 4JH-H= 2.5Hz, 1H, HC≡C). 
13C NMR (CDCl3, 75 MHz, ppm) δ = 167.1 (CO), 162.1 (CO), 132.2 (CH), 131.7 
(CBr), 76.4 (CH2), 72.1 (C) and 27.8 (CH). 
HR-MS (MaXis) - [M+Na]+ calculated m/z 235.9318, observed m/z 235.9316  
Matches literature data.57 
 3-bromo-pyrrole-2,5-dionefunctionalized PEG800 (2.5) 
 
Methoxypoly(ethylene glycol)-amine800 (Mn= 800 g/mol, 0.48 g, 0.6 mmol) 
was added to 15 mL of acetic acid. Bromomaleic anhydride (0.13 g, 0.75 mmol) 
was added and the solution was refluxed at 114 °C overnight. The solvent was 
removed in vacuo and the resultant orange oil purified by flash chromatography 
on a silica column (2:1 CH2Cl2:methanol) to give a viscous oil 2.5 that was ~90% 
functionalized with PEG, as determined by 1H NMR spectroscopy (0.403 g, 67%). 
Rf (2:1 CH2Cl2:methanol): 0.05-0.35. 
 
1H NMR (CDCl3, 300 MHz, ppm) δ = 6.88 (s, 0.9H, CHCBr), 3.77 (t, 3JH-H = 5.4Hz, 
2H, NCH2), 3.68-3.53 (br m, 76H, CH2-CH2), 3.38 (s, 3H, CH3-O). 
13C NMR (CDCl3, 125 MHz, ppm) δ = 168.4 (CO), 165.3 (CO), 132.0 (CH), 131.4 
(CBr), 71.9 (CH2), 70.6-70.5 (m, CH2), 70.1 (CH2), 67.7 (CH3), 38.08 (CH2).  
HR-MS (MaXis) - [M+Na]+ calculated m/z 872.3250, observed m/z 872.3257 
FTIR (cm-1) – 2824 (υC-H), 1720 (υC=O), 1106 (υC-O). 




Figure 2.20: 1H NMR spectrum of 2.5. 
 
Figure 2.21: 13C NMR spectrum of 2.5. 
 Chapter 2   81 



















1.10.4 Enzyme conjugations 






3 mg (0.12 µmol) of α-CT was dissolved in 1.3 mL pH 6 phosphate buffer 
(0.1 M), followed by the addition of 0.1 mL tris(2-carboxyethyl)phosphine (TCEP) 
solution (4 μmol in 18.2 MΩ.cm water). The reaction was vortexed and left to stir 
for 30 minutes. After this, a 0.1 mL of M-DBM (5 μmol in DMF) was added and 
mixture vortexed. Maximum degree of conjugation, identified by MALDI-ToF MS 
analysis, was reached after 30 minutes. The crude enzyme was purified by 
ultrafiltration (AMICON® stirred cell) and freeze-dried. 
 
Figure 2.22: MALDI-ToF spectra of conjugate and native enzyme (left) and 
SDS-PAGE of conjugation (right). 
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3 mg (0.17 µmol) of α-CT was dissolved in 1 mL of 0.1 M pH 8.5 tris buffer.  
0.5 mL of alkyne-DBM (2.3) solution (17 µmol in DMF) was added and the solution 
vortexed. Maximum degree of conjugation, identified by MALDI-ToF MS analysis, 
was reached after leaving overnight (approximately 15 hours). The crude enzyme 
was purified by ultrafiltration (AMICON® stirred cell) and freeze-dried. 
 
Figure 2.23: 2D excitation/emission spectrum of M-DTM α-CT conjugate in 
pH 6 buffer. 

































2D flourescence of M-MBM CT 






























Figure 2.24: MALDI-ToF  spectra of conjugate and native enzyme. 
 
Figure 2.25: 2D excitation/emission spectrum of alkyne-MAM α-CT 
conjugate in pH 6 buffer. 
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3 mg (0.2 µmol) of HLZ was dissolved in 0.9 mL of 0.1 M pH 6 phosphate 
buffer, followed by addition of addition of 0.1 mL tris(2-carboxyethyl)phosphine 
(TCEP) (4.5 μmol in 18.2 MΩ.cm water). The reaction was vortexed and left to stir 
for 30 minutes. After this, a 0.1 mL of M-DBM (6.3 μmol in DMF) was added and 
mixture vortexed. Optimal conjugation identified by MALDI-ToF MS analysis was 
reached after 30 minutes. The crude enzyme was purified by ultrafiltration 
(AMICON® stirred cell) and freeze-dried. 
 
Figure 2.26: MALDI-ToF  spectra of conjugate and native enzyme. 
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3 mg (0.2 µmol) of human lysozyme was dissolved in 1 mL of 0.1 M pH 8.5 
tris buffer.  0.5 mL of alkyne-DBM (2.3) solution (14 µmol in DMF) was added and 
the solution vortexed. Maximum degree of conjugation, identified by MALDI-ToF 
MS analysis, was reached after leaving overnight (aproximetly 15 hours). The 
crude enzyme was purified by ultrafiltration (AMICON® stirred cell) and freeze-
dried. 
 
Figure 2.27: 2D excitation/emission spectrum of M-DTM HLZ conjugate in 
pH 6 buffer. 
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Figure 2.28: MALDI-ToF  spectra of conjugate and native enzyme. 
 
Figure 2.29: 2D excitation/emission spectrum of M-DTM HLZ conjugate in 
pH 6 buffer. 
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ABM functionalized α-CT was synthesized as per alkyne-MBM (2.6.3.2), 







Figure 2.30: MALDI-ToF  spectra of conjugate and native enzyme. 
 
Figure 2.31: Excitation/emission spectrum of methyl-MAM α-CT conjugate 
in pH 6 buffer. 

















 Excitation (521 nm emission)
 Emission (368 nm excitation)
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ABM functionalized HLZ was synthesized as per alkyne-MBM (2.6.3.4), 
without purification, using M-DBM. 
 
 
Figure 2.32: MALDI-ToF of conjugate and native enzyme. 
 
Figure 2.33: Excitation/emission spectrum of M-ABM HLZ conjugate in pH 
8.5 buffer. 



































 Excitation (524 nm emission)
 Emission (364 nm excitation)
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MAM functionalized α-CT was synthesized as per alkyne-MBM (2.6.3.2), 
without purification, using M-MBM (2.3) 
 







Figure 2.34: MALDI-ToF  spectra of conjugate and native enzyme. 
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MAM functionalized HLZ was synthesized as per alkyne-MBM (2.6.3.4), 
without purification, using M-MBM (2.3). 
 







3 mg (0.17 µmol) of α-CT was dissolved in 0.9 mL of 0.1 M pH 6 phosphate 
buffer, followed by addition of 0.1 mL of TCEP solution (4 µmol in 18.2 MΩ.cm 
water). The reaction was vortexed and left to stir for 30 minutes. After this, a 0.5 
mL solution of PEG-DBM (2.2) (5 µmol in DMF) was added, the solution vortexed 
and left to react for an hour. The crude enzyme was purified by ultrafiltration 
(AMICON® stirred cell) and freeze-dried. 
 
Figure 2.35: MALDI-ToF  spectra of conjugate and native enzyme. 
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 Emission (386 nm excitation)
 Excitation (528nm emission)
 








Figure 2.36: MALDI-ToF  spectra of conjugate and native enzyme. 
 
Figure 2.37: Excitation/emission spectrum of PEG-DTM α-CT conjugate in 
pH 6 buffer. 
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3 mg (0.2 µmol) of HLZ was dissolved in 0.9 mL of 0.1M pH 6 phosphate 
buffer, followed by addition of 0.1 mL TCEP solution (4 μmol in 18.2 MΩ.cm water). 
The reaction was vortexed and left to stir for 30 minutes. After this, a 0.5 mL 
solution 3.5 mg (5 µmol) of PEG-DBM (2.2) in DMF was added and the reaction 
vortexed and left for an hour. The crude enzyme was purified by ultrafiltration 
(AMICON® stirred cell) and freeze-dried. 
 
 
Figure 2.38: MALDI-ToF  spectra of conjugate and native enzyme. 
 
Figure 2.39: Excitation/emission spectrum of PEG-DTM HLZ conjugate in 
pH 6 buffer. 
















 Emission (408 nm excitation)
 Excitation (538 nm emission)
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3 mg (0.17 µmol) of α-CT was dissolved in 0.9 mL of 0.1 M pH 8.5 
phosphate buffer. To this, a 0.5 mL solution of PEG-MBM (2.5) (5 µmol in DMF) 
was added and the reaction vortexed and left to react overnight. The crude 
enzyme was purified by ultrafiltration (AMICON® stirred cell) and freeze-dried. 
 
Figure 2.40: MALDI-ToF  spectra of conjugate and native enzyme. 
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3 mg (0.2 µmol) of HLZ was dissolved in 0.9 mL of 0.1 M pH 8.5 phosphate 
buffer. To this, a 0.5 mL solution of PEG-MBM (2.5) (5 µmol in DMF) was added 
and the reaction vortexed and left to react overnight. The crude enzyme was 
purified by ultrafiltration (AMICON® stirred cell) and freeze-dried. 
 
Figure 2.41: Excitation/emission spectrum of PEG-MAM α-CT conjugate in 
pH 6 buffer. 
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Figure 2.42: MALDI-ToF  spectra of conjugate and native enzyme. 
 
Figure 2.43: Excitation/emission spectrum of PEG-MAM HLZ conjugate in 
pH 6 buffer. 















 Excitation (508 nm emission)
 Emission (350 nm excitation)
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1.10.5 Enzyme assays 
 α-Chymotrypsin p-nitroaniline hydrolysis assay 
Activity and stability of the enzyme and conjugates were assessed by 
analysis of the initial velocity changes in absorbance with time. Native α-CT and 
conjugates (2 µg/ml) were incubated in 0.1 M sodium phosphate buffer (pH 6) at 
4 °C. 20 μl aliquots of these solutions were added to 160 μl of 0.1 M sodium 
phosphate buffer (pH 6) in a 96 well plate and 20 μl of N-Succinyl-Ala-Ala-Pro-
Phe p-nitroanilide in methanol (3 mg/ml) was added. Each sample was run in 
triplicate against buffer blanks. The initial rate of hydrolysis of the substrate was 
monitored through recording the rate of increase in absorption at 405 nm at 25 °C 
over 30 minutes. Background hydrolysis was subtracted to give initial rates of 
hydrolysis. 
 Human lysozyme EnzCheck® lysis assay 
Lysozyme assays were carried out as reported in the literature36. DQ 
Lysozyme substrate stock suspension (1.0 mg/ml) was prepared according to the 
manufacturer, and aliquots were diluted to 50 mg/ml for each assay. 
Prior to conjugate analysis, the substrate was used to generate a standard 
curve. 6 wells of a 96 well plate were filled with 50 μl of 0.1 M sodium phosphate 
buffer (pH 6) followed by a solution of 50 μl 500 U/mL of human lysozyme solution 
which was added to the first well. The solutions were mixed and 50 μl was 
transferred into a second well. This was repeated over 5 wells, with the final 50 μl 
from the 5th well discarded. To these solutions, 50 μl of the 50 mg/ml substrate 
solution was added. These solutions in triplicate were incubated at 37 °C in a plate 
reader and emission at 530 nm (excitation at 492 nm) was recorded vs. time. 
From this, a value of 62.5 U/ml was identified as the concentration for future 
assays. The standard curve is plotted below (Figure 2.44). 










For the stability assay, Native human lysozyme and conjugates (2 mg/ml) 
were incubated in 0.1 M sodium phosphate buffer (pH 6) at 4 °C. Aliquots of these 
solutions were diluted to 0.005 mg/ml and 50 μl of these solutions was pipetted 
onto a 96 well plate.  To these solutions, 50 μl of the 50 mg/ml substrate solution 
was added and these solutions, in triplicate, incubated at 37 °C in a plate reader. 
Analysis was carried out by measuring emission at 530 nm after 30 minutes, as 
per the manufacturer’s protocol. Errors were measured as a standard deviation 
over all time points for each triplicate.  
1.10.6 Quantum yield fluorescence analysis 
A solution of quinine sulfate dihydrate (15 µmol) in 0.105 M perchloric acid, 
was used a standard (Φf quinine = 59%), and UV-Vis spectrum was recorded. The 
conjugate of interest was diluted to a concentration affording an absorbance <0.1 
at the excitation wavelength determined by UV-Vis analysis. Both spectra were 
overlaid and the optimal excitation wavelength for the calculation was chosen to 
be the wavelength where the standard and the sample have the same absorption 
(Figure 2.45). 
Figure 2.44: Lysozyme standard curve. 
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Using 362 nm as the excitation wavelength for fluorescence, the emission 
of both samples was measured (Figure 2.45). To calculate the quantum yield 
Equation 1 is used, where F= Integral photon flux (emission integral), f= 
absorbance, n=refractive index of the solvent, 𝜆𝑒𝑚= emission wavelength, 
conj=conjugate sample, and st=quinine standard.   












As the absorbance for the standard and sample match, it can be neglected 
(fst/fconj=1). Refractive indices are found for the conjugate and quinine solvents at 
their respective average emission wavelengths (wavelength corresponding to the 
mean of the emission spectrum integration). The standard quantum yield 
Φf,st(Φquinine= 59%) was used to calculate the relative fluorescence of each 
conjugate.  
1.10.7 Circular dichroism of DTM HLZ conjugate 
Circular dichroism analysis was recorded for HLZ and the methyl DTM HLZ 
conjugate. By studying Δ[Ɵ]m at 222 nm the α-helicity of the enzyme can be 
Figure 2.45: UV-Vis (left) and fluorescence emission (right) spectra of 
DTM conjugate against quinine standard. 
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measured. A small reduction in Δ[Ɵ]m was noted for the conjugate (97% of the 
native HLZ), which is similar to the difference by T = 0 activity (96% - Table 2.5). 
This suggests there is a minimal reduction in enzyme integrity through conjugation 
of DTMs, the whole CD spectra also showed very similar structural features 
indicating good structure retention (Figure 2.11). 
Table 2.5: Molar elipticity difference of the DTM HLZ conjugate versus 















HLZ [Ɵ]222 -2.54E+14 degcm2dmol-1 
DTM HLZ [Ɵ]222 -2.46E+14 degcm2dmol-1 
Δ[Ɵ]222 97% 
Δactivity (t = 0) 96% 
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2 Chapter 3: Designing maleimide 
derived fluorophores for improved 
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2.1 Abstract 
 
In the previous Chapter, fluorescence quenching through hydrogen bonding 
interactions with water was observed in conjugated maleimide species. Based 
upon the principle of preventing this interaction, several ways of preventing this 
have been hypothesized and investigated. This Chapter covers the investigation 
into bulky imide substituents which are hypothesized to prevent H-bonding 
interactions through steric repulsion. This was achieved through introducing 
multiple benzyl groups to the imide and through using silylation reactions to 
produce silyl functionalized maleimides. Fluorescence analysis of the benzyl 
derivatives showed unexpected fluorescence behaviour, including what appeared 
to be aggregation induced emission (AIE) in a trityl-MAM. This observation is 
explored and explained through crystal structure analysis and computational 
simulation of electron distributions, which indicated a divergence from typical AIE 
mechanisms. Silyl derivatives indicated similar fluorescence properties to 
conventional maleimide fluorophores, however, the quantum yield of these was 
increased in methanol, attributed to successful shielding from solvent electron-
driven proton transfer (EDPT).  
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2.2 Introduction 
2.2.1 Quenching of charge transfer fluorophores  
 The properties of a fluorophore are greatly influenced by its environment, 
as discussed in Chapter 1. This is particularly true for photoinduced charge 
transfer dyes (PCT) such as aminomaleimide fluorophores,1,2 hence they exhibit 
solvafluorochromism and have been particularly successful as sensing dyes in 
polymer-based applications.3–6 
Intramolecular charge transfer fluorophores are compounds which upon 
excitation become charge separated. In essence the excitation leads to a 
separation of charge - an acceptor (-ve) and a donor (+ve) group (Figure 3.1). If 
the molecule is in a planar configuration, the orbitals are aligned and fluorescence 
is electronically allowed, leading to high emission. However, this excitation forms 
a diradical: one radical existing in the ground state HOMO and one in the LUMO. 
To reduce columbic repulsion, the molecule may rotate around a single bond-
forming a twisted intramolecular charge transfer state (TICT). This can lead to 
 
Figure 3.1: Illustration of absorption and relaxation events in a generalized 
maleimide skeleton in different solvents. ISC = intersystem crossing, PR = 
photo recombination. 
 Chapter 3   107 
electronic decoupling of the donor and acceptor before relaxation, which can forbid 
fluorescence emission or lead to red shifted emission.1,7⸸ In a sufficiently fluid 
medium, solvent molecules can adjust to stabilize the shift in electronic 
distribution. The more polar the solvent, the more effective this stabilization is; 
which leads to this charge stabilization becoming more dominant in polar solvents 
such as water and methanol.  
Concerning maleimide fluorophores in particular, a charge transfer 
quenching event occurs ~5 ps post excitation, which is favoured by higher solvent 
polarity (Figure 3.1). However, the effect is still minimal for aminomaleimides in 
aprotic polar solvents such as acetonitrile (MeCN).2 In addition, there is another 
quenching event in polar protic solvents. In protic solvents such as methanol, an 
electron driven proton transfer (EDPT) event also occurs leading to even greater 
quenching of fluorescence, and as a result, MAM dyes typically exhibit quantum 
yields (Φf) of around 1% in methanol and <0.1% in water.2,9 In such EDPT events, 
the movement of an electron from the solvent to the dye upon excitation, causes 
a charge difference which induces proton donation from the solvent.8 This transfer 
leads to a neutral di-radical species, in which fluorescence is forbidden (Figure 
3.2).  
It is hypothesized that prevention of EDPT would lead to a marked increase 
in emission intensity in protic solvents.2 Several changes to the maleimide motif 
to achieve this aim have been investigated and this Chapter will focus on using 
steric shielding of the carbonyl groups with the aim of preventing EDPT.  
 
⸸ Sometimes, this state can be fluorescent as a consequence of other effects, as 
observed for example, in DMABN (4-(dimethylamino)benzonitrile), which exhibits a TICT 
induced fluorochromic shift.7 
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2.2.2 Aggregation induced emission (AIE) 
Within this Chapter, a phenomenon analogous to aggregation induced 
emission (AIE) is serendipitously observed. AIE is a relatively recent but well-
studied, area of fluorescence, especially in regard to materials applications.10 
Initially reported in 2001 by Tang and co-workers when studying phenyl 
substituted siloles,11 AIE has now been observed in dyes from planar aromatics 
like tetraphenylethylene (TPE)12 and arylated BODIPY variants13 to metal 
complexes such as Au(I) thiolates.14 AIE is in contrast to aggregation caused 
quenching (ACQ) which is the phenomenon that most conventional dyes exhibit.15 
In general ACQ occurs when dyes that are fluorescent in solution aggregate or 
crystallize, in a manner in which π-π interactions are formed which cause self-
quenching of fluorescence.15,16 The major mechanism of AIE is through restriction 
of intramolecular motion (RIM) or restriction of intramolecular rotation (RIR). This 
RIM or RIR causes prevents the TICT quenching seen in solution,15 for example TPE 
dyes in solution are not fluorescent as the aryl substituents are free to rotate 
which allows for non-radiative relaxation, however upon aggregation this rotation 
 
Figure 3.2: Diagram of hypothesized EDPT mechanism for a maleimide solvated 
in MeOH. Electronic movement is indicated by the green dashed arrow and 
proton movement is indicated by the blue arrow. Reproduced from reference.8 
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and motion can no longer occur and thus the compound becomes fluorescent 
(Figure 3.3).17 Very recently Tang and co-workers have reported a new version of 
RIM in which prevention of access to a dark state (caused by lone-pair π 
interactions) can be achieved upon aggregation or complexation of metal ions.18 
 
Figure 3.3: Illustration of rotation-based relaxation of TPE (left), and the 
fluorescent aggregate state through RIM/RIR (right).   
Applications of AIE include OLED based applications, where a highly 
emissive species is required in the solid or film state,19 to explosives detection in 
which highly emissive solids can be quenched upon contamination with aromatic 
explosives such as TNT and picric acid.20,21  
 In regard to maleimide based fluorophores, AIE can be observed through 
aromatic substitution of the dye as reported by the Tang group.22 Substitution 
extends π conjugation beyond the maleimide ring through rotatable bonds which 
cause quenching in solution, however upon aggregation AIE can occur through 
restriction of these rotations. This has been applied to polymer-based materials to 
create condensation-based polymers which exhibited solid-state emission, and AIE 
behaviour at longer visible wavelengths (>600 nm).23 In both of these reports AIE 
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dyes exhibited solid-state Фf < 40%, which leaves room for improvement 
compared to other reported AIE dyes.10,22,23 
A thorough investigation into imide substitution in maleimide dyes has not 
been reported and many questions still exist about maleimide fluorophores, 
including explaining their solid-state fluorescence behaviour. In this Chapter, a 
systematic study into the effect of imide functionalization of MAMs was conducted. 
It was anticipated that tuning substitution may not only aid with steric shielding 
from protic quenching events, but may also significantly affect the fluorescence 
mechanism, for example, from AIE to ACQ, along with potentially creating new π-π 
or C-H-π interactions in the aggregate state which have been shown to tune 
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2.3 Results 
2.3.1 Synthesis of imide functionalized maleimides with 
benzyl groups to reduce solvent quenching effects 
As a consequence of the poor fluorescence properties of previously 
synthesized conjugates in aqueous environments, it was decided to investigate 
maleimide derivatives that may undergo less quenching in aqueous environments. 
O’Reilly and co-workers have shown that quenching in polar environments can be 
a consequence of hydrogen bonding interactions with solvent protons.8 Therefore, 
efforts will focus on preventing this interaction through the synthesis of sterically 
protected maleimides. Hypothetically, bulky imide substituents could provide 
steric hindrance to hydrogen bonding interactions, thus preventing quenching 
from protic solvents. Initially, phenyl substituted maleimides were targeted as the 
phenyl rings may also help introduce weak intra-molecular hydrogen bonding as 
shown in Figure 3.4.  
 
Figure 3.4: 2D Illustration of proposed interactions preventing solvent (R) 
hydrogen bonding in a phenyl substituted maleimide. 
Mono-benzyl and bis-benzyl functionalized maleimides were successfully 
synthesized by reacting benzyl amine and diphenylmethylamine respectively 
(Scheme 3.1) with bromomaleicanhydride, under acidic reflux conditions reported 
by Tedaldi et al.26  
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Scheme 3.1: Synthesis of mono- and bis-benzyl aminomaleimides 3.2 and 
3.4 via intermediate MBMs 3.1 and 3.3. 
The reaction of tritylamine under the same conditions did not proceed, 
hypothesized to be a result of greater steric hindrance from the trityl group 
preventing nucleophilic attack on the anhydride. Typically alkyl halides are 
unreactive towards bromomaleimide nucleophiles,27 unexpectedly however, the 
reaction of trityl chloride with MBM 2.1 and DBM did proceed (Scheme 3.2). This 
suggests an SN1 mechanism for such reactions, where a stable cation intermediate 
is required for attack of the maleimide to occur. This correlates with the poor 
nucleophilic nature of the imide group.  
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Scheme 3.2: Synthesis of trityl MAM 3.7 and ABM 3.8. 
For comparison to previously studied maleimide fluorophores, five 
standards containing an isopropylamine donor group were synthesized (Scheme 





Scheme 3.3: Synthesis of ABM/MAM dyes 3.9, 3.10, 3.12, 3.15 and 
3.16 used for fluorescence controls. 
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2.3.2 The synthesis of bulky silyl derived 
aminomaleimides as sterically hindered maleimide 
fluorophores 
It has been reported that silyl-maleimides can be formed through 
functionalization of the imide group,28 and based upon this several silyl-
aminomaleimides were targeted for synthesis. It was hoped that as well as giving 
more groups for steric hindrance, the silyl group may impart beneficial changes to 
the optical properties, for example Si-Rhodamines have been reported as near 
infrared dyes, which are highly stable to photo-bleaching.29,30 Firstly, a tert-
butyldimethylsilyl derivative was targeted, which would impart a large alkyl imide 
substituent for the study. The reaction of tert-butyldimethylsilyl 
trifluoromethanesulfonate was found to be successful with DBM and MBM under 
dry conditions (Scheme 3.4, 3.17-3.18). These were successfully reacted with i-
propylamine to give TBDMSi-MAM 3.21 and TBDMSi-ABM 3.22. Based upon this, 
the reactions were repeated with tert-butyldiphenylsiyl trifluoromethanesulfonate, 
to give benzyl-silyl functionalized aminomaleimides (TBDPSi-MAM 3.23 and 
TBDMSi-ABM 3.24). Reactions of trimethylsilyl chloride and triisopropylsilyl 
chloride were unsuccessful, suggesting either a more activated trifluoromethylsilyl 
group is required or a more substituted silyl reagent is required to stabilize the 
cation intermediate. Unfortunately, trimethylsilyl- or triisopropylsilyl-
trifluoromethanesulfonate were not commercially available.             
 
 












2.3.3 Fluorescence analysis of benzyl substituted 
maleimides 
To establish the effect of benzyl functionality on the optical properties of 
maleimides, the benzyl substituted dyes (3.2, 3.4, 3.7 and 3.8) synthesized in 
3.3.1 were measured (single measurements) and compared to standard 
aminomaleimides HMAM (3.9) and iPrMAM (3.12) and PhMAM (3.15). The 
absorption and emission wavelengths of the series, from no benzyl substituents 
(HMAM, Figure 3.6) to three benzyl substituents (Bz3MAM) varied only a little, with 
the compounds all exhibiting similar λmax (Figure 3.5). It was noteworthy that all 
aromatic functionalized dyes exhibited smaller changes in λmax between solvents, 
Scheme 3.4:  Synthesis of various silyl maleimides 3.21-3.24 via silyl 
bromomaleimide intermediates 3.17-3.20. 
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than the H and isopropyl imide functionalized dyes, suggesting a lesser influence 
from the environment in these dyes, as the charge transfer state is stabilized by 
interactions with polar solvents.1 Meanwhile, Stokes shifts in the series varied little 
between dyes indicating similar HOMO-LUMO separation.  
When studying the mono- and di-benzyl substituted MAMs, bright emission 
was noted in aprotic solvents, similar to HMAM, with comparable λex/em maxima. 
In contrast, very little fluorescence was observed for the trityl-MAM (Bz3MAM – 
3.7) in apolar solvents, notably increased emission was observed in methanol and 
dimethyl sulfoxide (DMSO), seemingly inverting the trend observed in standard 
aminomaleimide fluorophores. 
 
Figure 3.5:  Chart showing solution exitation (red) and emission (blue) λmax the 
benzyl maleimide series in various solvents, showing minimal variation in the 
series. * Too weak for measurement. 
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To quantify this, solution-state fluorescence quantum yield (Φf) analysis 
was undertaken for the series in a range of solvents (Figure 3.7). This confirmed 
initial observations, with BzMAM (3.2), Bz2MAM (3.4), HMAM (3.9), and iPrMAM 
(3.12) all exhibiting Φf(%) of 30-70% in non-polar solvents, and a significantly 
lower Φf in DMSO and methanol. The slight decrease in Φf displayed by iPrMAM 
(3.12) in all solvents could be attributed to the inductive effect of the isopropyl 
group. Likewise, PhMAM (3.15) was found to be non-fluorescent in solution, as 
previously reported for similar phenyl maleimides,9 attributed to TICT in the 
solution state.  
Most notably, however, Bz3MAM (3.7) exhibited increased Φf in DMSO and 
methanol (11.3% and 3.8%) but significantly less in apolar solvents (all exhibited 
Φf(%) < 1.5%). This quenching in apolar solvents is perplexing as no direct 
conjugation of aromaticity to the maleimide ring is present based upon sp3 
hybridization theory, the usual cause of such quenching (as seen in PhMAM). To 
ascertain if the quenching may be a result of extension of the π-system beyond 
 
Figure 3.6: Example excitation and emission spectrum for HMAM 3.9 in THF.  
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the maleimide ring, modelling of the HOMO-LUMO isosurfaces was completed by 
Dr Miquel Torrent-Sucarrat (University of the Basque Country). The results of this 
are plotted in Figure 3.8.  
This was numerically assessed through integration of electron density in the 
ring, in both the natural bonding orbital (NBO1) and the highest occupied 
molecular orbital (HOMO1). The electron density on the maleimide ring (Scheme 
3.5), for NBO1 and HOMO1 were integrated and calculated as Q using equations 
 
Figure 3.7:  Chart of solution and solid-state quantum yields of studied maleimide 
fluorophores, showing poor solution fluorescence of PhMAM and Bz3MAM compared 
to the series. Recorded by either reference or absolute method, respectively.  
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3.1 and 3.2. Lower 𝑄 values represent higher electron density on the maleimide 
ring and vice versa. 
𝑄𝑁𝐵𝑂1 = 𝑞𝑁𝐵𝑂,𝐶1 + 𝑞𝑁𝐵𝑂,𝐶2 + 𝑞𝑁𝐵𝑂,𝐶3 + 𝑞𝑁𝐵𝑂,𝐶4 + 𝑞𝑁𝐵𝑂,𝑂1 +
𝑞𝑁𝐵𝑂,𝑂2    
(Eq. 3.1) 
𝑄𝐻𝑂𝑀𝑂1 = ∫ 𝜌𝐻𝑂𝑀𝑂(𝑟)𝑤𝑖(𝑟)𝑑𝑟Ω𝑖=𝐶1,𝐶2,𝐶3,𝐶4,𝑂1,𝑂2







Scheme 3.5: Schematic representation of the atom enumeration used in the 
simulation of NBO1 and HOMO1 orbitals. 
 
 Based on the results obtained (Figure 3.8), we conclude that the imide 
substituent plays a crucial role in the electron distribution within the 
aminomaleimide ring and therefore, the resulting fluorescence emission of these 
 
Figure 3.8: HOMO isosurfaces of benzyl MAM series with their HOMO1 and NBO1 
atomic integrations - representing the π-conjugated structure of the 
aminomaleimide ring (lower Q values indicate greater electron density on the 
maleimide ring) and the solution state absolute quantum yields (in diethyl ether). 
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compounds. For instance, across the BzMAM, Bz2MAM, and Bz3MAM series, the 
HOMO isosurfaces and the electron density contributions of the substituents 
increase while exhibiting a corresponding decrease in the π-conjugated density on 
the aminomaleimide ring. This is visualized in Figure 3.8 where the HOMO1 of 
Bz3MAM is clearly located more towards the benzyl rings and this is shown by a 
high 𝑄𝐻𝑂𝑀𝑂1(0.006) compared to Bz2MAM (-0.036). This also correlates with a 
reduction in quantum yield in apolar solvents (58.4% to 1.4% in diethyl ether - 
Figure 3.8). 
These results strongly suggest that the withdrawal of maleimide electron 
density across a quaternary carbon, leads to characteristic TICT quenching in 
solution. Moreover, within this series, the trityl group shows the largest electron-
withdrawing character, which is evidenced by Bz3MAM also exhibiting the largest 
TICT quenching in solution. To explore this further analysis of a trityl-
aminobromomaleimide analogue (Bz3ABM, 3.8) was undertaken, in which the 
maleic proton is replaced by a bromine atom. Fluorescence analysis of this 
compound showed some quenching in apolar solvents, but not to the same degree 
as observed for Bz3MAM (for example, in toluene, the observed Φf(%) was 9.5% 
for the ABM and 1.39% for the MAM). By modelling the HOMO isosurface 
distribution of the compound, less electron density is located on the trityl group, 
which could be attributed to the electron-withdrawing character of the bromine 
atom (see Figure 3.8). It should be noted that the bromine atom is not included 
in the orbital integrations and therefore 𝑄 values are not comparable.  
 Chapter 3   121 
























Figure 3.9: Correlation between quantum yield, Φf(%), (in diethyl ether 
solution) and the atomic integration of HOMO1 along the  conjugated 
structure of the aminomaleimide ring, 𝑄𝐻𝑂𝑀𝑂1. 
 
This phenomenon shows that the fluorescence intensity of maleimide dyes 
can be tuned through the withdrawal of electrons to or from aromatic groups. 
Specifically, conjugation of electron density above the imide is correlated well with 
a reduction in quantum yield in the solution state by linear fit, R2 = 0.85 (Figure 
3.9). It could also be described by two quadrants in which a low 𝑄𝐻𝑂𝑀𝑂 (< 0.45) 
correlates to a low Φf (< 30%) and a higher 𝑄𝐻𝑂𝑀𝑂 (> 0.5) correlates to a high Φf 
(> 40%). Based upon this result, PhABM was analysed, which according to this 
theory should exhibit a higher Φf in solution than PhMAM. Indeed, the bromine 
substituent did increase quantum yield in all solvents albeit the increase was small 
(for example from 1.3% to 3.6% in DMSO).  
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In contrast to its solution state fluorescence, it was observed that Bz3MAM 
(3.7) was highly fluorescent in the solid-state. Therefore, it was decided to 
investigate any trends in solid-state fluorescence quantum yield for the series. 
BzMAM (3.2), Bz2MAM (3.4), HMAM (3.9), and iPrMAM (3.12) all exhibited Φf(%) 
around 25% (Figure 3.5). Notably however, Bz3MAM (3.7) showed very bright 
solid-state emission with a Φf(%) of 74% (Figure 3.7). To investigate the potential 
for AIE based applications, a solution of Bz3MAM (3.7) in dioxane was titrated with 
water to precipitate the dye. The low emission in dioxane gradually increased with 
increasing water content, as well as exhibiting a hypsochromic shift with 
increasing water content, indicative of fewer interactions with the solvent. In a 
water/dioxane (99/1) mixture, it exhibited over an eleven-fold increase in 
fluorescence emission compared to that exhibited in 100% dioxane, strongly 
suggesting AIE behaviour (Figure 3.10).  
Figure 3.10 Fluorescence of Bz3MAM (3.7) in water/dioxane mixtures: emission 
at 470 nm (375 nm excitation) against water content (left) and emission 
spectrum at 375 nm excitation at different percentages of water in dioxane 
(right). 



































% water in dioxane
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In an attempt to explain these observations, X-ray crystal structures were 
successfully obtained for the following compounds: BzMAM (3.2), Bz2MAM (3.4), 
HMAM (3.9), and Bz3MAM (3.7). From the molecular packing in the solved crystal 
structures, it was observed that HMAM, BzMAM, and Bz2MAM all form dimers 
connected by N−H∙∙∙O bonds with bond lengths of 2.07 to 2.19 Å (Table 3.1). In 
HMAM, it was also notable that the imide N-H formed an extra hydrogen bonding 
dimer with the other carbonyl group; with an N−H∙∙∙O bond length of 2.03 Å. In 
comparison, in Bz3MAM, the rings are no longer dimerized, possibly due to steric 
hindrances. Instead, maleimide rings form a chain of maleimide motifs with 
N−H∙∙∙O bond lengths of 2.11 Å (Table 3.1). 
 
Compound Bonds Length (dH-A) (Å) Angle (°) Form 
HMAM 
3.9 
N2−H2∙∙∙O1i 2.11 (±0.02) 167 (±2) Dimer 





N2−H2∙∙∙O2i 2.19 (±0.02) 151.7 (±1.7) Dimer 
H4∙∙∙O1i 2.47 (±0.10) 174.2 (±0.8) Dimer 
Bz2MAM 
3.4 
N2−H2∙∙∙O1i 2.07 (±0.04) 156 (±3) Dimer 
N102−H102∙∙∙O101i 2.11 (±0.04) 157 (±3) Dimer 
Bz3MAM 
3.7 
H3∙∙∙O1i 2.92 (±0.04) n.d.* Chain 
N2−H2∙∙∙O2i 2.14 (±0.06) 162 (±4) Chain 
 
 
Table 3.1 Hydrogen bonding data for solved crystals of the benzyl MAM series.  
*n.d. = not determined. HMAM i= 1-X, +Y, -1/2+Z; BzMAM i= 1-X, 1-Y, 1-Z; 
Bz2MAM i= 1-X, 1-Y, -Z;Bz3MAM i= +Y, +X, 1-Z. 
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It was hypothesized that steric hindrance arising from the trityl groups could 
be preventing the maleimide rings from coming in close proximity, reducing any 
intramolecular π-π interactions that could be causing quenching in the aggregated 
state. The lack of N−HO dimerization suggested that the rings may indeed be 
further separated. However, this can be further quantified through the 
measurement of maleimide ring distances to evaluate any π-π interactions that 
may be present. HMAM and BzMAM both crystalized with anti-parallel off centre 
maleimide rings, where the maleimide rings are orientated at 180°, suggestive of 
π-π stacking interactions.31,32 The distance between rings is 3.707 Å in HMAM and 
4.053 Å in BzMAM (Table 3.2), distances indicative of typical π-π interactions.33,34 
In Bz2MAM, inter-ring centroid distances became larger at 5.042 Å, while the inter-
plane distance decreased to 2.764 Å. This suggests an increase in the off-centre 

















































































150.1 °  
(±0.7) 
166.6 °  
(±0.3) 
Table 3.2 Solid state Φf and shortest maleimide crystal packing distances and 
angles for crystals of the benzyl MAM series. †Measured distance and angle 
between ring centroid of N1C1C2C3C4 and N1iC1iC2iC3iC4i. *Angles between mean-
plane created from atom selection N1C1C2C3C4 and N1iC1iC2iC3iC4i. ‡ Distance 
between ring centroid of N1C1C2C3C4 and plane of N1iC1iC2iC3iC4i. § Distance in 
horizontal shift between ring centroids of N1C1C2C3C4 and N1iC1iC2iC3iC4i. 
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distance in obtained crystal structures was 6.464 Å for Bz3MAM, significantly 
higher than in the other crystals (Table 3.2). 
To reveal this further, the visualization of noncovalent interactions (NCI) 
was performed (Figure 3.11). Clear π-π stacking between the aminomaleimide 
rings is observed in the NCI isosurfaces of HMAM (3.9), BzMAM (3.2), and Bz2MAM 
(3.4). On the other hand, in Bz3MAM (3.7) the NCI plot became more diffuse and 
π-π interactions are not observed; instead, above and below the maleimide rings 
sit methyl or benzyl groups of the neighbouring molecule. This can be visualized 
by plotting the HOMO or LUMO orbitals which show clear π overlap in all structures 
but Bz3MAM (Figure 3.12).  
 
Figure 3.11 CAM-B3LYP/6-311G(d,p) gradient isosurfaces with s=0.5 for the 
crystal structures of HMAM (3.9), BzMAM (2.3), Bz2MAM (3.4), and Bz3MAM 
(3.7) with a blue-green-red colour scale from -0.05 < ρ sign(λ2) < 0.05 au. 
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Despite the earlier AIE titration, the observation that the solid-state 
quantum yield may be negatively affected by π-π interactions in the solid-state, 
and potentially hydrogen bonds between maleimide dimers, suggested that 
Bz3MAM is not exhibiting traditional AIE behavior. To probe this mechanism 
further, the series of dyes were drop cast with 12 kDa polyethylene glycol (PEG) 
to form dye incorporated powders. The absolute quantum yields of these powders 
were then measured to establish if the polymer chains provide shielding of π-π and 
H-bonding interactions, thus increasing emission. As expected, the incorporation 
of dyes HMAM, BzMAM, and Bz2MAM into PEG led to an increase in emission, with 
an approximately two-fold increase in emission intensity observed for each dye, 
for example, the Φf(%) of HMAM increased from 25.3% to 49.4% (Figure 3.13). 
Bz3MAM however, showed a negligible increase in emission from 73.6% to 75.3%. 
These observations appear to confirm that prevention of π-π interactions through 
 
Figure 3.12 LUMO isosurfaces overlaid on the obtained crystal structures of 
the benzyl functionalized series. 
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sterics increases fluorescence in the solid-state, and that this can be achieved 
covalently through dye substitution or non-covalently through polymer shielding. 
To ascertain if this phenomenon was unique to maleimides, a known AIE 
dye tetraphenylethylenealdehyde (TPE) was incorporated with PEG. Quantum 
yield analysis of this powder indicated a reduction in emission upon incorporation 
with PEG (25.9% to 1.5%). This is in corroboration with hypothesis on AIE dyes 
which suggests separation in the solid-state increases vibrational relaxation 
viability.35 This suggests Bz3MAM exhibits purely solid-state emission in 
comparison to traditional AIE fluorophores and that these dyes could suit 
applications in material applications where separation in the solid-state maybe 
needed, for example explosives detection.36 This puts doubt into previous reports 
on maleimide AIEgens,22 and suggests future work should consider solid-state 
 
Figure 3.13 Chart displaying solid-state (solid colors) and PEG incorporated 
(striped colors) absolute quantum yields. Error bars represent standard 
deviation over 3 repeats. 
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separation to aid mechanistic understanding of AIE versus purely solid-state 
emission as seen here.  
2.3.4 Fluorescence analysis of silyl substituted 
maleimides 
In the hopes of realizing increased emission in protic solvents, the 
synthesised silyl derivatives were studied. The silyl derivatives appeared 
fluorescent, and were therefore analysed by steady-state fluorescence 
spectroscopy. All dyes showed emission in solution, with a slight blue shift 
compared to previous maleimide dyes - for example, TBDPSiMAM (3.21) λem = 
458 nm in dioxane (Figure 3.14), while BzMAM (3.2) λem = 469 nm. Notably, 
emission in methanol appeared to be significantly higher than expected, 
suggesting improved emission under protic conditions. To evaluate any change in 
this regard, Φf analysis was undertaken for the series in a range of solvents (Figure 
3.15) and compared to HMAM (3.9), HABM (3.10) and iPrMAM (3.12) controls.  
























Figure 3.14 Spectrum displaying solution state emission of TBDPSiMAM 
(3.21) in various solvents (λex = λmax). 
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First impressions show similar quantum yields for the silyl derivatives in 
apolar solvents compared to the control maleimides. TBDPSiMAM (3.23) does 
show slightly reduced emission in these solvents, which could be attributed to 
partial withdrawal of electrons from the maleimide into the imide substituent, as 
seen in Bz3MAM (3.7). The observation that the analogous ABM, TBDPSiAbM 
(3.24), does not show reduced emission also corroborates this phenomenon as it 
was shown in the benzyl series that the bromine atom redistributed electrons back 
into the maleimide ring from imide substituents.  
Comparing the polar solvent emission, however, it was clear that the 
quantum yield in methanol had increased. For the silyl-MAMs a Φf(%) of up to 
 
Figure 3.15 Chart showing solution state quantum yields of silyl substituted 
maleimide fluorophores and control dyes; measured by reference method. 
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11.4% (TBDMSiMAM) in methanol was recorded, a several fold increase from that 
recorded for the controls HMAM, HABM and iPrMAM (Φf(%) = 2.4%, 1.6% and 1.9% 
respectively). However, emission in DMSO was negligibly affected, indicating that 
the increase emission in methanol is from shielding of EDPT.2 To confirm this, it 
was decided to model the theoretical emissions with various solvent interactions 
and compare these to the experimental data. By doing this we hope to eliminate 
any effects, the silyl substitution may be imparting. Collaborator Dr Miquel 
Torrent-Sucarrat modelled the theoretical λex/em for the two silyl MAMs and for 
comparison HMAM and iPrMAM, when including zero, one or two explicit solvent 
molecules. These solvent molecules were considered to be bonding to either 













Figure 3.16 Illustration and modelling of hydrogen bonding interactions with 
TBDPSiMAM and methanol.  



















None 316.0 418.9 102.9 
0.66 369 489 120 
A 328.9 451.6 122.7 
B 322.4 430.9 108.5 
AB 334.9 463.8 128.9 
iPrMAM 
3.12 
None 326.8 444.4 117.6 
1.23 369 519 150 
A 338.3 474.4 136.1 
B 334.4 458.2 123.8 




None 316.1 416.5 100.4 
0.45 353 467 114 
A 326.7 434.9 108.3 
B 320.3 423.3 103.1 




None 316.1 417.7 101.7 
0.28 363 473 110 
A 328.6 448.5 119.9 
B 323.8 434.2 110.4 
AB 336.4 465.8 129.4 
 
Using these optimised geometries, the theoretical λex/em and thereby Stokes 
shift, Δλ, was calculated and compared to experimental observations (Table 3.3). 
Measured Stokes shifts of silyl-maleimides were smaller than controls and 
emission was blue-shifted (467 nm for TBDPSi-MAM and 489 nm for HMAM). Both 
these indicate fewer interactions with solvent as red-shifted emission is directly 
correlated to interactions with polar solvents due to the stabilization of the CT 
state.2 To establish a more quantifiable parameter the simulated data was fitted 
to a quadratic equation (Eq. 3.3) and solved for the measured values to establish 
a probability of hydrogen bonding, P. In this we let z be the empirical measurement 
of Stokes shift, 𝑢0 is the numerically estimated Stokes shift with no hydrogen 
bonding interactions, 𝑢𝑎 and 𝑢𝑏 are the estimated Stokes shifts with hydrogen 
bonding occurring at either side A or B, finally, 𝑢𝑎𝑏 is the calculated Stokes shift 
Table 3.3 Theoretical and observed fluorescence λex/em in methanol, used to 
calculate a probability of hydrogen bonding (P). 
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for both hydrogen bonding events occurring at A and B. Both hydrogen bonding 
events A and B are assumed to be of equal probability. Assuming this, the positive 
real root of P can be solved to give an average rate/probably of hydrogen bonding 
occurring.  
 
𝑝2(𝑢𝑎𝑏) +  𝑝(1 −  𝑝)(𝑢𝑎  +  𝑢𝑏) +  ((1 −  𝑝)2 ∗  𝑢0) −  𝑧 =  0 (Eq. 3.3)  
 
The trend observed in P values correlates well with the observed trend in 
Stokes shift and suggests that the bulky silyl groups are indeed providing 
protection from solvent quenching interactions. iPrMAM has the largest Stokes 
shift (150 nm) and P value at 1.23, suggesting the greatest influence of solvent. 
With a P value over 1, this suggests either an error with the theoretical modelled 
values or that more than two H-bonding events per molecule are occurring on 
average, which could be envisioned. At the other end of the scale, TBDMSi-MAM 
shows the lowest Stokes shift (110 nm) and the lowest P value (0.23). The 
combination of trend in Stokes shift and estimated P values suggests successful 
shielding against EDPT in methanol. Unfortunately, these compounds are not 
water-soluble and the increase in size negates the benefit of maleimide dyes being 
small, neutral fluorophores. Therefore, the use of these dyes for peptide-based 
applications, such as fluorescent labelling, will not be investigated further. 
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2.4 Conclusions 
 
To summarize, the effect of imide substitution on the emission of maleimide 
fluorophores has been explored, through introduction of aryl and silyl groups. In 
general, direct conjugation of an aromatic group to the maleimide unit quenches 
fluorescence in solution. However, this quenching is also observed in a trityl 
functionalized dye where electron density is withdrawn through a quaternary 
carbon. This same dye also appeared to exhibit AIE as the quantum yield 
significantly increased to 79% in the aggregate state. However, by analyzing the 
crystal structures of the series, including measuring π-π separation and modelling 
the NCI and HOMO-LUMO isosurfaces, it is clear that most dyes exhibit mild 
aggregation caused quenching as a cause of π-π and H-bonding interactions. 
However, in Bz3MAM the presence of a bulky trityl group simply prevents such 
interactions leading to the impressive solid-state quantum yield. This was proven 
further through polymer powder incorporation which increased the emission of all 
non-shielded dyes, suggesting that ‘AIE’ effects can be amplified through 
increasing dye separation in the solid-state, an important consideration when 
designing AIE probes for macromolecular applications.  
In regards to the silyl derivatives, the steric hindrance introduced through 
silyl derivatives has been shown to increase fluorescence emission in polar protic 
solvents, with a Φf(%) up to 11% in MeOH. The reduced interaction with solvent is 
also exhibited by reduced Stokes shift in silyl-maleimides, and expressed as an 
estimated probability of hydrogen bonding or P.  
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2.5 Experimental 
2.5.1 Materials and instrumentation 
All chemicals were obtained from either: Sigma Aldrich, Fisher Chemicals, 
Acros Chemicals, Carbosynth or Alfa Aesar and used as received.  
NMR spectra were recorded on a Bruker Advance 300, a Bruker Advance III 
HD 400 or a Bruker Advance III HD 500 spectrometer at 300, 400 and 500 MHz 
respectively. Shifts are quoted in δ in parts per million (ppm) and quoted relative 
to the internal standard trimethylsilane (TMS) or the solvent peak. 
High Resolution Mass Spectra (HR-MS) were conducted by Dr Lijiang Song 
(University of Warwick) on a Bruker UHR-Q-ToF MaXis spectrometer with 
electrospray ionization, or by Dr Christopher Williams (University of Birmingham) 
on a Waters Xevo G2-XS.  
Infrared spectra were recorded on neat samples using a Perkin Elmer 
Spectrum 100 FT-IR Spectrometer. UV-Vis spectroscopy was carried out on a 
Perkin Elmer Lambda 35 UV/vis spectrometer or an Agilent Cary 60 UV-Vis 
Spectrometer at room temperature.  
Fluorescence emission and excitation spectrum were obtained with an 
Edinburgh Instruments FS5 Spectrofluorometer in quartz 3.5 mL cuvettes for liquid 
samples (Starna Cell, Type: 3/Q/10), and analyzed in Fluoracle (Edinburgh 
Instruments) and Origin 2019 (Origin Labs). Solution state quantum yield analysis 
was based on a previously reported literature procedure.37 In short, a solution of 
quinine sulfate dihydrate (15 µmol) in 0.105 mol/L perchloric acid was used a 
standard (Φqunine = 59%), from which a UV–visible spectrum was recorded. The 
sample was diluted until the absorbance was between 0.05 - 0.1 and then the 
emission spectra at λmax was measured.   
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For solid-state fluorescence, absolute fluorescence quantum yields were 
recorded with an integrating sphere set up. The dye solid was crushed into a fine 
powder, and approximately 1-10 mg of the dye was placed onto a circular solid-
state holder for analysis. All dyes were recorded with 375 nm excitation; with a 
7-8 nm excitation slit and 0.1-0.2 nm emission slit width. Dyes were measured in 
triplicate and the mean and standard deviation (σ) recorded. 
Crystals were grown by dissolving several milligrams of the dye in around 
5 mL of CH2Cl2/hexane, in a small vial with a lid. This was placed in a sealed jar 
quarter filled with hexane. A needle was placed into the vial to allow solvent 
exchange with the jar reservoir. This was left on a windowsill for 2-4 weeks until 
crystals were observed. The datasets for HMAM, BzMAM, Bz2MAM and Bz3MAM 
were measured on an Agilent SuperNova diffractometer using an Atlas detector. 
Structures were collected and solved by Dr Louise Male. More information on the 
structures can be found in the publication. CCDC1955637 – CCDC1955640 contain 
the supplementary crystallographic data for this Chapter. These can be obtained 
free of charge from The Cambridge Crystallographic Data Centre via 
www.ccdc.cam.ac.uk/data_request/cif. 
2.5.2 Small molecule synthesis and characterization 






Bromomaleic anhydride (1 g, 5.6 mmol) was dissolved in acetic acid (25 
mL) in a round bottom flask containing a stirrer bar. To this benzylamine (642 mg, 
6.4 mmol) was slowly added. This was refluxed for 4 hours and then left to cool. 
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The solvent is removed in vacuo and then purified by silica column 
chromatography and eluted with 20% CHCl2 in hexane. The product was obtained 
as a yellow powder (984 mg, 26%). 
1H NMR (300 MHz, CDCl3, ppm) δ = 7.38 – 7.28 (m, 5H, ArH), 6.87 (s, 1H, CH), 
4.71 (s, 2H, CH2). 
13C NMR (101 MHz, CDCl3, ppm) δ = 168.21 (CO), 165.04 (CO), 135.63 (CH), 
131.92 (CBr), 131.51 (ArC), 128.80 (ArC), 128.62 (ArC), 128.14 (ArC), 42.40 
(CH2). 
HR-MS (MaXis) - [M+Na+] – calculated m/z 265.9813, observed m/z 265.9817;  
FTIR (cm-1) - 3093 (υAr-H), 2933 (υC-H), 1705 (υC=O).  
 
Figure 3.17: 1H NMR spectrum of 3.1 (300 MHz, CDCl3). 
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Bromomaleic anhydride (1 g, 5.6 mmol) was dissolved in acetic acid (25 
mL) in a round bottom flask containing a stirrer bar. To this diphenylmethylamine 
(1.03 g, 5.6 mmol) was slowly added. This was refluxed for 15 hours and then left 
to cool. The solvent is removed in vacuo and then the orange solid was purified 
by silica column chromatography and eluted with 10% diethyl ether in hexane (Rf 
= 0.1). The product was obtained as a yellow powder (415 mg, 22%). 
 
Figure 3.18: 13C NMR spectrum of 3.1 (101 MHz, CDCl3). 
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1H NMR (500 MHz, CDCl3, ppm) δ = 7.48 – 7.17 (m, 10H, ArH), 6.89 (s, 1H, CH), 
6.54 (s, 1H, ArCH). 
13C NMR (126 MHz, CDCl3, ppm) δ = 168.1 (CO), 164.9 (CO), 137.6 (CH), 131.8 
(CBr), 131.5(CAr), 128.6 (ArC), 128.5 (ArC), 128.0 (ArC), 58.6 (CH). 
HR-MS (MaXis) - [M+Na+] – calculated m/z 363.9944 observed m/z 363.9942;  
FTIR (cm-1) – 3096 (υAr-H), 2910 (υC-H), 1705 (υC=O), 1656 (υC=O). 
 
Figure 3.19: 1H NMR spectrum of 3.3 (500 MHz, CDCl3). 
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Under dry conditions, a solution of monobromomaleimide (2.1, 0.25 g) and 
trityl chloride (0.42 g) in dry CHCl2 was cooled to 0 °C. To this, triethylamine (160 
mg) was added gradually. After 1 h the reaction was dried. The crude product was 
isolated via column chromatography using 2-3% EtOAc in petroleum ether as the 
eluent to afford cream solid (580 mg, 47%).   
 
1H NMR (500 MHz, CDCl3, ppm) δ = 7.38 (d, 3JHH = 7.5 Hz, 6H), 7.32 – 7.14 (m, 
9H), 6.76 (s, 1H). 
 
 
Figure 3.20: 13C NMR spectrum of 3.3 (126 MHz, CDCl3). 
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13C NMR (126MHz, CDCl3, ppm) δ = 168.4 (CO), 165.1 (CO), 142.0 (CBr), 132.6 
(CH), 131.9 (CAr), 128.6 (CAr), 127.7 (CAr), 127.0 (CAr), 76.4 (C). 
HR-MS (MaXis) - [M+Na+] – calculated m/z 440.0257 observed m/z 440.0256;  




Figure 3.21: 1H NMR spectrum of 3.5 (500 MHz, CDCl3). 
 
Figure 3.22: 13C NMR spectrum of 3.5 (126 MHz, CDCl3). 
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Under dry conditions, a solution of dibromomaleimide (0.5 g) and trityl 
chloride (0.6 g) in dry CHCl2 was cooled to 0 °C. To this, triethylamine (218 µl) 
was added gradually. After 1 h 15 min the reaction was dried. The crude product 
was isolated via column chromatography using 5% EtOAc in petroleum ether as 
the eluent, to afford cream solid (240 mg, 26%).   
 
1H NMR (400 MHz, CDCl3, ppm) δ = 7.31 – 7.21 (m, 5H, ArH). 
13C NMR (101 MHz, CDCl3, ppm) δ = 163.7 (CO), 141.7 (CBr), 130.2 (CAr), 128.5 
(CAr), 127.8 (CAr), (CAr), 127.0 (CAr), 75.2 (CN). 
HR-MS (Xevo) - [M+Na++MeOH] – calculated m/z 549.9624 observed m/z 
549.9611; 
FTIR (cm-1) – 3056 (υC-H), 1716 (υC=O) 






Figure 3.23: 1H NMR spectrum of 3.6 (500 MHz, CDCl3). 
 
Figure 3.24: 13C NMR spectrum of 3.6 (126 MHz, CDCl3). 
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Overnight, a solution of bromomaleimide (2.1, 1 g) and isopropyl amine 
(480 µl) in acetic acid (25 ml) was refluxed at 118 °C. After, the reaction was 
dried in vacuo with the addition of toluene. The crude product was isolated via 
column chromatography using 10-20% EtOAc in petroleum ether as the eluent to 
afford cream solid (409 mg, 34%).    
 
1H NMR (300 MHz, CDCl3, ppm) δ = 6.82 (s, 1H, CH), 4.39 (Hept., 3JHH = 6.8 Hz, 
1H, CH), 1.41 (d, 3JHH = 6.8 Hz, 6H, CH3). 
13C NMR (75 MHz, CDCl3, ppm) δ = 169.0 (CO), 164.9 (CO), 131.7 (CH), 131.1 
(CBr), 43.8 (CH), 20.1 (CH3). 
HR-MS (MaXis) - [M+Na+] – calculated m/z 216.9738 observed m/z 216.9736;  
FTIR (cm-1) - 2974 (υC-H), 1705 (υC=O), 1690 (υC=O)  
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Figure 3.25: 1H NMR spectrum of 3.11 (300 MHz, CDCl3). 
 
Figure 3.26: 13C NMR spectrum of 3.11 (75 MHz, CDCl3). 
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 General procedure for the synthesis of silyl functionalized 
bromomaleimides.  
The reactions followed a similar protocol to Prishchcenko et al.28 In 
summary, the bromomaleimide was dissolved into dry CH2Cl2 under dry 
conditions. To this DIPEA (2.1 eqiuv.) was added followed by the trifluoromethyl 









The crude product obtained from the general procedure, was purified via 
silica column chromatography using 10% EtOAc in petroleum ether as the eluent 
to afford a white solid (197 mg, 20 %).  
 
1H NMR (500 MHz, CDCl3, ppm) δ = 6.83 (s, 1H, CH), 0.92 (s, 9H, CH3), 0.43 (s, 
6H, CH3). 
13C NMR (101 MHz, CDCl3, ppm) δ = 173.8 (CO), 170.5 (CO), 134.0 (CH), 133.4 
(CBr), 26.1 (CH3), 25.7 (CH3), 18.9 (CH). 
HR-MS (Xevo) - [M+Na++MeOH] – calculated m/z 549.9624 observed m/z 
549.9611; 
FTIR (cm-1) – 3056 (υC-H), 1716 (υC=O) 
 Chapter 3   146 
 
 
Figure 3.27: 1H NMR spectrum of 3.17 (500 MHz, CDCl3). 
 
Figure 3.28: 13C NMR spectrum of 3.17 (126 MHz, CDCl3). 









The crude product obtained from the general procedure, was purified via 
silica column chromatography using hexane as the eluent to afford a white solid 
(245 mg, 34 %).  
 
1H NMR (500 MHz, CDCl3, ppm) δ = 6.83 (s, 1H, CH), 0.92 (s, 9H, CH3), 0.43 (s, 
6H, CH3). 
13C NMR (101 MHz, CDCl3, ppm) δ = 168.8 (CO), 131.6 (CBr), 26.1 (CH3), 18.89 
(CCH3), -4.59 (CH3). 
HR-MS (Xevo) - [M+NH3+] – calculated m/z 384.9577 observed m/z 384.9576, 
FTIR (cm-1) - 3052 (υC-H), 1708 (υC=O)  
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Figure 3.29: 1H NMR spectrum of 3.18 (500 MHz, CDCl3). 










The crude product obtained from the general procedure, was purified via 
silica column chromatography using hexane as the eluent to afford a white solid 
(703 mg, 65 %).  
 
 
Figure 3.30: 13C NMR spectrum of 3.18 (101 MHz, CDCl3). 
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1H NMR (500 MHz, CDCl3) δ = 7.60 (d, 3JHH = 7.3 Hz, 4H, ArH), 7.38 (m, 6H, ArH), 
6.89 (s, 1H, CH), 1.21 (s, 9H, CH3).  
13C NMR (126MHz, CDCl3,  ppm) δ = 170.76 (CO), 167.4 (CO), 136.8 (CH), 135.0 
(CAr), 134.0 (CAr), 131.4 (CBr), 129.6 (CAr), 128.0 (CAr), 27.0 (C), 19.15 (CH3). 
HR-MS (MaXis) - [M+Na+] – calculated m/z 436.0339 observed m/z 436.0342;  
FTIR (cm-1) - 3050 (υC-H), 1708 (υC=O), 1690 (υC=O) 
 
Figure 3.31: 1H NMR spectrum of 3.19 (500 MHz, CDCl3). 









The crude product obtained from the general procedure, was purified via 
silica column chromatography using hexane as the eluent to afford a white solid 
(197 mg, 20 %). 
 
Figure 3.32: 13C NMR spectrum of 3.19 (126 MHz, CDCl3). 
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1H NMR (500 MHz, CDCl3, ppm) δ = 7.54 (d, 3JHH = 7.4 Hz, 1H), 7.39 (t, 3JHH = 7.4 
Hz, 1H), 7.32 (t, 3JHH = 7.4 Hz, 1H), 1.15 (s, 2H). 
13C NMR (126 MHz, CDCl3, ppm) δ = 168.2 (CO), 135.5 (CAr), 131.9 (CAr), 130.6 
(CBr), 130.3 (CAr), 127.9 (CAr),  27.8 (CMe3), 19.7 (CH3). 
HR-MS (Xevo) - [M+NH3+] – calculated m/z 508.9896 observed m/z 508.9911,  
FTIR (cm-1) - 2941 (υC-H), 2859 (υC-H), 1705 (υC=O), 1679 (υC=O). 
 
Figure 3.33: 1H NMR spectrum of 3.20 (500 MHz, CDCl3). 
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 General procedure for the synthesis of aminobromo- and 
monoaminomaleimides from bromomaleimides 
The reactions were based of a previously reported procedure.9 For all 
reactions the bromomaleimide (1 equiv.), was dissolved in THF with sodium 
carbonate (2 equiv.). To this a solution of amine in THF (1.05-1.1 equiv.) was 
added dropwise over 30 min. After 40 min – 1 hour the reaction mixture was 
filtered, the filtrate collected and the solvent was removed in vacuo. The resultant 
residue was then purified via column chromatography on silica gel, generally with 






Figure 3.34: 13C NMR spectrum of 3.20 (126 MHz, CDCl3). 
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The crude product synthesized by the above procedure was purified using 
silica column chromatography with an eluent of 5% ethyl acetate in petroleum 
ether, to isolate a yellow solid (107 mg, 40%).  
 
1H NMR (300 MHz, CDCl3) δ = 5.19 (s, 1H), 4.75 (s, 1H), 4.30 (dt, 3JHH = 13.9, 
7.0 Hz, 1H), 3.51 (dq, 3JHH = 13.1, 6.5 Hz, 1H), 1.39 (d, 3JHH = 6.9 Hz, 6H), 1.27 
(d, 3JHH = 6.5 Hz, 6H) 
13C NMR (126 MHz, CDCl3, ppm) δ = 172.7 (CO), 167.6 (CO), 147.8 (CNH), 83.8 
(CH), 46.2 (CH), 42.3 (CH), 21.9 (CH3), 20.2 (CH3) 
HR-MS (MaXis) - [M+Na+] – calculated m/z 219.1104 observed m/z 219.1109; 
FTIR (cm-1) - 2974 (υC-H), 1698 (υC=O), 1636 (υC=O)  
 Chapter 3   155 
 
 
Figure 3.35: 1H NMR spectrum of 3.11 (500 MHz, CDCl3). 
 
Figure 3.36: 13C NMR spectrum of 3.11 (126 MHz, CDCl3). 
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The crude product obtained by the general procedure was purified by silica 
column chromatography (30% EtOAc in petroleum ether) to afford a yellow solid 
(227 mg, 66 %). 
 
1H NMR (300 MHz, CDCl3) δ = 7.37-7.28 (m, 5H), 5.29 (br, 1H), 4.82 (br d, 3JHH 
= 13.1 Hz, 1H), 4.65 (s, 2H), 3.51 (dq, 3JHH = 13.1, 6.5 Hz, 1H), 1.27 (d, 3JHH = 
6.5 Hz, 9H). 
13C NMR (126 MHz, CDCl3, ppm) δ = 172.9 (CO), 167.5 (CO), 148.5 (CNH), 136.5 
(CAr), 127.4-128.7 (m, ArC), 84.4 (CH), 46.1 (CH), 41.0 (CH2), 21.8 (CH3) 
HR-MS (MaXis) - [M+Na+] – calculated m/z 267.1104 observed m/z 267.1104; 
FTIR (cm-1) - 3103 (υAr-H), 2971 (υC-H), 1698 (υC=O), 1621 (υC=O) 




Figure 3.37: 1H NMR spectrum of 3.2 (300 MHz, CDCl3). 
 
Figure 3.38: 13C NMR spectrum of 3.2 (126 MHz, CDCl3). 
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The crude product obtained by the general procedure was purified by silica 
column chromatography (10% EtOAc in petroleum ether) to afford a deep yellow 
solid (198 mg, 62 %). 
 
1H NMR (300 MHz, CDCl3, ppm) δ = 7.28 (m, 10H, ArH), 6.49 (s, 1H, ArCH), 5.19 
(s, 1H, NH), 4.84 (s, 1H, CH), 3.51 (dt, 3JHH = 6.5 Hz, 1H, CH), 1.25 (d, 3JHH = 
6.5 Hz, 6H, CH3). 
13C NMR (126 MHz, CDCl3, ppm) δ = 171.91 (CO), 167.20 (CO), 147.81(CN), 
138.7 (CAr), 128.6 (CAr), 128.3 (CAr), 127.5 (CAr), 84.0 (CH), 56.9 (CH), 46.3 
(CH), 21.8 (CH3). 
HR-MS (MaXis) - [M+Na+] - calculated m/z  343.1417 observed m/z 343.1422; 
FTIR (cm-1) – 2973 (υC-H), 1704 (υC=O), 1634 (υC=O). 










Figure 3.39: 1H NMR spectrum of 3.4 (300 MHz, CDCl3). 
 
Figure 3.40: 13C NMR spectrum of 3.4 (126 MHz, CDCl3). 
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The crude product obtained by the general procedure was purified by silica 
column chromatography (5% EtOAc in petroleum ether) to afford a lime yellow 
solid (36 mg, 37 %). 
 
1H NMR (500 MHz, CDCl3) δ = 7.33 (s, 6H), 7.11-7.20 (m, under solvent peak), 
5.02 (d, 1H), 4.68 (s, 1H), 3.37 (m, 1H), 1.13 (s, 6H). 
13C NMR (CDCl3, 126 MHz, ppm) δ = 172.1 (CO), 168.0 (CO),  147.5 (CN), 142.9 
(ArC), 128.8 (ArC), 127.4 (ArC), 126.5 (ArC), 85.7 (CH), 72.9 (CPh3), 46.1 (CH), 
21.8 (CH3). 
HR-MS (MaXis) - [M+Na+] – calculated m/z 419.1703 observed m/z 419.1730; 
FTIR (cm-1) – 3018 (υAr-H), 2983 (υC-H), 1700 (υC=O), 1624 (υC=O) 







Figure 3.41: 1H NMR spectrum of 3.7 (500 MHz, CDCl3). 
 
Figure 3.42: 13C NMR spectrum of 3.7 (126 MHz, CDCl3). 









The crude product obtained by the general procedure was purified by silica 
column chromatography (2-3% EtOAc in petroleum ether) to afford a lime yellow 
solid (16 mg, 9%). 
 
1H NMR (300 MHz, DMSO-d6, ppm) δ = 7.38 – 7.00 (m, 15H, ArH), 5.06 (d, J = 
8.9 Hz, 1H, NH), 4.33 – 4.08 (m, 1H, CH), 1.17 (d, 3JHH = 6.6 Hz, 6H, CH3). 
13C NMR (126 MHz, CDCl3, ppm) δ = 171.1 (CO), 162.4 (CO), 146.9 (CN), 142.4 
(CBr), 128.7 (CAr), 128.0 (CAr), 127.3 (CAr), 126.7 (CAr), 44.7 (CH), 21.8 (CH3). 
HR-MS (MaXis) - [M+Na+] - calculated m/z 497.0838 observed m/ 497.0841; 
FTIR (cm-1) – 2966 (υC-H), 1704 (υC-H), 1620 (υC-H). 





Figure 3.43: 1H NMR spectrum of 3.8 (300 MHz, CDCl3). 
 
Figure 3.44: 13C NMR spectrum of 3.8 (126 MHz, CDCl3). 









The crude product obtained from the general procedure, was purified via 
silica column chromatography using 5% EtOAc in petroleum ether as the eluent 
to afford clear pale yellow crystals (67 mg, 74 %). 
 
1H NMR (500 MHz, CDCl3, ppm) δ = 5.09 (d, 3JHH = 5.7 Hz, 1H, CH), 4.83 (s, 1H, 
NH), 3.50 (m, 1H, CH), 1.24 (dd, 3JHH = 5.6 Hz, 9H, CH3), 0.94 (s, 9H, CH3), 0.41 
(s, 6H, CH3). 
13C NMR (126MHz, CDCl3, ppm) δ = 177.4 (CO), 173.4 (CO), 148.9 (CN), 87.2 
(CH), 46.3 (CH), 26.3 (CH3), 21.8 (CH3), 18.9 (CH), -4.4 (SiCH3) 
HR-MS (MaXis) - [M+Na+] - calculated m/z   291.1499 observed m/z 291.1502; 
FTIR (cm-1) – 2972 (υC-H), 2938 (υC-H), 1697 (υC=O), 1627 (υC=O). 
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Figure 3.45: 1H NMR spectrum of 3.21 (300 MHz, CDCl3). 
 
Figure 3.46: 13C NMR spectrum of 3.21 (126 MHz, CDCl3). 










The crude product obtained from the general procedure, was purified via 
silica column chromatography using 100% petroleum ether as the eluent to afford 
a yellow solid (110 mg, 47 %). 
 
1H NMR (500 MHz, CDCl3) δ 5.14 (br, 1H, NH), 4.3 (m, 1H, CH), 1.27 (t, 3JHH = 
9.1 Hz, 6H, CH3), 0.94 (s, 9H, CCH3), 0.42 (s, 6H, SiCH3). 
13C NMR (CDCl3, 126MHz, ppm) δ = 172.2 (CO), 171.3 (CO), 143.2 (CNH), 44.5 
(CH), 26.2 (CH), 23.8 (CH3), 18.8 (CMe3), 20.22 (CH3), -4.4 (SiCH3)  
HR-MS (MaXis) - [M+Na+] - calculated m/z 369.0604 observed m/z 369.0601; 
FTIR (cm-1) – 2960 (υC-H), 1701 (υC=O), 1634 (υC=O) 




Figure 3.47: 1H NMR spectrum of 3.22 (500 MHz, CDCl3). 
 
 
Figure 3.48: 13C NMR spectrum of 3.22 (126 MHz, CDCl3). 









The crude product obtained from the general procedure, was purified via 
silica column chromatography using 5% EtOAc in petroleum ether as the eluent 
to afford a pale yellow solid (53 mg, 17 %). 
 
1H NMR (500 MHz, CDCl3, ppm) δ = 7.61 (d, 3JHH = 6.9 Hz, 4H, ArH), 7.45 – 7.30 
(q, 3JHH = 6.9 Hz, 6H, ArH), 5.12 (d, 3JHH = 7.0 Hz, 1H, NH), 4.90 (s, 1H, CH), 
3.57 – 3.42 (m, 1H, CH), 1.27 – 1.17 (m, 15H, CH3). 
13C NMR (126 MHz, CDCl3, ppm) δ = 176.9 (CO), 172.7 (CO), 149.3 (CN), 136.3 
(CAr), 134.3 (CAr), 132.6 (CAr), 130.0 (CAr), 127.7 (CAr), 127.3 (CAr), 87.4 
(CH), 46.8 (CH), 28.0 (CH3), 26.7 (CH), 22.0 (CH3). 
HR-MS (MaXis) - [M+Na+] - calculated m/z 415.1812 observed m/z 415.1813; 
FTIR (cm-1) – 2941 (υC-H), 2859 (υC-H), 1694 (υC=O), 1623 (υC=O). 





Figure 3.49: 1H NMR spectrum of 3.23 (500 MHz, CDCl3). 
 
Figure 3.50: 13C NMR spectrum of 3.23 (126 MHz, CDCl3). 









The crude product obtained from the general procedure, was purified via 
silica column chromatography using 5% EtOAc in petroleum ether as the eluent 
to afford a pale yellow solid (17 mg, 27 %). 
 
1H NMR (500 MHz, CDCl3, ppm) δ = 7.60 (d, 3JHH = 7.7 Hz, 4H, ArH), 7.40 (m, 
6H, ArH), 5.16 (d, 3JHH = 12.2 Hz, 1H, NH), 4.44 – 4.33 (m, 1H, CH), 1.27 (t, 3JHH 
= 7.3 Hz, 6H, CH3), 1.21 (s, 9H, CCH3). 
13C NMR (75 MHz, CDCl3, ppm) δ = 135.5 (CAr), 129.9 (CAr), 127.7 (CAr), 28.0 
(CH3), 23.8 (CH3). 
HR-MS (MaXis) - [M+Na+] – calculated m/z 493.0920 observed m/z 493.0901; 
FTIR (cm-1) – 3019 (υAr-C-H), 2964 (υC-H), 1701 (υC=O), 1636 (υC=O) 
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Figure 3.51: 1H NMR spectrum of 3.24 (500 MHz, CDCl3). 
 
Figure 3.52: 13C NMR spectrum of 3.24 (126 MHz, CDCl3). 
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2.5.3 Fluorophore incorporation into PEG powders 
Fluorophore containing PEG powders were prepared as follows. Firstly, PEG 
(12 kDa) was dissolved into chloroform (20 mg/mL). To this, the selected MAM or 
4-(1,2,2-Triphenylvinyl)benzaldehyde was added at 0.1 mg/mL and this solution 
was dropped into a circular mould of approx. 1 cm depth. The chloroform was left 
to evaporate, and the resultant powder was then added to the fluorimeter solid-
state holder for analysis. Powders without MAM were also prepared using the same 
method, and used as scattering controls for the absolute quantum yield analysis.  
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3 Chapter 4:  Synthesis of 
aminomaleimide functionalized 
fluorescent amino acids for 
incorporation into peptides through 
codon re-allocation techniques 
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3.1 Abstract 
 
The uniquely small size of maleimide dyes means that there are numerous 
novel applications for them in enzyme-based research where larger dyes would 
not be appropriate. It is hypothesized herein that these dyes could be incorporated 
into buried residues of enzymes without disturbing enzyme integrity, a challenge 
currently unrealized. This chapter will focus on synthesizing non-canonical amino 
acids functionalized with aminomaleimide dyes for genetic expression into 
peptides. Four probes were targeted: two zwitterionic amino acids for traditional 
tRNA orthogonal synthetase incorporation, and two activated ester variants for 
flexizyme based incorporation. Difficulties were encountered with the synthesis of 
un-activated aminomaleimides, mainly a result of purification and solubility issues. 
However, aminobromomomaleimide functionalized lysine and 
aminochloromaleimide functionalized ornithine were synthesized successfully and 
the former was isolated using preparative HPLC. In regards to the activated 
compounds, the activated dinitrobenzyl (DNB)-ester variant was synthesized 
successfully over four steps. Unfortunately, incorporation into peptides was poor 
and therefore a more water-soluble amino-derivatized benzyl thioester (ABT) 
ester variant was targeted. Synthesis of this ABT derivative was successful over 
an eight-step divergent synthesis through reaction of a synthesized ABT group 
with previously realized ACM-ornithine. This compound has been sent to 
collaborators and has been successfully incorporated into peptides mediated 
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3.2 Introduction 
3.2.1 Non-canonical amino acid incorporation into 
peptides 
Polypeptides have a wide variety of structures and functions, yet nature has 
a toolbox of only 20 standard amino acids for their synthesis. However, over 500 
examples of rare non-canonical amino acids have been observed in nature, for 
example, selenocystine and D-serine.1,2 The observation of these rarer amino 
acids has led researchers to focus on synthesizing novel amino acids which may 
impart useful novel functions to peptides.3 These unnatural amino acids (uAA) can 
be incorporated by in vivo protein biosynthesis via processes such as amber 
suppression.4,5 In this process a stop codon (specifically UAG) is re-assigned to a 
new uAA. This is achieved through derivatization of the tRNA/synthetase pair, 
which recognizes this codon, through aminoacylation of tRNA with the new uAA.5 
This process is catalyzed by an orthogonal aminoacyl tRNA synthase (Figure 4.1). 
This process requires directed evolution of this enzyme towards the aim of 
specifically recognizing the new unnatural amino acid over all other natural amino 
acids that will be present in expression media. Once achieved, this uAA 
functionalized tRNA/synthetase pair can then be utilized in translation of peptides; 
instead of stopping the synthesis at a UAG codon, the uAA is incorporated and 
translation can continue (Figure 4.1B). A limitation of this methodology, is that 
the amino acid must fit into the active site of an extensively evolved orthogonal 
synthetase, hence limiting the introduction of some non-natural amino acids.5 
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Recently, new machinery has been developed to overcome this hurdle. One 
such technology is flexizymes, which are ribozymes that have been developed to 
catalyze the aminoacylation step.6,7 They are evolved to recognize only activated 
amino acids ensuring that only the desired amino acid will be acylated (Figure 
4.2). Two activating groups that have been successfully utilized for this include 
cyanomethyl esters (CME) and 3,5-dinitrobenzyl esters.7 
 
Figure 4.1: (A) Aminoacylation of tRNA with a uAA and (B) subsequent 
incorporation of the uAA into a peptide by a ribosome. 
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Figure 4.2: Illustration of flexizyme charging with a CME activated amino 
acid. 
 
3.2.2 Fluorescent labelling of proteins though genetic 
incorporation   
Fluorescent labelling of proteins is a widespread practice.  It is used for 
many applications, including studying intracellular trafficking,8,9 tracking cellular 
uptake,10 measuring conformational changes,11–13 and environmental sensing.14 
Commonly this is achieved by conjugating fluorescent proteins to the target.15 Not 
only may the large size of such proteins have a significant effect on the properties 
and function of the target, but they are prone to photobleaching.16,17 Another 
strategy is to conjugate a small molecule fluorophore to the studied protein via an 
amino acid residue.18,19  Often this is achieved by incorporating a non-natural 
amino acid into the protein through genetic expression, which can then be 
selectively conjugated to a dye, for example, azide functionalized amino acids can 
be modified using CuAAC.20–23    
The incorporation of fluorescent dyes genetically, eliminating the need for 
conjugation, is seen as the best way to site selectively label proteins, as tricky 
purification steps can be avoided, and side reactions can be eliminated.24 The 
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Schultz group has successfully genetically incorporated several dyes including 
dansyl,25 7-hydroxycoumarin26 and prodan27 (Figure 4.3).  
 
Figure 4.3: Fluorescently labelled amino acids that have been genetically 
expressed into proteins by the Schultz group.25–27 
 
These dyes were utilized for various applications, for example, the dansyl 
labelled amino acid was incorporated into human superoxide dismutase (hSOD) 
using an amber nonsense codon and corresponding orthogonal tRNA/aminoacyl-
tRNA synthetase pair.25 The denaturing of the labelled enzyme could be measured 
by studying fluorescence emission wavelength and intensity. Notably, the 
expressed amino acids are incorporated at solvent-accessible residues, such as in 
place of Gln-16 and Trp-33 in hSOD. 
Genetic expression could theoretically allow incorporation of residues 
anywhere in an enzyme sequence - dependent on enzyme-specific factors - so 
that the maleimide dye could theoretically be buried deep within the tertiary 
structure where it would be shielded from the solvent, and where traditional 
conjugations would not be able to target. It could also be site-specifically 
incorporated for applications such as active site labelling, and for studying protein-
protein interactions, a topic of great importance to research into protein 
aggregation related diseases such as Creutzfeldt–Jakob disease (CJD) and 
Alzheimer's.28,29 The goal of this chapter will be to synthesize aminomaleimide 
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functionalized amino acids for genetic expression testing, towards applications 
such as these. Initially, this will focus on synthesis of zwitterionic amino acids for 
expression through an orthogonal aminoacyl tRNA synthetase catalyzed ligation 
to tRNA.   
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3.3 Results 
3.3.1 Synthesis of an aminomaleimide based amino acid 
for incorporation into aminoacyl tRNA  
Aminoacyl tRNA synthetase catalyzes the formation of aminoacyl tRNA 
between the reaction of an amino acid and the 2'- or the 3'-OH of the final 
nucleotide at the 3' tRNA end.11 This is the target for initial incorporation, and 
therefore a maleimide functionalized unnatural amino acid suitable for this 
application was targeted. As DTMs have shown to be susceptible to thiol 
exchange,30 which could easily occur in cellular growth media, an aminomaleimide 
product was designed.  
 
The first targets were MAM variants which are smaller than their 
corresponding halogenated maleimide dyes and were theorized to be simply 
synthesized from functionalization of readily available amino functionalized amino 
acids for example: lysine or DAP (2,3-diaminopropionic acid). Initially 
monobromomaleimide (4.1) was synthesized as per a literature procedure,31 for 
reaction with Fmoc protected amino acids (Scheme 4.1). 
 
Scheme 4.1: Synthesis of MAM-Fmoc-lysine (4.3) via bromomaleimide (4.1). 
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The reaction of 4.1 with both Fmoc-DAP and Fmoc-lysine, did not proceed 
appreciably in either THF or acetonitrile with NaHCO3 as a base. The reaction of 
Fmoc-lysine did proceed in DMF, however, only a yield of 20% could be obtained 
(which also contained residual DMF). It was decided to focus on the reaction of N-
methyl-dibromomaleimide (M-DBM) with Fmoc-lysine, because of these issues. 
O’Reilly and co-workers have found that the allylic hydrogen on 
monobromomaleimide can be more reactive than the bromine analogue.32 In 
addition, the methyl imide was targeted to prevent imide nucleophillicty. The 
reaction of M-DBM with Fmoc-lysine in the presence of Na2CO3 in MeOH gave 4.4 
in 24% isolated yield (Scheme 4.2). Unexpectedly, it was noted that precipitation 
of dibenzofulvene occurred during the reaction, suggesting a cause for the poor 
yield could be unexpected Fmoc deprotection.   
Deprotection of 4.4 was attempted under several conditions including 
piperidine in THF and in 1:1 mixture of piperidine : DMF (v/v). However, all 
conditions explored resulted in a poor yield (1-10%) of impure ABM-lysine (4.5), 
which could not be successfully purified by extraction or column chromatography. 
It has been reported in the literature that piperidine-dibenzofulvene adducts can 
 
Scheme 4.2: Synthesis of ABM-Fmoc-lysine 4.4 and attempted deprotection to 
ABM-lysine 4.5. 
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form in these reactions.33 In these cases piperazine loaded polystyrene can be 
utilized to scavenge any dibenzofulvene adducts.34 Thus, resin-bound piperazine 
was treated with 4.4, which produced ABM-lysine (4.5) in 21% yield, but at only 
67% purity according to 1H NMR spectroscopy. A preparative HPLC purification 
method was developed, and this achieved successful isolation of 52 mg of pure 
compound 4.5, pure by 1H NMR spectroscopy (Figure 4.4). 
 
During this time, work in the group developed aminochloromaleimides 
(ACMs) which are smaller, more fluorescent and less reactive towards some 
nucleophiles than their ABM analogues.35 As a result of this and the issues 
encountered above with Fmoc chemistry, a new synthetic route was proposed 
through the reaction of a synthesized dichloromaleimide (4.6 or 4.7) with N-Boc-
OtBu-ornithine. This route requires the large scale synthesis of chlorinated 
maleimides. However, while syntheses of chlorinated maleimides have been 
reported in the literature,36,37 attempts at repeating them were unsuccessful with 
low yields. Therefore, investigation into optimizing the synthesis of both H-DCM 
 
Figure 4.4: 1H NMR spectrum of 4.5 (400 MHz, D2O). 
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Table 4.1: Summary of conditions attempted for the synthesis of 
dichloromaleimides 4.6 and 4.7. 
. 
(4.6) and M-DCM (4.7), both suitable for ornithine substitution, was conducted 
(Table 4.1). 
Initially, a synthesis from dichloromaleic acid using methyl ammonia was 
attempted as reported by Nirogi et al. (entry 1).37 However this resulted in a 
fluorescent yellow solid isolated as the major product, identified to be 




It was hypothesized that the presence of base favoured chloro- substitution 
over imide substitution, thus leading to the observation of significant side product. 
However, removal of base led to very slow conversion when using the 
methylammonium HCl salt (entry 2), and when used as the free base in solution 
double addition was again observed (entry 3).  
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Another literature protocol had been reported, which involved the 
chlorination of maleimide species using thionyl chloride.36 This synthesis was 
attempted and it was noted that upon addition of piperidine to thionyl chloride a 
violent reaction took place, resulting in a brown precipitate (entries 4-5). Cooling 
to -78 C for the piperidine addition, and adding the piperidine dropwise and 
diluted in CH2Cl2 avoided formation of the precipitate, and the isolated yield from 
the reaction could be considerably increased to around 50% (entries 7-8 and 
Scheme 4.3). 
 
Having obtained 4.6 in a reliably sufficient yield, its reaction with N-Boc-
OtBu-Ornithine was attempted (Scheme 4.4). Using previously developed 
aminomaleimide synthesis conditions, specifically with base in THF for an hour, 
formation of the protected ACM functionalized amino acid 4.8 was successful, in 
fair yield (32%). Longer reaction times led to imide substitution side reactions. 
The convenient one-step deprotection of 4.8, to form ACM amino acid 4.9, was 
completed in TFA/CH2Cl2 (1:1) over 4 hours. Compound 4.9 was characterized by 
1H NMR spectroscopy (Figure 4.4.5), 13C NMR spectroscopy (Figure 4.20), high 
resolution mass spectroscopy and infrared spectroscopy.   
 
Scheme 4.3: Optimized synthesis of chlorinated maleimides 4.6 and 4.7.  
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Fluorescence excitation and emission were recorded for both 4.9 and 4.5 
to ensure they exhibited suitable fluorescence for the application. Both dyes 
showed fluorescence with characteristic λmax and weak emission in water (Figure 
4.6), as expected from maleimide fluorophores. 
 
Scheme 4.4: Synthesis of  ACM-N-Boc-OtBu-Ornithine 4.8 and deprotection to 
ACM-Ornithine 4.9. 
 
Figure 4.5: 1H NMR spectrum of 4.9 (400 MHz, D2O). 
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3.3.2 Synthesis of an activated aminomaleimide based 
amino acid for flexizyme incorporation 
 Flexizyme based methods of tRNA acylation have recently been 
developed as discussed in the introduction, and this technique can save a 
considerable amount of time in the expression and optimization stages, compared 
to tRNA synthetase based expression. Unfortunately, compounds 4.4 and 4.9 are 
not compatible with flexizyme based incorporation techniques and therefore a new 
synthetic target was required. Loading of the flexizyme with an amino acid 
requires activation of the carboxylic acid via a water-soluble activated ester. Early 
work had shown the dinitrobenzyl (DNB) activating group to be effective and 
generally easy to synthesize.38 Therefore, the dinitrobenzyl ester of compound 4.8 
was targeted, by synthesis through an N-Boc-ACM-ornithine intermediate 
(Scheme 4.5).  
 
Figure 4.6: Fluorescence excitation (dashed line) and emission (full line) of 
4.5 and 4.9 at 10 µM in water. 
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 The synthesis of M-DCM, 4.7, was targeted to help add stability to the 
maleimide, while also preventing the imide from acting as a nucleophile. The new 
chlorination reaction developed for 4.6 was found to also work well for this 
derivative producing 4.7 in 55% yield. This was used to functionalize N-Boc-
ornithine to form Nδ-methyl-ACM-N-Boc-ornithine, 4.10, however the yield for 
this reaction was again low (15%). To create the DNB ester, 4.10 was reacted 
with 3,5-dinitrobenzyl chloride, under basic conditions in the dark, which formed 
DNB ester, 4.11, in 49% yield. Finally, the deprotection of 4.11 was completed 
through treatment with 1 M HCl in dry ethyl acetate, overnight in the dark. The 
product precipitated and could be isolated through centrifugation to produce the 
product amino acid 4.12 in 60% yield.  
 
Scheme 4.5: Synthesis of DNB ester of ACM-Ornithine (4.12) via N-Boc-ACM-
Ornithine (4.10). 
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Activated amino acid, 4.12, was sent to collaborators for flexizyme 
incorporation evaluation. Unfortunately, only partial N-terminal incorporation 
could be achieved, and no mid-chain incorporation – attributed to poor solubility 
of the hydrolysis product in water. During the development of this synthesis, the 
group had increased success with a new amino-derivatized benzyl thioester (ABT) 
activating ester. As a result, the synthesis of an ABT activated ACM functionalized 
amino acid was targeted, in the hopes of increased flexizyme charging. To achieve 
this the ABT activating group was synthesized based on a literature procedure.39 
Modifications were made to this protocol primarily as a result of solubility issues 
not described in the manuscript. Formation of disulfide acid 4.13 was successfully 
reproduced in 70% yield over 2 steps (Scheme 4.6). However, this product was 
not soluble in dioxane as described and therefore reaction of 4.13 with 
ethylenediamine (EDA) was conducted in DMF using an EDC coupling (Scheme 
4.6). The purified disulfide 4.14 was then reduced with TCEP to form the free thiol 
ABT 4.15 in >95% yield. 
  
 
Scheme 4.6: Synthesis of disulfide ABT precursor (4.13) and subsequent 
synthesis of ABT thiol (4.15) via reduction of disulfide 4.14 formed by EDC 
coupling of EDA and 4.13. 
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The previously synthesized methyl-ACM-N-Boc-ornithine 4.10 was then coupled 
with 4.15 and EDC.HCl to give the Boc protected ABT thioester ACM-ornithine 
4.16 in 9% yield (Scheme 4.7). TLC analysis (hexane : ethyl acetate) of this 
reaction indicated the formation of many products, with several yellow and UV 
active species observed. Helpfully, only one new fraction was fluorescent, thus 
isolation could be completed via silica column chromatography. The isolated 
product 4.16 was reacted with 1 M HCl in EtOAc under dry conditions to give the 
final ABT activated amino acid 4.17 in 81% yield, which could be isolated by 
simple centrifugation of the crude solution resulting from the precipitation of 4.17. 
Amino acid 4.17 was characterized again by 1H NMR spectroscopy (Figure 4.7), 
13C NMR spectroscopy (Figure 4.34), high resolution mass spectroscopy and 
infrared spectroscopy.   
 
Scheme 4.7: Synthesis of methyl-ACM-ABT-ornithine (4.17) via a Boc-
ABT intermediate (4.16).  
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Analogously to previously synthesized dyes, optical characterization of the 
activated amino acids 4.12 and 4.17 was undertaken, to ensure the dye exhibited 
characteristic maleimide fluorescence properties. Excitation and emission 
wavelengths closely matched expected maleimide values for both dyes with 
quenched red-shifted emission in water (~550 nm – Figure 4.8). For 4.12, no 
obvious effect of the dinitrobenzyl ester on fluorescence emission is observed, 
although this would not be present in the expressed peptide in-any-event. 
 
Figure 4.7: 1H NMR spectrum of 4.17 (300 MHz, DMSO-d6). 
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While synthesis was successful in a yield sufficient for initial testing of 
flexizyme charging, future scale-up may be required for use in vitro. To achieve 
this, optimization of the ornithine ABT coupling in the synthesis of 4.16 is 
suggested. On the other hand, it may be convenient to redesign the synthesis so 












Figure 4.8: Fluorescence excitation (dashed line) and emission (full line) of 
4.12 and 4.17 at 10 µM in water. 
































Scheme 4.8: Suggested alternative synthesis of methyl-ACM-ABT-ornithine 
(4.17). 
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3.3.3 Expression of peptides by ACM charged flexizymes 
Activated amino acids (4.12) and (4.17) were both sent to Dr Joongoo Lee 
of the Jewett group (Northwestern University, IL) for initial incorporation tests 
using their PURExpress cell-free system.39,40 In summary of their work, 4.12 
exhibited poor charging efficiency which was attributed to poor solubility of the 
DNB ester group. However, 4.17 did successfully couple to the 3'-end of two 
flexizymes: fMet(CAU) tRNA and Pro1E2(GGU) tRNA. These charged flexizymes 
were then both added to the PURExpression system and the subsequent product 
peptides were isolated and characterized by MALDI-ToF (Figure 4.9). While the 
ACM containing peptides did not appear to be the major products, ACM containing 
peptides were seen for both C-terminal and N-terminal incorporation sequences.  
 
Figure 4.9: MALDI-ToF spectra of purified peptides obtained by PURExpression 
with amino acid 4.17 charged (top) fMet(CAU) tRNA and (bottom) 
Pro1E2(GGU) tRNA (recorded by Dr Joongoo Lee, Northwestern).  
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3.4 Conclusions  
 
 In conclusion, the synthesis of four new unnatural amino acids has been 
realized. The fluorescence of these has been confirmed in both water and dioxane, 
and while water quenching effects were strong these were expected and 
potentially beneficial for some applications, for example the monitoring of 
denaturing or protein-protein interactions. Incorporation of a DNB activated 
modified amino acid into flexizyme based amino-acylation led to poor 
incorporation efficiencies, while an ABT activated amino has led to successful 
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3.5 Future work  
 
As genetic expression of an ACM amino acid has been realized, using a 
flexizyme based tRNA charging technique, there are several research targets that 
could be investigated. Firstly, incorporation at buried residues should be targeted, 
where emission should be high due to prevention of quenching interactions with 
water. Likely candidates for replacement by an ACM amino acid are large buried 
aromatic residues, such as tyrosine and tryptophan. If the tertiary structure of the 
enzyme can be retained upon the incorporation of the ACM amino acid, along with 
enzyme activity, many applications could be realized. This will be particularly 
powerful as a result of the ACMs uniquely sensitive fluorescence emission to protic 
solvents. For example, as buried ACMs will be shielded from the solvent, they will 
be highly emissive while protein tertiary structure is retained, but upon denaturing 
and unfolding the ACM will be exposed to water and be quenched. Therefore, 
enzyme integrity will be directly relatable to fluorescence emission and in addition, 
fluorescence lifetime may be even more informative of enzyme configuration as 
small changes in nearby residues may impart changes to fluorescence lifetime. An 
example buried residue for mutation could be W28 in HLZ (Figure 4.10), which is 
completely solvent inaccessible and an enzyme of familiarity to the group. More 
complex applications can also be envisioned, such as incorporating the dye near 
to the active site of an enzyme to visualize docking of substrates or inhibitors. 
Through expulsion of water from the active site upon substrate binding, 
fluorescence intensity and lifetime will increase giving an enzyme activity or 
inhibition responsive fluorescence emission. Such a residue in HLZ could be W109 
which is located on the opposite side of the pocket to the nucleophilic aspartic acid 
residue (Figure 4.10). 






















Figure 4.10: Location of W28 (yellow) and W109 (green) in HLZ, potential 
mutation targets for an ACM amino acid, with nearby active site for W109 
(red). PDB structure: 1LZ1.41 
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3.6 Experimental 
3.6.1 Materials and instrumentation 
Amino acids were received from BACHEM or Iris Biotech. All other chemicals 
were obtained from either: Sigma Aldrich, Fisher Chemicals, Acros Chemicals, 
Carbosynth or Alfa Aesar and used as received.  
NMR spectra were recorded on a Bruker Advance 300, a Bruker Advance III 
HD 400 or a Bruker Advance III HD 500 spectrometer at 300, 400 and 500 MHz 
respectively. Shifts are quoted in δ in parts per million (ppm) and quoted relative 
to the solvent peak. 
High Resolution Mass Spectra (HR-MS) were conducted by Dr Lijiang Song 
(University of Warwick) on a Bruker UHR-Q-ToF MaXis spectrometer with 
electrospray ionization, or By Dr Chi Tsang or Dr Christopher Williams (University 
of Birmingham) on a Waters Xevo G2-XS.  
FTIR spectroscopy was carried out using an Agilent Technologies Cary 630 
FTIR spectrometer. 16 Scans from 600 to 4000 cm-1 were taken at a resolution of 
4 cm−1, and the spectra were corrected for background absorbance. 
UV-Vis spectroscopy was performed on Evolution 350 UV-Vis 
spectrophotometer equipped with Xenon Flash Lamp light source and Dual 
Matched Silicon Photodiode detectors. 
Fluorescence emission and excitation spectrum were obtained with an 
Edinburgh Instruments FS5 Spectrofluorometer in quartz 3.5 mL cuvettes for liquid 
samples (Starna Cell, Type: 3/Q/10), and analyzed in Fluoracle (Edinburgh 
Instruments) and Origin 2019 (Origin Labs).  
Prep-HPLC was carried out on an Agilent 1260 infinity system on an ACE 
C18 150 x 21.1mm column using a water (0.03% formic acid): acetonitrile (0.03% 
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formic acid) gradient. Specific methods are given specifically in each molecules 
experimental method.  
3.6.2 Small molecule synthesis  






The synthesis was based on a previously reported literature procedure.31 
Maleimide (10 g, 0.102 mol) and bromine (20 g, 0.13 mol) were solubilized in 
chloroform (200 ml) and were refluxed for 1 hour. The solution was cooled to 
precipitate a product. The product was filtered and washed with very cold 
chloroform, to afford 16.4 g (40%) of 2,3-dibromosuccinimide. Subsequently, 12 
g (0.046 mol) of 2,3-dibromosuccinimide was dissolved in THF, and to this NaHCO3 
(4.3 g, 0.051 mol) was added. The mixture was refluxed for 2 hours. Solvent was 
removed in vacuo and the product was re-dissolved in ethyl acetate (EtOAc) and 
this was washed with water and brine, and then dried over MgSO4. Solvent 
removal in vacuo afforded the product as a pale yellow solid (60%). Rf (9:1 
petroleum ether: EtOAc): 0.45. 
 
1H NMR (DMSO-d6, 400 MHz, ppm): δ = 11.28 (br, 1H, NH) 7.31 (s, 1H, CH); 
MS (ESI) - [M+H]+: observed: 175.9 calculated: 175.9 
Matches literature data.31  









To a solution of dibromomaleimide (2 g, 7.4 mmol) in methanol (100 ml) 
was added Fmoc-lysine-OH (2.2 g, 6 mmol) and K2CO3 (1.24 g, 9 mmol). The 
solution was stirred for 3 hours after which the solution was filtered to remove 
salts and the filtrate was evacuated in vacuo.  The resultant solid was purified by 
silica column chromatography and eluted with a mixture of EtOAc: petroleum 
ether: acetic acid (10:10:1) (Rf = 0.20 – broad). The product was obtained as a 
yellow solid 4.4 (24%).  
 
1H NMR (500 MHz, DMSO-d6, ppm) δ = 7.90 (d, 3JHH = 7.5 Hz, 2H, ArH), 7.80 – 
7.69 (m, 2H, ArH), 7.64 (d, 3JHH = 8.0 Hz, 1H, NH), 7.43 (t, 3JHH = 7.5 Hz, 2H, 
ArH), 7.33 (t, 3JHH = 7.5 Hz, 2H, ArH), 4.35 – 4.19 (m, 3H, CH + CH2), 3.93 (dt, 
3JHH = 8.6, 4.8 Hz, 1H, CH2), 3.47 (t, 3JHH = 7.2 Hz, 2H, CH2), 2.85 (s, 3H, CH3), 
1.76 – 1.49 (m, 4H, CH2), 1.38 (m, 2H, CH2). 
13C NMR (125 MHz, DMSO-d6, ppm) δ = 174.4 (CO), 166.0 (CO), 156.6 (CO), 
144.3 (COON), 141.2 (CN), 128.1 (CAr), 127.5 (CAr), 125.7 (CAr), 120.9 (CAr), 
66.1 (CH), 54.2 (CH2), 47.1 (CH), 42.3 (CH2), 30.8 (CH2), 30.8 (CH2), 24.5 (CH3), 
23.0 (CH2). 
HR-MS (MaXis): [M+H]+ calculated m/z 555.1004 observed m/z – 555.0083; 
FTIR (cm-1): 3320 (υO-H), 2900 (υC-H), 1704 (υC=O), 1643 (υC=O). 
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Figure 4.11: 1H NMR spectrum of 4.4 (500 MHz, DMSO-d6). 
 
Figure 4.12: 13C NMR spectrum of 4.4 (125 MHz, DMSO-d6). 









Piperazine functionalized polystyrene resin (3.5 g, 3.5 mmol) was swollen 
with DMF (5 ml) in an end-capped syringe. ABM-Fmoc-Lysine 4.4 (300 mg, 0.5 
mmol) was dissolved in DMF (5 mL) and added to the syringe. The vessel was 
stirred overnight. The resin was then washed with DMF and water to collect 
product. The solvent was removed in vacuo to produce a yellow solid, which was 
isolated by prep-HPLC to give a yellow solid 4.5 (52 mg isolated). The eluent used 
was a gradient of acetonitrile in water, see HPLC chromatogram (Figure 4.17) for 
exact composition.  
 
1H NMR (300 MHz, D2O, ppm) δ = 3.65 (t, 3JHH = 6.2 Hz, 1H, CH), 3.57 (t, 3JHH = 
7.0 Hz, 2H, CH2), 2.87 (s, 3H, CH3), 1.82 (dd, 3JHH = 10.4, 5.7 Hz, 2H, CH2), 1.72 
– 1.57 (m, 2H, CH2), 1.46 – 1.28 (m, 2H, CH2). 
13C NMR (101 MHz, D2O, ppm) δ = 174.7 (CO), 171.4 (CO), 166.8 (CO), 145.1 
(CN), 54.6 (CH2), 41.9 (CH), 26.3 (CH2), 23.8 (CH2), 21.4 (CH3). 
HR-MS (Xevo): [M+H]+ calculated m/z 262.0595 observed m/z 262.0602; 
 


















Figure 4.13: 1H NMR spectrum of 4.5 (400 MHz, D2O). 
 
Figure 4.14: 13C NMR spectrum of 4.5 (101 MHz, D2O). 
 









Figure 4.15:  HPLC chromatogram of prep-HPLC run (blue = 375 nm 
detector, red = acetonitrile% in water). 
 





































Figure 4.16: Fluorescence excitation and emission map of 4.5 in dioxane 
(5 µM). 
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The synthesis was developed from a previously reported protocol.36 Initially, 
maleimide (15 g, 0.15 mol) was added to a 500 mL round bottom flask, which 
contained 100 mL of freshly distilled thionyl chloride and a magnetic stirrer bar. 
This solution was put onto a dry ice/acetone bath to cool. To this a solution of 
pyridine in dichloromethane (2.7 M pyridine in 50 mL CH2Cl2) was added dropwise 
over 30 mins. This was left for another hour on the dry ice bath and left to warm 
to room temperature over 4 hours. The solution was then refluxed at 78 C 
overnight. After being left to cool, volatiles were removed in vacuo. The solid 
mixture was then washed with ethyl acetate and brine three times. The ethyl 




































Figure 4.17: Fluorescence excitation and emission map of 4.5 in water 
(2.5 µM). 
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acetate layer was collected and dried in vacuo. This solid was recrystallized in hot 
toluene to produce clear lime colored crystals of 4.6 (9.81 g, 40 %). 
 
13C NMR (CDCl3, 101 MHz, ppm) δ = 162.09 (CO), 134.15 (CCl). 
HR-MS (Xevo) - [M+H+] – calculated m/z 165.9463 observed m/z 165.9470;  
Matches literature data.36  






The synthesis was developed from a previously reported protocol.36 Initially, 
Methyl maleimide (7 g, 63 mmol) was added to a 250 mL round bottom flask, 
which contained 100 mL of freshly distilled thionyl chloride and a magnetic stirrer 
bar. This solution was put onto a dry ice/acetone bath to cool. To this a solution 
of pyridine in dichloromethane (2.7 M pyridine in 50 mL CH2Cl2) was added 
dropwise over 30 mins. This was left for another hour on the dry ice bath and left 
to warm to room temperature over 4 hours. The solution was then refluxed at 78 
C overnight. After being left to cool, volatiles were removed in vacuo. The solid 
mixture was then purified by silica column chromatography with a diethyl ether: 
petroleum ether (1:3) eluent. The fractions containing product were combined and 
dried slowly in vacuo, to produce a clear crystals of 4.7 (6.03 g, 55%). 
 
1H NMR (300 MHz, CDCl3, ppm) δ = 3.16 (s, 3H, Me). 
13C NMR (101 MHz, CDCl3, ppm) δ = 163.08 (CO), 133.36 (CCl), 25.09 (CH3). 
HR-MS (Xevo) - [M+H+] – calculated m/z 179.9619 observed m/z 179.9618;  
Matches literature data.36 
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 tert-butyl-(R)-2-((tert-butoxycarbonyl)amino)-5-((4-chloro-








Firstly, DCM 4.6 (8.6 mmol, 1.45 g) was dissolved into 40 mL of THF. To 
this Na2CO3 (17 mmol, 1.8 g) was added. A solution of OtBu-N-Boc-ornithine (2.5 
g, 8.6 mmol) in 25 mL of THF was added to a dropping funnel. Over 10 minutes 
this was added dropwise to the stirred solution of base and CH2Cl2. This was left 
for another 90 minutes, after which it was filtered to remove base and the residual 
THF was washed with brine three times and dried in vacuo. The crude solid was 
purified by silica column chromatography with a 10-20% ethyl acetate eluent in 
hexane, to elute the yellow product. This was dried in vacuo to afford yellow solid 
4.8 (1.09 g, 31%).  
 
1H NMR (400 MHz, CDCl3, ppm) δ = 7.23 (br, 1H), 5.50 (br, 1H), 5.09 (br d, 3JHH 
= 7.9 Hz, 1H), 4.14 (m, 2H), 3.58 (q, 3JHH = 4.1 Hz, 2H), 1.89 – 1.60 (m, 4H), 
1.40 s, 6H), 1.38 (s, 6H). Spectrum peaks are broader and poorly resolved than 
expected attributed to partial aggregation in the NMR solvent.  
13C NMR (101 MHz, DMSO-d6, ppm) δ = 171.62 (CO), 168.19 (CO), 166.00 (CO), 
161.83 (CO), 155.46 (CO), 141.67 (CN), 80.17 (CMe3), 77.99 (CMe3), 54.07 
(CH2), 41.51 (CH2), 28.14 (CH3), 27.64 (CH2), 27.57 (CH3), 26.93 (CH2).  
HR-MS (Xevo) - [M+H+] –calculated m/z 398.1095 observed m/z 398.1094;  
FTIR (cm-1): 2929 (υC-H), 1772 (υC=O), 1708(υC=O), 1667 (υC=O), 1649 (υC=O). 




Figure 4.18: 1H NMR spectrum of 4.8 (400 MHz, CDCl3). 
 
Figure 4.19: 13C NMR spectrum of 4.8 (101 MHz, DMSO-d6). 
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 tert-butyl-(R)-2-((tert-butoxycarbonyl)amino)-5-((4-chloro-







ACM-N-Boc-Ornithine (4.8, 150 mg, 0.35 mmol) was added to a round 
bottom flask with 9 mL CH2Cl2. To this 1 mL of trifluoroacetic acid (TFA) was added. 
This was stirred with a magnetic stirrer for 24 hours. After which the solution was 
washed with water and the aqueous layer was separated and dried in vacuo to 
yield yellow solid 4.9 (10 mg, 73%).   
 
1H NMR (400 MHz, D2O, ppm) δ = 4.00 (t, 3JHH = 6.1 Hz, 1H), 3.01 – 2.83 (t, 3JHH 
= 6.2 Hz, 3H), 2.03 – 1.52 (m, 4H). 
13C NMR (101 MHz, D2O, ppm) δ = 174.33 (CO), 171.53 (CO), 166.89 (CO), 
142.59 (CN), 54.41 (CH2), 41.56 (CH), 27.35 (CH2), 25.92 (CH2).  
FTIR (cm-1): 2933 (υC-H), 1768 (υC=O), 1716 (υC=O), 1656 (υC=O).  
HR-MS (Xevo) - [M+H+] – calculated m/z 262.0595, observed m/z 262.0594; 


























Figure 4.21: 13C NMR spectrum of 4.9 (101 MHz, D2O). 









































Figure 4.22: Fluorescence excitation and emission map of 4.9 in dioxane 
(1 µM). 




































Figure 4.23: Fluorescence excitation and emission map of 4.9 in water 
(10 µM). 









Firstly, DCM 4.7 (23 mmol, 8 g) was dissolved into 100 mL of methanol. To 
this NaHCO3 (34 mmol, 2.85 g) was added. A solution of O-Boc-Ornithine (4.13 g, 
23 mmol) in 50 mL of methanol was added to a dropping funnel. Over 10 minutes 
this was added dropwise to the stirred solution of base and ACM. This was left for 
another 90 minutes, after which it was filtered to remove base and dried in vacuo. 
The crude solid was purified by silica column chromatography with an ethyl acetate 
eluent to elute side products followed by ethyl acetate with 1 % MeOH/acetic acid 
added to elute the yellow product. This was dried in vacuo to afford yellow solid 
4.10 (1.11 g, 15%).  
 
1H NMR (300 MHz, DMSO-d6, ppm) δ = 7.96 (t, 3JHH = 5.5 Hz, 1H), 7.15 (d, 3JHH = 
8.0 Hz, 1H), 3.93 (m, 1H), 3.52 (m, 2H), 2.91 (s, 3H), 1.81 – 1.56 (m, 4H), 1.44 
(s, 9H). 
13C NMR (101 MHz, DMSO-d6, ppm) δ = 174.5 (CO), 168.0 (CO), 165.5 (CO), 
156.0 (COO), 142.2 (CN), 78.5 (CCH3), 53.7 (CH), 42.2 (CH2), 28.7 (CCH3), 28.2 
(CH2), 27.6 (CH2), 24.3 (CH3) 
HR-MS (Xevo) - [M+Na+] – calculated m/z 398.1095 observed m/z 398.1094; 
FTIR (cm-1) - 3379 (υO-H), 2929 (υC-H), 1742 (υC=O), 1705 (υC=O), 1653 (υC=O). 




Figure 4.24: 1H NMR spectrum of 4.10 (300 MHz, DMSO-d6). 
 
Figure 4.25: 1H NMR spectrum of 4.10 (300 MHz, DMSO-d6). 












Firstly, the modified amino acid 4.10 (2.6 mmol, 1 g) was dissolved into 20 
mL of acetonitrile. This was kept in the dark and to it diisopropylethylamine (5.2 
mmol, 0.67 g) was added. The reaction mixture was stirred and to this 
dinitrobenzyl chloride (5.2 mmol, 1.3 g). This was heated at reflux for 18 hours 
after which it was concentrated in vacuo. The crude solid was purified by silica 
column chromatography with an ethyl acetate/petroleum ether gradient eluent 
(10% ethyl acetate to 50% ethyl acetate). This was dried in vacuo to afford yellow 
solid 4.11 (706 mg, 49%).  
 
1H NMR (300 MHz, CDCl3, ppm) δ = 9.03 (t, 3JHH = 2.1 Hz, 1H), 8.56 (d, 3JHH = 2.1 
Hz, 2H), 5.38 (m, 3H), 5.02 (br d, 3JHH = 8.2 Hz, 1H), 4.40 (m, 1H), 3.64 (m, 2H), 
3.00 (s, 3H), 1.97 (s, 1H), 1.78 (m, 2H), 1.43 (s, 9H). 
13C NMR (101 MHz, CDCl3, ppm) δ = 172.0 (CO), 167.7 (CO), 165.6 (CO), 155.4 
(COO), 148.7 (CAr), 140.3 (CAr), 139.7 (CN), 127.9 (CAr), 118.8 (CAr), 80.7 
(CCH3), 64.7 (CH2), 53.0 (CH), 42.4 (CH2), 29.5 (CH2), 28.2 (CCH3), 27.0 (CH2), 
24.3 (CH3) 
HR-MS (Xevo) - [M+H+] – calculated m/z 578.1266 observed m/z 578.1267;  
FTIR (cm-1) – 2940 (υC-H), 1746 (υC=O), 1708 (υC=O), 1649 (υC=O), 1530 (υN=O), 









Figure 4.27:  13C NMR spectrum of 4.11 (101 MHz, CDCl3). 











DNB-ACM-Boc-Orn (4.11, 300 mg, 0.54 mmol) was added to a dried round 
bottom flask containing 8 mL of 1M HCl in dry ethyl acetate and a magnetic stirrer. 
This was sealed and stirred overnight after which the volatiles were removed. This 
was dissolved into acetonitrile (10 mL) and precipitated with the addition of diethyl 
ether (100 mL). This was filtered and dried to yield a yellow solid 4.12 (90 mg, 
36%). 
 
1H NMR (300 MHz, DMSO-d6, ppm) δ = 8.82 (t, 3JHH = 2.1 Hz, 1 H), 8.74 (d, 3JHH 
= 2.1 Hz, 2 H), 7.92 (t, 3JHH = 6.6 Hz, 1 H), 5.52 (s, 2 H), 4.23 (t, 3JHH = 6.2 Hz, 
1 H), 3.45 (q, 3JHH = 6.6 Hz, 2 H), 2.84 (s, 3 H), 1.96 – 1.50 (m, 5 H). 
13C NMR (101 MHz, DMSO-d6, ppm) δ = 169.52 (COO), 167.82 (CO), 165.37 (CO), 
148.50 (CAr), 142.00 (CAr), 140.05 (CNH), 128.93 (CAr), 118.87 (CAr), 65.44 
(CH2), 52.10 (CH), 41.82 (CH2), 27.47 (CH2), 26.52 (CH2), 24.26 (CH3). 
HR-MS (Xevo) - [M+H+] - calculated m/z 456.0922 observed m/z 456.0922 
FTIR (cm-1) –3353 (υN-H), 2933 (υC-H), 1746 (υC=O), 1705 (υC=O), 1649 (υC=O), 1534 
(υN=O), 
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Figure 4.28: 1H NMR spectrum of 4.12 (300 MHz, DMSO-d6). 
 
Figure 4.29:  13C NMR spectrum of 4.12 (101 MHz, DMSO-d6). 
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Figure 4.30: Fluorescence excitation and emission map of 4.12 in dioxane 
(5 µM). 



































Figure 4.31: Fluorescence excitation and emission map of 4.12 in water 
(2.5 µM). 
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 4,4'-(disulfanediylbis(methylene))dibenzoic acid (4.13)  
 
The synthesis was repeated as per a literature protocol.39 A solution of 
4-chloromethylbenzoic acid (10 g, 58 mmol) was added to 120 mL of 18.2 MΩ·cm 
water, followed by thiourea (6.6 g, 87 mmol). This was heated to reflux for two 
hours.  
To this was added NaOH (70 mL of 10% w/v in water). This was heated to 
reflux for an hour, followed by cooling to room temperature in an ice bath. This 
solution was acidified until pH < 2 using concentrated HCl. The white precipitate 
was filtered and isolated. This was washed with water and dried in vacuo. This 
was dissolved into ethanol (150 mL), and to this iodine was added until the orange 
colour remained. This was left for an hour, after which sodium thiosulfate was 
added until the colour disappeared again. Volatiles were removed in vacuo, and 
the solid was rinsed thoroughly with water and dried to give solid 4.13 (9.1 g, 
67%).  
 
1H NMR (DMSO-d6, 300 MHz, ppm) δ = 7.91 (d, 3JHH = 8.1 Hz, 1H), 7.39 (d, 3JHH 
= 8.1 Hz, 1H), 3.83 (s, 1H). 
MS (ESI) - [M+H+] – calculated m/z 335.0 observed m/z 335.0 
Matches literature data.39 









Solid 4.13 (7 g, 2.1 mmol), was added to a round bottom flask with a 
magnetic stirrer, followed by 50 mL of DMF. To this solution N-Boc-ethylene 
diamine (3.8 g, 2.4 mmol) was added, followed by EDC.HCl (3.72 g, 2.4 mmol). 
This was left to stir overnight followed by concentration in vacuo. The solid was 
dissolved in CH2Cl2 and washed with NaHCO3 solution, 1 M HCl and brine three 
times. This was dried in vacuo and purified by silica column chromatography on a 
12 g RediSep Rf silica flash column and eluted with an CH2Cl2 and methanol (0-
10%) gradient eluent on a CombiFlash Rf+ Lumen by Teledyne, to produce an off 
white solid 4.14 (6.1 g, 50%).  
 
1H NMR (400 MHz, CDCl3, ppm) δ = 12.55 (d, 3JHH = 7.9 Hz, 2H), 12.10 (d, 3JHH = 
8.3 Hz, 2H), 8.07 (s, 2H), 8.03 (d, 3JHH = 6.1 Hz, 2H), 7.86 (t, 3JHH = 6.2 Hz, 2H), 
6.12 (d, 3JHH = 1.2 Hz, 9H). 
13C NMR (101 MHz, DMSO-d6, ppm) δ = 166.52 (CON), 156.21 (COON), 141.03 
(CAr), 140.17 (CS), 133.93 (CAr), 129.66 (CAr), 127.80 (CAr), 78.14 (CBoc), 
42.01 (CH2), 41.37 (CH2), 28.70 (CH3). 
HR-MS (Xevo) - [M+H+] – calculated m/z 619.2624 observed m/z 619.2618;  
Matches literature data.39 








6 g of solid 4.14 (9.6 mmol), was dissolved in ethanol (150 mL) and heated 
to 60 C to ensure dissolution. To this TCEP (3 g, 12 mmol) was added and the 
reaction was left overnight at 60 C. This was dried and dissolved into CH2Cl2, and 
washed with water and brine three times. The CH2Cl2 was removed in vacuo to 
yield white solid 4.15 (5.8 g, >95%). 
 
1H NMR (DMSO-d6, 300 MHz, ppm) δ = 7.84 (d, 3JHH = 8.0 Hz, 2H), 7.47 (d, 3JHH 
= 8.2 Hz, 2H), 3.83 (d, 3JHH = 7.9 Hz, 2H), 3.33 (q, 3JHH = 6.1 Hz, 2H), 3.16 (q, 
3JHH = 6.1 Hz, 2H), 1.44 (s, 9H). 
MS (ESI) - [M+H+] – calculated m/z 311.1 observed m/z 311.1; 
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Boc-Ornithine (4.10, 100 mg, 0.32 mmol) was added to 25 mL of 
acetonitrile in a round bottom flask with a magnetic stirrer. To this EDC.HCl (180 
mg, 0.47 mmol) was added followed by Boc-ABT (4.15, 120 mg, 0.32 mmol). This 
was stirred overnight after which solvent was removed in vacuo. The crude yellow 
solid dissolved in ethyl acetate and washed with water and brine three times. To 
the organic layer was added iodine until an orange colour remained. Boc-ABT 
precipitated, and sodium thiosulfate was added until the colour of iodine 
disappeared. This solution was filtered and then concentrated and purified by silica 
column chromatography with an CH2Cl2 eluent to elute side products followed by 
CH2Cl2 with 5 % MeOH added to elute the yellow product. This was dried in vacuo 
to afford yellow solid 4.16 (85 mg, 9%). 
 
1H NMR (400 MHz, DMSO-d6, ppm) δ = 8.47 (t, 3JHH = 5.4 Hz, 1H), 7.96 (t, 3JHH = 
6.4 Hz, 1H), 7.81 (d, 3JHH = 8.0 Hz, 2H), 7.73 (d, 3JHH = 7.9 Hz, 1H), 7.40 (d, 3JHH 
= 8.3 Hz, 2H), 6.97 (t, 3JHH = 5.7 Hz, 1H), 4.23 – 4.07 (m, 3H), 3.58 – 3.42 (m, 
2H), 3.33 (q, 3JHH = 6.1 Hz, 2H), 3.15 (q, 3JHH = 7.3, 6.6 Hz, 2H), 2.91 (s, 3H), 
1.85 – 1.53 (m, 5H), 1.45 (s, 7H), 1.43 (s, 11H). 
13C NMR (101 MHz, DMSO-d6, ppm) δ = 202.53 (CS), 168.01 (CO), 166.44 (CNO), 
165.48 (CO), 156.19 (CBoc), 155.92 (CBoc), 142.35 (CNH), 141.56 (CAr), 133.71 
(CAr), 128.93 (CAr), 127.84 (CAr), 79.18 (CBoc), 78.13 (CBoc), 60.86 (CH2), 
42.06 (CH2), 31.98 (CH), 29.00 (CH2), 28.69 (CBoc), 28.65 (CBoc), 28.23 (CH2), 
27.33 (CH2), 24.30 (CH3) 
HR-MS (Xevo) - [M+Na+] – calculated m/z 690.2340 observed m/z 690.2336;  
FTIR - 2959 (υC-H), 1705 (υC=O), 1686 (υC=O), 1653 (υC=O), 1641 (υC=O) 
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Figure 4.32: 1H NMR spectrum of 4.16 (400 MHz, DMSO-d6). 
 
Figure 4.33: 13C NMR spectrum of 4.16 (101 MHz, DMSO-d6). 










Boc-ABT-ACM-Boc-Orn (4.16, 75 mg, 0.11 mmol) was added to a dried 
round bottom flask containing 5 mL of 1M HCl in dry ethyl acetate and a magnetic 
stirrer. This was sealed and stirred overnight after which the solution was 
transferred to a falcon tube and centrifuged. This was decanted, re-solvated in 
ethyl acetate (10 mL) and centrifuged twice more. After three centrifuges the solid 
was dried in vacuo to yield a yellow solid 4.17 (41 mg, 81%). 
 
1H NMR (300 MHz, DMSO-d6, ppm) δ = 8.83 – 8.74 (t, 1H), 8.61 (br, 3H), 8.11 
(br, 4H), 7.91 (t, 3JHH = 6.7 Hz, 1H), 7.83 (d, 3JHH = 8.2 Hz, 2H), 7.35 (d, 3JHH = 
8.1 Hz, 2H), 4.23 (d, 3JHH = 2.5 Hz, 3H), 3.46 (q, 3JHH = 5.1, 4.3 Hz, 3H), 3.38 (d, 
3JHH = 6.6 Hz, 2H), 2.91 (q, 3JHH = 6.0 Hz, 3H), 2.79 (s, 3H), 1.88 – 1.42 (m, 6H). 
13C NMR (101 MHz, D2O, ppm) δ = 197.29, 170.50, 166.21, 141.66, 131.91, 
129.02, 127.49, 58.32, 41.18, 39.31, 37.29, 32.32, 27.72, 24.87, 23.60. 
HR-MS (Xevo) - [M+H+] – calculated m/z 468.1472 observed m/z 468.1474;  
FTIR - 2959 (υC-H), 1705 (υC=O), 1653 (υC=O), 1649 (υC=O) 
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Figure 4.34: 1H NMR spectrum of 4.17 (300 MHz, DMSO-d6). 
 
Figure 4.35: 13C NMR spectrum of 4.17 (101 MHz, D2O). 







































Figure 4.36: Fluorescence excitation and emission map of 4.17 in dioxane 
(10 µM). 



































Figure 4.37: Fluorescence excitation and emission map of 4.17 in water 
(2.5 µM). 
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4 Chapter 5: Synthesis of maleimide 
based fluorescent probes for 
investigation of enzyme mechanisms 
and intermediates
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4.1 Abstract 
 
The environmental sensing abilities of maleimide dyes, along with their 
significantly smaller size compared to fluorophores currently used in biological 
research, means that there are numerous novel applications in this field. This 
Chapter focuses on the synthesis of various alkyne functionalized maleimide dyes 
for use in probing the biosynthesis of natural products, a collaborative project with 
the group of Manuela Tosin. Various alkyne functionalized maleimides were 
synthesized for coupling with azide containing probes, which have been shown by 
the Tosin group to capture intermediates in natural product biosynthesis. A range 
of alkyne maleimides were synthesized, including a DTM, ACM and an activated 
alkyne MAM. Their ability to capture intermediates has been initially evaluated by 
the Tosin group (University of Warwick). As these dyes will be used in vivo, we 
wanted to establish the stability of these moieties to cellular incubation conditions 
including various cell growth media. To achieve this, dyes were incubated in the 
broths over several days at raised temperature and under sterile and non-sterile 
conditions to mimic a range of incubation conditions. GCMS, HPLC and 
fluorescence analysis all indicated no loss of dye integrity and that no dye adducts 
were forming, suggesting full stability to broth ingredients under raised 
temperature conditions, indicating a promising future for the dye in these 
applications.
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4.2 Introduction 
4.2.1 Probes for capturing enzyme intermediates 
For the first part of this Chapter, the synthesis of maleimide based probes 
for studying enzyme catalyzed biosynthesis, was undertaken. Such probes could 
improve detection of intermediates in the synthesis of various natural products 
and could provide more information into understanding how many important 
biomolecules are synthesized in vivo.1,2 The probes are substrate mimics and have 
been used to elucidate the mechanism of several enzymatic pathways that utilize 
acyl carrier proteins (ACPs), including non-ribosomal peptide synthetases (NRPS)3 
and polyketide synthetases (PKS).4,5 Such pathways require ACPs to shuttle 
intermediates between local catalytic domains, a process which leads to a diverse 
range of natural products.6 
The Tosin group have pioneered work in this field through the development 
of chemical probes that aid in the capture and identification of intermediates in 
such biosynthetic pathways.1,2,7,8 The probes are designed to mimic the natural 
substrate, however they are functionalized to prevent product formation and aid 
characterization and isolation of intermediates. This provides insight into substrate 
flexibility and provides a mechanism for the synthesis of novel compounds through 
diversification of unnatural substrates. Initial research was focused on probing 
polyketide biosynthesis to obtain unnatural functionalized intermediates, 
concentrating on the well understood biosynthetic pathway of polyketide 
formation catalyzed by polyketide synthase (PKS). The group synthesized non-
hydrolysable malonate analogues (Figure 5.1) which would be recognized by PKS 
and undergo polyketide differentiation pathways with the aid of ACP.7 Off-loading 
of products from ACP is naturally achieved through a nucleophilic PKS based 
cysteine residue with the aid of NADPH;9 however this process cannot occur in the 
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mutant probes. Therefore, the intermediate species are derivatives of the modified 
probes, and can be isolated and characterized by LCMS. These studies proved 
tolerance and processing of unnatural analogues, in addition to providing kinetic 
insights into the assembly and the amenability of polyketides to further structural 
modifications.1,8   
After studying PKS and the kinetic transformation of intermediates in 
polyketide assembly, the group has focused on a new variant of probes for the 
elucidation of nonribosomal peptide synthesis.2  Specifically, they have probed the 
synthesis of echinomycin in cultures of S. lasaliensis though a new generation of 
chain transfer termination probes (Figure 5.2). Several intermediate peptide 
species were captured by these probes, which provided new information on the 
biosynthetic pathway and substrate flexibility/specificity.2 
 
Figure 5.1: Simplified mechanism of normal polyketide synthesis (black) and 
mechanism of trapping intermediates with probe (blue). 
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Based upon this earlier work it was hypothesized that the small size of 
maleimide fluorophores would allow for attachment to these probes, without 
affecting their intermediate capture ability. As the probes would now be tagged 
with a fluorophore, the process of isolation and detection of off-loaded 
intermediates in such complex systems should be easier through being able to 
utilize UV and fluorescence detection. The environmental response of the dye, 
along with its wide lifetime range, may also find future applications in the 
monitoring of kinetics in these multi-step syntheses. Therefore, the first goal of 
this Chapter was to synthesize maleimide based alkynes for reaction with azide 
functionalized probes previously developed by the Tosin group, to create 
maleimide tagged probes for in vivo testing.  
The second goal of this Chapter was to establish that the maleimide motif 
was stable to the complex environment of cell expression media. This will be 
established by incubating the dye in commonly used cell media, under the 
conditions used for the intermediate trapping conditions, including at raised 
temperature. The contents of such bacterial expression media are extremely 
Figure 5.2: Illustration of normal non-ribosomal peptide synthesis (A) and 
capture of intermediates by chemical probe mimics (B), also a target of this 
Chapter, developed by Ho et al. Figure reproduced from ref.2 
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complex and include sugars, proteins, amino acids, vitamins, sulfates and more 
depending on the media.10 The cell expression media is essential for the growth 
of E. Coli used to express the enzymes studied.11 If it were to be found that the 
maleimide was susceptible to degradation or reaction under these conditions, then 
the dyes will not be reliably useful in the isolation of intermediates, as the probes 
need to be isolatable at the end of the experiment. 
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4.3 Results 
4.3.1 Synthesis of alkyne functionalized maleimide 
fluorophores for utilization as enzyme intermediate 
probes 
To attach the maleimide motifs to the biosynthesis probe, Copper(I)-
catalyzed alkyne-azide cycloaddition (CuAAC) was chosen due to its high 
selectivity and reliability, and its proven effectiveness for previous probe 
functionalization.1 Therefore, maleimide motifs (DTM, MAM, ABM and ACM) were 
designed with alkyne functionality at the imide position. 
Initially, DTM and ABM dyes were targeted as they were the most studied 
dyes at the initiation of the project. The formation of alkyne-dibutylthiomaleimide 
(5.1) was achieved via the formation of intermediate DTM 5.2 (Scheme 5.1). 
Formation of alkyne-DBM could be achieved, however subsequent treatment with 
butanethiol led to derivatization of the alkyne in preference to DBM substitution.   
On the other hand, formation of ABM alkyne-ethylaminobromomaleimide 
(5.4) could be achieved over two steps from alkyne-DBM (5.3) (Scheme 5.2), 





Scheme 5.1: Synthesis of alkyne-dibutylthiomaleimde, 5.2. 
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While less stable and more reactive,13 monoaminomaleimdes are smaller 
and brighter than ABM analogues. Therefore, alkyne-monoaminomaleimde 5.6 
was also synthesized, via intermediate alkyne-MBM 5.5, for study in these 




During the course of this project aminochloromaleimides (ACMs) were 
developed by our group,14 and were found to be a good compromise between the 
stability of ABMs, and the improved brightness and size of MAMs. Therefore, 
synthesis of ACM alkyne probe 5.8 was subsequently developed (Scheme 5.4) 







Scheme 5.3: Synthesis of alkyne-ethylaminomaleimide 5.6. 
 
Scheme 5.4: Synthesis of alkyne-ethylaminochloromaleimide 5.8. 
 
Scheme 5.2: Synthesis of alkyne-ethylaminobromomaleimide 5.4. 
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Finally, the synthesis of an activated alkyne probe was undertaken to 
potentially facilitate a higher yielding probe formation step, while also removing 
the need for copper catalysts which requires removal prior to enzyme 
incorporation. Towards this, an activated alkyne amine 5.11 was synthesized 
according to a literature method,15 which was subsequently reacted with 
bromomaleic anhydride and then ethylamine to form the activated alkyne MAM 
product 5.13 (Scheme 5.5). 1H and 13C NMR analysis indicated the presence of a 
small impurity (Figure 5.3) which integrated to < 5% by 1H NMR. A smaller amount 
of impurity was later noticed in the 1H NMR of 5.12. This is attributed to 
derivatization of the previous alkyne 5.11, forming an unidentified vinyl side-
product. Alkynes are known to react with nucleophiles, for example alcohols, 
under basic conditions.16,17 It was not envisioned that this impurity would affect 
the coupling reaction, and therefore this was used for coupling to the azide-probe 
without further purification.  
 
Scheme 5.5: Synthesis of activated alkyne-ethylaminomaleimide 5.13. 
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4.3.2 Studying the stability of maleimide fluorophores in 
cellular media 
As discussed in the introduction, the dyes will be incubated in E. Coli growth 
media and therefore, the tolerance of substituted maleimides to such media was 
investigated. Degradation or reaction of the probe with chemical species in the 
broths would lead to significant complication of the analysis, and loss of probe 
efficiency. To achieve this, precursor ABM 5.4 was chosen as a model for 
incubation. This was placed into four cell media formulations, along with a 
deionized water control. These were: 
• SMM – Supplemented minimal media.18 
• MYM – Minimal yeast media.2 
• YEME – Yeast and malt extract broth.19 
• TSB – Tryptic soy broth.20 
 
Figure 5.3: 1H NMR spectrum of 5.13 in CDCl3, with impurity circled.  
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The dissolved dye was then incubated at 30 C to replicate the conditions 
of the in vivo experiments that will be used to trap enzyme intermediates. 
However, after an initial test over a day, emission of the dye in YEME under UV 
illumination was clearly exhausted (Figure 5.4), suggesting loss of integrity of the 
probe. YEME medium contains yeast and malt cell extracts, therefore the contents 









 As these initial results indicated poor stability of the ABM probe to 
YEME and research in the group had moved onto more stable ACM probes, we 
incubated ACM 5.8 under the same conditions. After initial incubation for 24 hours, 
UV illumination showed that emission of the dye was visible in YEME (Figure 5.5), 
unlike for the ABM. Therefore, the dye was incubated over two weeks in the broths 
and progress of the incubation was monitored by fluorescence emission, GCMS 







Figure 5.4: Structure and photo of fluorescence under UV illumination of 
ACM 5.4 after 24 hour incubation in cell media, showing YEME quenching. 
Figure 5.5: Structure and photo of fluorescence under UV illumination of 
ACM 5.8 after 24 hour incubation in cell media. 










In regards to the fluorescence analysis, the dye incubated in 18.2 MΩ·cm 
water showed very good retention of emission over 14 days (Figure 5.6). This was 
also true for MYM, YEME and TSB broths, all showing negligible change in 
fluorescence emission. On the other hand, incubation in SMM led to fluorescence 
emission increasing over the period of the study significantly (Figure 5.7). Two 
hypotheses were proposed for this phenomenon. Firstly, the dye was aggregating 
slowly in the broth causing aggregation enhanced emission; or secondly, that 
bacteria was growing in the sample providing a more hydrophobic environment 
for the dye, thus increasing emission. To eliminate the second hypothesis the 
study was repeated under sterile conditions, however, the same phenomenon was 
observed with incubation in SMM, albeit to a significantly lower degree (Figure 
5.8). Based upon this the cause for these observations is still unclear, but in vitro 





Figure 5.6: Fluorescence emission of 5.8 in 18.2 MΩ·cm water over two 
weeks (375 nm excitation), illustrating retention of fluorescence. 


























Figure 5.8: Fluorescence emission (λex = 375 nm λem = 500 mm) of ACM 5.8 
in sterile cell media. Note the increase in fluorescence for SMM is lower in 
magnitude than for the dye under non-sterile conditions (Figure 5.7).  
Figure 5.7: Fluorescence emission (λex = 375 nm λem = 500 mm) of ACM 5.8 in 
non-sterile cell media, showing the increase in fluorescence in SMM. Note that the y- 
axis is split and has different scales for the upper and lower part of the axes. 
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HPLC was conducted on the broths during the incubation period to establish 
integrity of the dye – additional peaks in the 375 nm region would suggest 
derivatization of the dye (for example reaction of the alkyne), whereas absorbance 
at other wavelengths may suggest loss of integrity of the maleimide motif. The 
water control showed dye elution at around 15.5 minutes, which continued for 14 
days (Figure 5.9). Positively, no additional peaks could be seen in the dye or UV 
region, suggesting full retention of the maleimide structure corroborating 
fluorescence results. The fluorescence detector (375 nm excitation and 500 nm 
emission) also confirmed this peak was fluorescent (Figure 5.10), however 
possibly due to the poor emission in aqueous solution, this detector did show 








Figure 5.9: HPLC chromatograms of 5.8 in water over 14 days, with 
254 nm detection (top) and 375 nm detection (bottom). 


















































HPLCs were also run of the dye incubated in the other broths and the 
obtained chromatograms suggested complete integrity of the dye across all broths 
(Figure 5.11 – Figure 5.13). 
 
Figure 5.11: HPLC chromatograms of 5.8 in SMM over 14 days, with 254 nm 
detection (top) and 375 nm detection (bottom). 
Figure 5.10: HPLC chromatograms of 5.8 in water over 14 days, recorded 
with a fluorescence detector (375 nm excitation and 500 nm emission). 
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Figure 5.13: HPLC chromatograms of 5.8 in TSB over 14 days, with 254 nm 
detection (top) and 375 nm detection (bottom). 
Figure 5.12: HPLC chromatograms of 5.8 in YEME over 14 days, with 254 nm 
detection (top) and 375 nm detection (bottom). 
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While HPLC and fluorescence emission both suggested good purity and 
stability in cell media, it was posited that a mass-based characterization technique 
would also be useful to detect the existence of side products that may not be 
water-soluble or UV active. Therefore, samples from the study were extracted with 
CH2Cl2 and then analyzed by GCMS. GCMS analysis indicated only pure dye was 
observable over the duration of the study for all broths (Figure 5.14-5.17), 
corroborating the conclusion that the dye is stable in the cell media under 
incubation conditions. The day 0 chromatograms are from the unincubated alkyne 

















Figure 5.14: GCMS chromatograms of 5.8 over 7 days extracted from water. 















































Figure 5.15: GCMS chromatograms of 5.8 over 7 days extracted from 
MYM. 
Figure 5.16: GCMS chromatograms of 5.8 over 7 days extracted from 
SMM. 





















































With no identifiable impurities forming in any of the analytical techniques 
used for the study and dye integrity remaining under all conditions, it is concluded 
that the dye is highly suitable for use in enzyme trapping experiments. Not only 
do these results suggest the dye is a good candidate for this study, but this 
suggests that the dye will be suitable for other cellular expression applications 









Figure 5.17: GCMS chromatograms of 5.8 over 7 days extracted from 
YEME. 
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4.3.3 Evaluating the effectiveness of synthesized probes 
for detecting enzyme intermediates in natural 
product biosynthesis 
Evaluation of the dyes for intermediate capture was completed by the Tosin 
group. Firstly, dyes were coupled to their azide functionalized intermediate probe 
through CuAAC (Scheme 5.6). This was completed by Dr Ina Wilkening for alkyne-
DTM 5.2 and activated alkyne 5.13, however, conversion was low for copper-free 
click of activated alkyne-DTM 5.13 and therefore only 5.2 was investigated. 
Alkyne-ACM 5.8 has also been successfully coupled (by Dr Rob Jenkins) to a 
photo-labile nitrobenzyl protected azide probe for in vitro studies (Scheme 5.6).  
 
Scheme 5.6: Synthesized maleimide functionalized intermediate probes by the 
Tosin group, from alkyne dyes 5.2 (top) and 5.8 (bottom) using CuAAC. 
To validate the use of the dye in a known system, the in vivo polyketide 
synthesis of 6-methylsalicylic acid (6-MSA) was investigated, the system 
previously studied by the Tosin group,1 using the DTM functionalized probe 5.2. 
Using this, probe the group were able to identify a putative off-loaded triketide 
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intermediate, through fragments observed by LCMS-MS (Figure 5.18). This 
intermediate is analogous to that observed using the standard probes, suggesting 
compatibility of the fluorophore with the in vivo system.   
 
Figure 5.18: Proposed isolated intermediate and obtained mass spectrum in 
the probing of 6-MSA synthesis. 
To help identify intact biosynthetic intermediates captured by the 
fluorescent probe, an in vitro system is under investigation using the ACM 
functionalized photolabile protected probe. Preliminary investigations were 
completed on an iterative type II polyketide synthetase. These were the 
biosynthesis of SEK4 and SEK4b using malonyl-CoA, ACP and KS-CLF protein 
(from S. coelicolor).21 By substituting the malonyl-CoA with our probe we hope to 
capture intermediates in this synthesis. Panward Prasongpholchai from the Tosin 
group completed incubation of our ACM probe after photolysis with ACP and KS-
CLF, and could identify a few promising putative intermediates, including a 
dehydrated pentaketide species (Figure 5.19). Work is ongoing into investigating 
this further, however, these initial results suggest the dye has promising 
compatibility with enzyme intermediate capturing. Future work may include 
studying the fluorescence lifetime when bound and unbound to enzymes, with the 
long term goal of studying kinetics of these processes.  
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Figure 5.19: Three hypothesized species detected by MS-MS upon 
incubation of ACM probe with ACP and KS-CLF by the Tosin group. 
 Chapter 5   254 
4.4 Conclusions  
 
This Chapter covers the application of maleimide fluorophores to the field 
of isolating enzyme intermediates, with the goal of increasing sensitivity and ease 
of isolation and identification of intermediates. Towards this aim alkyne 
functionalized maleimide have been synthesized for CuAAC coupling with azide 
functionalized probes developed by the Tosin group. Successful efficient coupling 
was observed for both the DTM and ACM alkynes, and the Tosin group had 
preliminary success in isolating offloaded intermediates using these coupled 
probes. To check for compatibility with enzymatic media, which are also relevant 
to in vivo expression of amino acids developed in Chapter 4, ACM alkyne was 
tested for degradation and stability in several cellular media: YEME, SMM, MYM 
and TSB.  Fluorescence, HPLC and GCMS analysis all indicated complete 
compatibility with all broths under cellular incubation conditions, excluding an 
unusual fluorescence phenomenon observed during incubation in SMM, 
hypothesized to be a result of dye aggregation. 
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4.5 Experimental 
 Materials 
All chemicals were obtained from either: Sigma Aldrich, Fisher Chemicals, 
Acros Chemicals, Carbosynth or Alfa Aesar and used as received. Sterilized growth 
mediums TSB, YEME, SMM and MYM were prepared and provided by Mr Rob 
Jenkins.  
 Instrumentation 
NMR spectra were recorded on a Bruker Advance 300, a Bruker Advance III 
HD 400 or a Bruker Advance III HD 500 spectrometer at 300, 400 and 500 MHz 
respectively. Shifts are quoted in δ in parts per million (ppm) and quoted relative 
to the internal standard trimethylsilane (TMS) or the solvent peak. 
High Resolution Mass Spectra (HR-MS) were conducted by Dr Lijiang Song 
on a Bruker UHR-Q-ToF MaXis spectrometer with electrospray ionization. 
Infrared spectra were recorded on neat samples using a Perkin Elmer 
Spectrum 100 FT-IR Spectrometer. 
UV-Vis spectroscopy was carried out on a Perkin Elmer Lambda 35 UV/vis 
spectrometer or an Agilent Cary 60 UV-Vis Spectrometer at room temperature. 
Fluorescence emission and excitation spectrum were obtained with an Edinburgh 
Instruments FS5 Spectrofluorometer in quartz 3.5 mL cuvettes (Starna Cell, Type: 
3/Q/10), and analyzed in Fluoracle (Edinburgh Instruments) and Origin 2019 
(Origin Labs). 
Reverse-phase high pressure liquid chromatography (HPLC) analysis was 
performed on a modular Shimadzu instrument with the following modules: CBM-
20A system controller, LC-20AD solvent delivery module, SIL-20AC HT 
autosampler, CTO-20AC column oven, SPD-M20A photodiode array UV-Vis 
detector, RF-20A spectrofluorometric detector and a FRC-10 fraction collector (not 
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used). Chromatography was performed on a Shim-pack GISS 5 μm C18 
(4.6×125mm) reverse phase column heated at 30 °C. Flow rate was set at 0.8 
mL/min and the products were eluted using a gradient of 18.2 MΩ·cm water and 
acetonitrile. A typical elution gradient is shown in Figure 5.20.   
 
 
Figure 5.20: Elution gradient of water/acetonitrile used for dye incubation 
analysis by HPLC.  
 
Gas chromatography-mass spectrometry (GCMS) was performed on a 
Shimadzu GCMS QP2010 SE system with a Zebron ZB-5HT Inferno® column of 30 
m length and 0.25 mm I.D. Samples were prepared by extraction from 5-10 mL 
of incubation solution 1:1 with CH2Cl2. The injector temperature was 350 C with 
1.0 μL injection volume (splitless). The helium carrier gas flow rate was set at 
(20.6 mL/min), with a column flow rate of 1.6 mL/min. MS detection was used 
with selective ion scanning of 1.5-1000 m/z. The typical temperature gradient for 
runs is shown in Figure 5.21, after one or two blank runs were completed before 
each batch to reset/clean the column. 
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Figure 5.21: Temperature gradient used for GCMS runs of 5.8. 
 Dye incubation 
Dyes were dissolved in 15 mL of either water or the sterilized broth at 0.5 
mg/ml in 15 mL centrifuge tubes. These were placed in an incubator at 30 oC with 
5% CO2 supply. Aliquots of 1 mL were taken after time periods and diluted to 3 
mL with water for fluorescence analysis. These were then extracted with 3 mL of 
CH2Cl2 for GCMS analysis. 1 mL of this was dried in vacuo and re-solvated in 2 mL 
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4.5.2 Small molecule synthesis  






Dibromomaleimide (2 g, 7.8 mmol) was added to a round bottom flask 
containing a stirrer bar and 80 mL of methanol. To this NaOAc (1.4 g, 17.2 mmol) 
and secondly, butanethiol (1.58 g, 17.2 mmol) was added. The solution was 
stirred for 2 hours followed by removal of volatiles using evaporation. The obtained 
oil was purified by silica column chromatography in a petroleum ether and ethyl 
acetate gradient (0% EtOAc to 8%). The fractions containing product were dried 
in vacuo to yield yellow solid 5.1 (344 mg, 18%). 
 
1H NMR (300 MHz, CDCl3, ppm) δ = 3.29 (t, 3JHH = 7.3 Hz, 2H, CH2), 1.73 – 1.61 
(q, 3JHH = 7.3 Hz, 2H, CH2), 1.45 (q, 3JHH = 7.2 Hz, 2H, CH2), 0.93 (t, 3JHH = 7.2 
Hz, 3H, CH3) 
13C NMR (75 MHz, CDCl3, ppm) δ = 166.1 (CO), 136.7 (CS), 32.5 (CH2), 31.4 
(CH2), 21.6 (CH2), 13.6 (CH3); 
Matches literature data.22 
 










This two-step procedure was based on a literature protocol.23 Initially, 
compound 5.1 was dissolved into 20 mL of ethyl acetate in a round bottom flask 
with a stirrer bar. To this N-methyl morpholine (111 mg, 1.1 mmol) was added 
and secondly, methyl chloroformate (114 mg, 1.2 mmol). Immediate precipitation 
of a solid was noted, along with a purple color appearing. This was left to stir for 
2 hours, followed by washing with water and brine three times. The organic layer 
was dried in vacuo and was used directly for the next step. 
Next, this intermediate was added to a round bottom flask containing a 
stirrer bar and 40 mL of CHCl2.  To this propylamine (96.6 µL, 1.5 mmol) was 
added slowly. This was left to stir for 4 hours and then directly loaded onto silica. 
This was purified by silica column chromatography using a petroleum ether and 
ethyl acetate gradient (0% EtOAc to 10%). This was dried in vacuo to yield a 
yellow solid 5.2 (387 mg, 85%).  
 
1H NMR (400 MHz, CDCl3, ppm) δ = 4.27 (t, 4JHH = 2.1 Hz, 2H, CH2), 3.41 – 3.22 
(t, 3JHH = 7.3 Hz 2H, CH2), 2.22 (s, 4JHH = 2.0 Hz, 1H, CH), 1.64 (p, 3JHH = 7.4 Hz, 
2H, CH2), 1.52 – 1.38 (m, 2H, CH2), 0.93 (t, 3JHH = 7.3 Hz, 3H, CH3). 
13C NMR (101 MHz, CDCl3, ppm) δ = 165.3 (CO), 136.0 (CS), 71.5 (CH), 32.5 
(CH2), 31.6 (CH2), 27.5 (CH2), 21.7 (CH2), 13.6 (CH3)  
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Matches literature data.23 




Dibromomaleimide (1 g, 3.9 mmol) was added to a round bottom flask 
containing a stirrer bar and 10 mL of THF. To this K2CO3 (0.59 g, 4.3 mmol) was 
added and the solution stirred. Finally, propargyl chloride (80 % in THF – 410 µL, 
4.3 mmol) was added dropwise to the solution and this was left overnight. This 
was filtered and then dried in vacuo to yield solid 5.3 (360 mg, 32 %).  
 
1H NMR (400 MHz, CDCl3, ppm) δ = 4.38 (d, 4JHH = 2.5 Hz, 2H, CH2), 2.27 (t, 4JHH 
= 2.5 Hz, 1H, CH). 
13C NMR (101 MHz, CDCl3, ppm) δ = 162.6 (CO), 129.81 (CBr), 76.05 (C), 72.57 
(CH), 28.59 (CH2). 
Matches literature data.24 
 
 3-bromo-4-(ethylamino)-1-(prop-2-yn-1-yl)-1H-pyrrole-





Initially, compound 5.3 (300 mg, 1 mmol) was dissolved in THF (20 mL). 
To this Na2CO3 was added (265 mg, 2.5 mmol) followed by ethylamine solution 
(68 % in H2O – 47 µL, 1.05 mmol), after which a color change from clear to yellow 
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was observed. After 90 mins of stirring the solution, it was filtered to remove base 
and then dried in vacuo. This solid was washed with CHCl2 and water three times 
and then dried with addition and filtration of MgSO4. This solid was purified by 
column chromatography using a 10 : 1 petroleum spirits : ethyl acetate eluent. 
The product was dried in vacuo to yield yellow solid 5.4 (201 mg, 78%).  
 
1H NMR (500 MHz, CDCl3, ppm) δ = 4.28 (d, 4JHH = 2.5 Hz, 2H), 3.71 (p, 3JHH = 
7.2 Hz, 2H), 2.22 (t, 4JHH = 2.5 Hz, 1H), 1.32 (t, 3JHH = 7.2 Hz, 3H). 
13C NMR (126 MHz, CDCl3, ppm) δ = 166.3 (CO), 165.0 (CO), 143.4 (CN), 71.6 
(CH2), 38.2 (CH2), 27.5 (CH), 16.0 (CH3).  
MS (ESI) - [M+H+] – calculated m/z 280.0 observed m/z 279.9;  
FTIR (cm-1) – 3333 (υC-H), 2977 (υC-H), 2130 (υC≡C), 1706 (υC=O), 1643 (υC=O). 
 
Figure 5.22: 1H NMR spectrum of 5.4 
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Propargyl amine (0.16 mL, 2.3 mmol) was added slowly to a stirred solution 
of bromomaleicanhydride (1.2 g, 6.9 mmol) in acetic acid (15 mL). This was then 
heated to reflux for 6 hours, after which solvent was removed in vacuo with the 
aid of toluene azeotrope. The dried crude solid purified by column chromatography 
using a 100% CH2Cl2 eluent. This was dried in vacuo to yield yellow solid 5.5 (1.13 
g, 78%).  
 
Figure 5.23: 13C NMR spectrum of 5.4 
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1H NMR (300 MHz, CDCl3, ppm) δ = 6.93 (s, 1H), 4.34 (d, 4JHH = 2.5 Hz, 2H), 2.24 
(t, 4JHH = 2.5 Hz, 1H). 
13C NMR (101 MHz, CDCl3, ppm) δ = 167.0 (CO), 164.0 (CO), 132.2 (CH), 131.7 
(CBr), 76.8 (C), 72.0 (CH), 27.7 (CH2) 









Compound 5.5 (0.5 g, 2.3 mmol) was dissolved in 50 mL of THF in a round 
bottom flask with a stirrer bar. To this NaHCO3 was added (210 mg, 4.1 mmol) 
followed by ethylamine solution (68 % in H2O – 110 µL, 12.3 mmol), after which 
a color change from clear to yellow was observed immediately. After 45 mins this 
reaction was filtered and then dried in vacuo. The crude solid was purified by silica 
column chromatography with a CH2Cl2/petroleum ether eluent (75% CH2Cl2). This 
was dried in vacuo to afford yellow solid 5.6 (104 mg, 75%).  
 
1H NMR (300 MHz, CDCl3, ppm) δ = 5.35 (br, 1H, NH), 4.86 (s, 1H, CH), 4.25 (d, 
4JHH = 2.5 Hz, 2H, CH2), 3.24 (m, 2H, CH2), 2.19 (t, 4JHH = 2.5 Hz, 1H, CH), 1.29 
(t, 3JHH = 7.3 Hz, 3H, CH3). 
13C NMR (101 MHz, CDCl3, ppm) δ = 170.8 (CO), 166.5 (CO), 149.3 (CN), 84.4 
(CH), 77.6 (C), 71.1 (CH), 39.1 (CH2), 26.5 (CH2), 13.7 (CH3). 
HR-MS (Xevo) - [M+H+] – calculated m/z 179.0821 observed m/z 179.0820;  
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FTIR (cm-1) – 3300 (υC-H), 2977(υC-H), 2131 (υC≡C), 1704 (υC=O), 1644 (υC=O). 
 
 
Figure 5.24: 1H NMR spectrum of 5.6 
 
Figure 5.25: 13C NMR spectrum of 5.6 
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To a solution of acetic acid (15 mL) was added dichloromaleic anhydride (1 
g, 6.1 mmol) and a stirrer bar. To this propargylamine (390 µl, 6.1 mmol) was 
added and the solution was heated to reflux overnight, attached to a condenser. 
After this, the dark solution was dried in vacuo with the aid of toluene azeotrope. 
This solid was purified by column chromatography using a 1 : 2 petroleum spirits 
: ethyl acetate eluent. The product was dried in vacuo to yield yellow solid 5.7 
(723 mg, 60%).  
 
1H NMR (300 MHz, CDCl3, ppm) δ = 4.37 (t, 4JHH = 2.3 Hz, 2H), 2.28 (d, 4JHH = 2.4 
Hz, 1H). 
13C NMR (101 MHz, CDCl3, ppm) δ = 161.7 (CO), 133.8 (CCl), 75.91 (C), 72.63 
(CH), 28.24 (CH2). 
HR-MS (Xevo) - [M+H+] – calculated m/z 203.9619 observed m/z 203.9625;  
FTIR (cm-1) –3254 (υC-H), 2130 (υC≡C), 1704 (υC=O), 1664 (υC=O). 
 
 







Figure 5.26: 1H NMR spectrum of 5.7 
 
Figure 5.27: 13C NMR spectrum of 5.7  








To start, compound 5.7 (500 mg, 2.5 mmol) was dissolved in THF (20 mL). 
To this Na2CO3 was added (530 mg, 5 mmol) followed by ethylamine solution (68 
% in H2O – 140 µL, 2.5 mmol), on which a colour change from clear to yellow was 
observed. After 30 mins of stirring the solution, it was filtered to remove base and 
then dried in vacuo. This solid was purified by column chromatography using a 10 
: 1 petroleum spirits : ethyl acetate eluent. This was dried in vacuo to yield yellow 
solid 5.8 (197 mg, 40%).  
 
1H NMR (300 MHz, CDCl3, ppm) δ = 5.35 (br, 1H, NH), 4.27 (d, 4JHH = 2.5 Hz, 2H, 
CH2), 3.68 (p, 3JHH = 7.1 Hz, 2H, CH2), 2.21 (t, 4JHH = 2.5 Hz, 1H, CH), 1.31 (t, 
3JHH = 7.2 Hz, 3H, CH3). 
13C NMR (126 MHz, CDCl3, ppm) δ = 166.3 (CO), 164.6 (CO), 140.6 (CN), 71.6 
(CH), 38.2 (CH2), 27.3 (CH2), 16.1 (CH3). 
HR-MS (Xevo) - [M+H+] – calculated m/z 213.0431 observed m/z 213.0433;  
FTIR (cm-1) – 3249 (υC-H), 2119 (υC≡C), 1705 (υC=O), 1688 (υC=O)  






Figure 5.28: 1H NMR spectrum of 5.8 
 
Figure 5.29: 13C NMR spectrum of 5.8 
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 3-aminopropyl propiolate (5.11) 
 
The synthesis of alkyne 5.11 was completed as previously reported, over 3 
steps with no alterations to the procedure. The final product contained a residual 
amount of methanol.15 
 
1H NMR (300 MHz, CDCl3, ppm) δ = 4.26 (t, 3JHH = 5.9 Hz, 2H), 3.22 (q, 3JHH = 6.0 
Hz, 2H), 2.89 (s, 1H), 1.89 (q, 3JHH = 6.0 Hz, 2H), 1.44 (s, 9H). 
MS (ESI) [M+H+] calculated m/z 127.1 observed m/z 127.1  









Bromomaleic anhydride (2.4, 1.2 g, 6.9 mmol) was dissolved into 15 mL of 
acetic acid in a round bottom flask with stirrer bar. To this compound 5.11 (0.95 
g, 7.1 mmol) was added and the mixture was stirred and heated to reflux (117 C) 
for 6 hours. This was dried in vacuo to yield a crude oil which was purified by silica 
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column chromatography in CHCl2. This was dried in vacuo to afford yellow solid 
5.12 (477 mg, 25%).  
 
1H NMR (400 MHz, CDCl3, ppm) δ = 6.89 (s, 1H, CH), 4.21 (t, 3JHH = 6.1 Hz, 2H, 
CH2), 3.71 (t, 3JHH = 6.8 Hz, 2H, CH2), 2.90 (s, 1H, CH), 2.02 (m, 2H, CH2). 
13C NMR (126 MHz, CDCl3, ppm) δ = 168.4 (CO), 165.3 (CO), 152.4 (COO), 131.9 
(CH), 131.5 (CBr), 75.1 (C), 74.4 (CH), 63.5 (CH2), 35.9 (CH2), 27.2 (CH2). 
HR-MS (maXis) - [M+H+] – calculated m/z 307.9527 observed m/z 307.9529;  
FTIR – 3245 (υC-H), 2115 (υC≡C), 1703 (υC=O),  
 
Figure 5.30: 1H NMR spectrum of 5.12 
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 3-(3-(ethylamino)-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-






Firstly, ethylamine solution (68% in water, 120 µL, 1.4 mmol) was added 
to a round bottom flask containing THF (20 mL) and a stirrer bar. To this Na2CO3 
(3.5 mmol, 280 mg) was added followed by alkyne 5.12 (400 mg, 1.4 mmol). 
This was left for two hours, after which it was filtered to remove base and dried in 
vacuo. The crude solid was purified by silica column chromatography in CHCl2. 
This was dried in vacuo to afford yellow solid 5.13 (145 mg, 41%) which contained 
 
Figure 5.31: 13C NMR spectrum of 5.12 
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a residual impurity (<5% by 1H NMR), however would hypothetically not affect the 
next coupling step.  
 
1H NMR (500 MHz, CDCl3, ppm) δ = 5.35 (br t, 1H, NH), 4.81 (s, 1H, CH), 4.19 
(t, 3JHH = 6.3 Hz, 2H, CH2), 3.60 (t, 3JHH = 6.7 Hz, 2H, CH2), 3.23 (dt, 3JHH = 7.3 
Hz, 6.9 Hz, 2H, CH2), 2.88 (s, 1H), 1.99 (p, 3JHH = 6.5 Hz, 2H, CH2), 1.29 (t, 3JHH 
= 7.3 Hz, 3H, CH3). 
13C NMR (126 MHz, CDCl3, ppm) δ = 172.25 (CO), 167.48 (CO), 152.61 (COO), 
149.06 (CH), 84.07 (CN), 74.77 (CH), 74.59 (CC), 63.68 (CH2), 39.06 (CH2), 
34.28 (CH2), 27.57 (CH2), 13.77 (CH2). 
HR-MS (maXis) - [M+H+] – calculated m/z 250.1032 observed m/z 250.1033;  
FTIR – 3326 (υC-H), 2108 (υC≡C), 1715 (υC=O), 1664 (υC=O),  
 
Figure 5.31: 1H NMR spectrum of 5.13 
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Figure 5.33: 13C NMR spectrum of 5.13 
 Chapter 5   274 
4.6 References 
 
(1) Wilkening, I.; Gazzola, S.; Riva, E.; Parascandolo, J. S.; Song, L.; Tosin, 
M. Chem. Commun. 2016, 52, 10392. 
(2) Ho, Y. T. C.; Leng, D. J.; Ghiringhelli, F.; Wilkening, I.; Bushell, D. P.; 
Köstner, O.; Riva, E.; Havemann, J.; Passarella, D.; Tosin, M. Chem. 
Commun. 2017, 53, 7088. 
(3) Sundlov, J. A.; Shi, C.; Wilson, D. J.; Aldrich, C. C.; Gulick, A. M. Chem. 
Biol. 2012, 19, 188. 
(4) Worthington, A. S.; Hur, G. H.; Meier, J. L.; Cheng, Q.; Moore, B. S.; 
Burkart, M. D. ChemBioChem 2008, 9, 2096. 
(5) Worthington, A. S.; Rivera, H.; Torpey, J. W.; Alexander, M. D.; Burkart, 
M. D. ACS Chem. Biol. 2006, 1, 687. 
(6) Gulick, A. M.; Aldrich, C. C. Nat. Prod. Rep. 2018, 35, 1156. 
(7) Tosin, M.; Spiteller, D.; Spencer, J. B. ChemBioChem 2009, 10, 1714. 
(8) Riva, E.; Wilkening, I.; Gazzola, S.; Li, W. M. A.; Smith, L.; Leadlay, P. 
F.; Tosin, M. Angew. Chem. Int. Ed. 2014, 53, 11944. 
(9) Du, L.; Lou, L. Nat. Prod. Rep. 2010, 27, 255. 
(10) Studier, F. W. Protein Expr. Purif. 2005, 41, 207. 
(11) Sivashanmugam, A.; Murray, V.; Cui, C.; Zhang, Y.; Wang, J.; Li, Q. 
Protein Sci. Publ. Protein Soc. 2009, 18, 936. 
(12) Wang, H.; Xu, M.; Xiong, M.; Cheng, J. Chem. Commun. 2015, 51, 4807. 
(13) Robin, M. P. Bromo and thio maleimides for functionalisation and 
fluorescent labelling of polymers and polymer nanoparticles, University of 
Warwick, 2014. 
(14) Xie, Y.; Husband, J. T.; Torrent-Sucarrat, M.; Yang, H.; Liu, W.; O’Reilly, 
R. K. Chem. Commun. 2018, 54, 3339. 
(15) Mehlich, J.; Ravoo, B. J. Org. Biomol. Chem. 2011, 9, 4108. 
(16) Ireland, R. E.; Wipf, P.; Xiang, J. N. J. Org. Chem. 1991, 56, 3572. 
(17) Patel, M.; Sushmita; Verma, A. K. Indian J. Heterocycl. Chem. 2018, 28, 
169. 
(18) Amberg, D. C. Methods in yeast genetics : a Cold Spring Harbor 
Laboratory course manual; 2005 ed.; Cold Spring Harbor Laboratory 
Press,: Cold Spring Harbor, N.Y. :, 2005. 
(19) Kieser, T.; Bibb, M. J.; Buttner, M. J.; Chater, K. F.; Hopwood, D. A. 
Practical Streptomyces genetics; The John Innes Foundation: Norwich, 
2000. 
(20) BAM Media M154: Trypticase (Tryptic) Soy Broth; Center for Food Safety 
and Applied Nutrition. FDA 2018. 
(21) Fu, H.; Hopwood, D. A.; Khosla, C. Chem. Biol. 1994, 1, 205. 
(22) Robin, M. P.; Wilson, P.; Mabire, A. B.; Kiviaho, J. K.; Raymond, J. E.; 
Haddleton, D. M.; O’Reilly, R. K. J. Am. Chem. Soc. 2013, 135, 2875. 
(23) Hedir, G. G.; Pitto‐Barry, A.; Dove, A. P.; O’Reilly, R. K. J. Polym. Sci. Part 
Polym. Chem. 2015, 53, 2699. 
(24) Castañeda, L.; Wright, Z. V. F.; Marculescu, C.; Tran, T. M.; Chudasama, 
V.; Maruani, A.; Hull, E. A.; Nunes, J. P. M.; Fitzmaurice, R. J.; Smith, M. 
E. B.; Jones, L. H.; Caddick, S.; Baker, J. R. Tetrahedron Lett. 2013, 54, 
3493. 
(25) Smith, M. E. B.; Caspersen, M. B.; Robinson, E.; Morais, M.; Maruani, A.; 
Nunes, J. P. M.; Nicholls, K.; Saxton, M. J.; Caddick, S.; Baker, J. R.; 
Chudasama, V. Org. Biomol. Chem. 2015, 13, 7946. 
 Chapter 6   275 
 
  
 Chapter 6   276 
5 Chapter 6: Peptide functionalized 
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5.1 Abstract 
 
The primary driving force for polymerization-induced self-assembly (PISA) 
is well known to be hydrophobicity, however, little work has focused on tuning or 
templating the assembly of polymers during this process through interactions such 
as hydrogen bonding. We hypothesized that by utilizing peptide-based 
intramolecular interactions, for example hydrogen bonding pairs in -sheets, we 
could template the assembly of polymers during PISA to encourage the formation 
of higher-order morphologies, such as vesicles and ribbons.  
Towards this aim, -helix, -sheet and random coil peptides were 
synthesized as macro-CTAs for RAFT polymerization of PISA monomers diacetone 
acrylamide (DAAm) and N-hydroxypropyl methacrylate (HPMA). While synthesis 
of the macro-CTAs was successful and polymerization could be achieved, 
aggregation of assemblies was universally encountered. Calculation of the 
LogPoct/SA of the CTAs suggested they were very polar in nature, and should make 
good stabilizing blocks, which confused results. Several design changes were 
investigated with no success at preventing aggregation until it was decided to 
functionalize the core-forming monomer with peptide instead of CTA. In this case 
a PEG macro-CTA was used as a solvophilic block and used to graft through a 
peptide acrylamide monomer to create stable particles through RAFT mediated 
PISA. The assembly of particles was observed by DLS, whereas none was observed 
without peptide, confirming that the peptides are driving assembly through a 
process which is not hydrophobicity driven. Future work will investigate this 
further with a range of peptide-functionalized monomers.   
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5.2 Introduction 
 
5.2.1 Polymerization-induced self-assembly (PISA) 
Block copolymer self-assembly is a well-understood phenomenon dating 
back over half a century,1 as discussed in the introduction to this thesis.  This 
assembly is typically driven post-polymerization, with methods such as solvent 
switching and direct dissolution in a selective solvent. However, a relatively new 
and rapidly growing field of self-assembly is polymerization induced self-assembly 
(PISA). PISA under dispersion conditions, occurs when a stabilizing, or solvophilic 
block, is extended with a monomer that is solvent miscible. Upon reaching a 
particular degree of polymerization this block becomes solvophobic (Scheme 
6.1).2 This block, forms the core of the forming assembly and can continue to grow 
upon the addition of more monomer. Typically, the onset of assembly is followed 
by a marked increase in polymerization kinetics as monomer can be sequestered 
into the solvophobic domain, leading to an increase in the local concentration of 
monomer.3  
 
Scheme 6.1: Illustrated representation of the dispersion PISA process.  
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There are numerous advantages of PISA over traditional self-assembly 
methods, especially for industrial applications. In particular this includes reducing 
the steps in synthesis, assembly and purification, as quantitative monomer 
conversion is usually achieved and no dilute scale assembly steps are required - 
as PISA can be conducted at very high percentage solids (typically 5-50 w%, 
compared to <1 w% for conventional self-assembly methodologies).4 
These advantages have led to a rapid growth in the technique, with many 
different reported types and applications. A vast array of morphologies can be 
accessed via PISA, determined primarily by the packing parameter (P), 
comparable to traditional self-assembly methods. Examples range from the 
traditional spheres and worms,5,6 to higher-order morphologies such as 
multilamellar vesicles and tubular vesicles.7 Applications range from cell 
preservation and storage;8,9 drug delivery through encapsulation during or post-
PISA;10-13 to PISA in oil for lubrication applications.4 
Using PISA for peptide-based applications has been previously explored. In 
our group, work has focused on the entrapment and encapsulation of enzymes 
and peptides within vesicles,11,14 and within polymer membranes during PISA.15 
Entrapment of enzymes was shown to provide effective protection from 
immunogenicity and proteolysis,11 problems typically associated with peptide-
based therapeutics.16 Gianneschi and co-workers have demonstrated a peptide 
based-monomer that can undergo ring-opening metathesis polymerization 
(ROMP) mediated PISA.17 While a range of morphologies were obtained, the 
peptide was modified with protecting groups to increase hydrophobicity, thus 
allowing aqueous phase PISA, but limiting therapeutic applications.  
Near universally, PISA is regarded to proceed as a consequence of 
solvophobicity, which in aqueous media is the hydrophobicity of the growing 
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polymer chain.5,18 However, one report of polymerization induced electrostatic 
self-assembly (PIESA) has recently been published, which details the induction of 
assembly through ionic interactions in the case of a histamine acrylamide 
polymerization by a poly(HPMA)-co-poly(AMPS) macro-CTA (Figure 6.2).19 As the 
length of ionic blocks increased, larger assemblies from spheres, to worms to films 
were observed. Hydrogen bonding is another intermolecular interaction that has 
been well-known to affect self-assembly behaviour,20-22 and work by Reiger and 
co-workers has shown how urea functionalized seeds can template the assembly 
of fibres through PISA of HPMA.23 It is hypothesized that peptides can utilize both 
effects, allowing greater control over hydrogen bonding and ionic effects to 
template the formation of therapeutic nanoparticles via PISA.  
 
 
Scheme 6.2: Illustration of PIESA reported by Cai et al.19 
 
5.2.2 Reversible addition-fragmentation chain-transfer 
(RAFT) polymerization 
The requirement for well-defined diblock copolymer synthesis for PISA 
necessitates the use of a controlled polymerization technique. The majority of 
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literature examples, therefore, employ reversible-addition fragmentation 
chain-transfer (RAFT) polymerization to achieve this.12,21–25 Other 
methodologies have been reported, including other radical polymerizations, 
such as ATRP-PISA,26 and non-radical polymerizations, for example, ROMP-
PISA.27 
For this chapter, RAFT will be relied upon to synthesize peptide-polymer 
conjugates. RAFT is a type of reversible-deactivation radical polymerization 
(RDRP) or controlled radical polymerization technique, as presented in the 
introduction to this thesis. RAFT relies on the use of a chain transfer agent 
(CTA), specifically, a thiocarbonylthio compound for example 
dithiocarbamates,27 or used in this Chapter, trithiocarbonates. This CTA 
transfers the activity of a growing polymer chain to another polymer chain, 
thus averaging the molecular weight of polymer chains in the environment 
through giving equal probability to all chains to grow.28 It also provides a 
dormant species which reduces the concentration of active radicals in solution, 
therefore reducing termination and increasing propagation lifetime. By 
reducing initiator concentration, thereby keeping radical concentration low (< 
1 mol%), Perrier and co-workers have shown termination can effectively be 
eliminated enabling end-group fidelity of 97 % and a ĐM close to 1.1.29 
The mechanism of RAFT (Scheme 6.3) starts with activation through 
initiation and generation of radicals, typically created through thermal initiation 
of a radical initiator. These radicals (I•) can then react with monomers (M) to 
form propagating chains (Pn•) and can then be captured by a CTA, entering 
into an equilibrium between the active and dormant states.29,30 This dormant 
state can fragment to produce a new initiating group (R•), which can re-initiate 
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a propagating chain (Pm•). Now a rapid equilibrium is formed in which Pm• or 
Pn• have an equal chance to fragment and propagate, leading them to exhibit 
similar degrees of polymerization over time. The termination reaction often is 
inevitable in a radical polymerization system, and this is still true with RAFT. It is 
noteworthy that as bimolecular termination does not lead to loss of CTA activity 
in RAFT, the amount of terminated chains in solution will be equal to the amount 




Scheme 6.3: Proposed RAFT mechanism. 
 
The success of RAFT polymerization is dependent upon the judicious 
choice of CTA. As seen in Figure 6.3, CTAs are variable in R and Z functionality, 
which each have different effects on the polymerization. The Z-group 
significantly affects stability of the radical intermediates in the chain transfer 
steps, thus affecting the rate of fragmentation of the CTA.32 Furthermore, 
through activation of the C=S bond, it affects rate of addition of propagating 
radicals.32 Specifically, the Z-group should be chosen so that the CTA is 10-
100 times more reactive towards the propagating chain than the target 
monomer.33 The R-group, in comparison, should be chosen to be a good 
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leaving group from the chain transfer radical intermediate and should undergo 
effective re-initiation with monomer.31 A schematic representation to illustrate 




Scheme 6.4: Structure of generic RAFT agent, and empirical guide to 
R and Z-group selection for selected monomers, adapted from ref.33 
 
5.2.3 Peptide synthesis  
6.2.4.1 Preparation of synthetic peptides 
Nature is well developed to synthesize peptide chains, with eukaryotes able 
to synthesize around 6 aa/sec per chain.34 Synthetically, in contrast, chemists with 
the latest microwave-assisted methods can realistically achieve 3-4 aa/hour. In 
most labs, this is achieved with Fmoc protected, solid-phase peptide synthesis 
(SPPS).35 In this the peptide bond formation occurs via activated carboxylic acid 
couplings to amines supported on a solid phase resin. This allows easy purification 
through removal of unbound side products and unused reagents, allowing large 
excesses to help achieve high conversion, and eliminating the laborious process 
of peptide isolation between each coupling. While Boc protected peptide coupling 
is used and has its advantages (for example all deprotection side products are 
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volatile), Fmoc SPPS has become the standard methodology due to its 
orthogonality with the other chemistries involved. In particular, the basic 
deprotection of Fmoc protected backbone amines is orthogonal to the acid labile 
chemistries used to protect side groups and to enact resin cleavage. While for Boc 
SPPS, HF is required for resin cleavage which has many issues associated with its 
use, including handling a low boiling point liquid (19.6 C), the inability to use 
glassware, and handling an extremely toxic reagent.36 
6.2.4.2 Activation and amide bond formation  
To achieve conversions in peptide couplings required for multistep peptide 
synthesis, very efficient amide coupling conditions are required.37 The activation 
used to achieve this is a cause for many of the issues encountered in the synthesis 
including racemization issues at the chiral backbone carbon. Therefore, a range of 
specialized peptide coupling reagents have been developed from original 
carbodiimide based couplings to more recent uronium salt-based coupling agents 
(Scheme 6.5), which combine uronium activating chemistry with a racemization 
suppressing additive such as 1-hydroxy-benzotriazole (HOBt). If a carbodiimide 
based coupling agent is used (for example diisopropylcarbodiimide, DIC) a 
racemization reducing additive is also required, so triazoles such as HOBt are 
added separately. Recently, ethyl 2‐Cyano‐2‐(hydroxyimino)acetate (OXYMA) has 
been developed as a safer and equally efficient racemization reducing additive,38 
and it will therefore be used in this study.  























Scheme 6.5: Simplified scheme of the coupling step and selection of example 
activators and racemization reducing reagents. 
6.2.4.3 Sidechain protection  
The incoming amino acid may contain reactive moieties in the side chain, 
and these require protection orthogonally to the -amino Fmoc. Except for a few 
special circumstances (for example selective disulfide bridging),39 side chain 
protection groups must be stable to coupling and Fmoc deprotection conditions, 
and should be cleaved effectively under the resin cleavage conditions (for example 
95% TFA). This protecting group varies depending on the functionality but some 
groups encountered in this chapter include: Nε-Boc protection of lysine residues, 
and O-tBu protection of aspartic acid residues (Table 6.1) 
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Table 6.1: Selected side chain protection strategies employed in this chapter.   
6.2.4.4 Resins used for SPPS  
While the principle of a solid phase support for peptide synthesis may 
appear trivial, the resin used has to: be stable to all reaction conditions including 
high temperature in microwave-assisted synthesis; be selectively cleaved under 
suitable conditions; and swell with addition of reaction solvent to allow efficient 
diffusion, while not swelling to a degree which increases the already high solvent 
consumption of SPPS.40  
The first resin reported by Merrifield was a polystyrene resin cross-linked 
with 2% 4-divinylbenzene, with a chloromethyl benzene linker for peptide 
attachement.41 However issues are associated with its use, for example the resin 
is particularly hydrophobic leading to increased peptide-peptide chain interactions, 
and therefore lower coupling yields and poorer swelling as peptide weight 
increases.42 The linker used in this resin also required HF cleavage, which is  















N-Pbf Arginine >90% TFA 
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undesirable as discussed earlier.  More recently PEG-based resins have become 
popular as they exhibit better swelling properties.43  
 
Importantly, newer linkers have been developed which require milder 
cleavage conditions and can give specific C-terminus functionalization (Table 6.2). 
For example, Wang resins include a 4-hydroxybenzyl ether linker,44 which are 
cleaved by TFA and leave a C-terminus acid. While Rink-Amide resins contain a 4-
((2,4-dimethoxyphenyl)(Fmoc-amino)methyl)phenoxyalkyl linker that is cleaved 
by TFA to produce a C-terminus amide (Table 6.2).45  














1-5% TFA Acid 
 
Rink amide >90% TFA Amide 
Table 6.2: Structure of selected risin linkers, with their cleavage conditions 
and produced C-terminus. 
. 
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5.3 Results 
5.3.1 Synthesis of peptide-functionalized chain transfer 
agents  
Peptides are perfectly sequence controlled polymers that can assemble into 
distinct controllable assemblies dependent upon their sequence, for example 
barrels and ribbons,46,47 as discussed in the introduction to this thesis. It was 
hypothesized that de novo peptides could be designed to template and direct the 
assembly of higher order morphologies during polymerization induced self-
assembly (PISA). For example, β-sheet forming peptides could help template 
linear higher order morphologies such as ribbons through parallel hydrogen 
bonding interactions,46 or alpha helices could template the formation of chiral 
vesicles through twisted stacking interactions,48 that would also have other 
applications like enantiomer screening in supported stereoselective catalysis.49 
To investigate the effect of peptide secondary structure on the assembly of 
peptide-polymer conjugates, a series of peptides were selected for comparison. 
Based upon the two main types of secondary structure observed in nature, an α-
helix forming peptide and a β-sheet forming peptide were chosen to compare to a 
random coil control peptide sequence. Based on the work of Baldwin and co-
workers, an (ER)i+4 -helix was targeted (Scheme 6.6), as this was shown to 
possess exceptional α-helical character in solution.50,51 For the β-sheet comparison 
an RADAn repeating sequence was selected as it possesses a repeating unit of a 
strong β-sheet domain, shown to form β-sheet nanofibrils in aqueous solution.52 
Finally, for the control random coil a sequence was selected from a known non-
assembling peptide subunit, the kinase-independent domain of the cAMP response 
element-binding protein (KID-CREB).53,54 It is also a useful sequence as it contains 
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eight amino acids, including amino, alcohol, aromatic and acid functionality, a 
good test for the compatibility of this technique to a range of peptide functionality.  
 
 Firstly, the helical peptide (ER)i+4 was targeted for CTA functionalization, 
because of familiarity with its synthesis as a result of other projects and the ease 
of characterizing α-helices via circular dichroism. The peptide was synthesized via 
Fmoc assisted solid-phase peptide synthesis (SPPS) using microwave-assisted 
couplings and an OXYMA/DIC reagent system. After synthesis of the main chain a 
small proportion of the resin (<5%) was taken and cleaved to assess success of 
the synthesis. LCMS of this confirmed good purity, so the remaining resin bound 
peptide was derivatized with the appropriate acid functionalized CTA via DIC 
mediated coupling. For this coupling, a nitrile derivatized trithiocarbonate CTA 
(CETPA) was targeted as it was suitable for polymerizing the most ubiquitous PISA 
monomer N-hydroxypropyl methacrylate (HPMA). This acid functionalized CTA 
was coupled to the synthesized peptide via solid-phase mediated amide coupling 
(Scheme 6.7). The resin-bound CTA-peptide was then cleaved using trifluoroacetic 
acid to give CTA 6.1. While HPLC results suggested good purity, mass 
spectroscopy gave an m/z of 1997, 18 m/z higher than expected, indicative of 
hydrolysis or adduct formation upon ionization. Also, an initial test polymerization 
Scheme 6.6: Sequences of the three targeted peptide sequences. 
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of HPMA with this CTA, to a degree of polymerization (DP) of 50, showed poor 
control (ĐM= 3.79) by DMF size exclusion chromatography (SEC) (Figure 6.1). It 
is hypothesized that the nitrile group is hydrolyzed during the TFA deprotection 
step leading to the mass observed and the poor control of polymerization. Nitrile 
based CTAs have been reported to hydrolyze to the amide under acidic aqueous 
environments.55  It is not reported why further hydrolysis to the amine is not 
observed, however it could be envisioned that this product would lead to CTA 
aminolysis. A test deprotection was re-attempted without water in the 











Scheme 6.7: Unsuccessful synthesis of CETPA functionalzied (ER)i+4 peptide 
CTA 6.1. 
 











As a result of the nitrile hydrolysis seen in CETPA, a propanoic acid butyl 
trithiocarbonate (PABTC) CTA was targeted instead. PABTC can polymerize the 
aqueous PISA monomer DAAm with good control. Therefore, PABTC was 
synthesized as per Skey and O’Reilly56 and coupled to the peptide using the 
OXYMA/DIC system employed for CTA 6.1. This time HPLC and mass spectroscopy 
proved good purity and retention of structure in CTA 6.2. Circular dichroism of 
this CTA was conducted (Figure 6.2), and good α-helical character was observed 
at 222 nm compared to a random coil peptide 6.5.  
 
Figure 6.1: DMF SEC (DRI) molecular weight distribution of PHPMA (DP = 
50) polymerized using macro-CTA 6.1. 
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Figure 6.2: Circular dischroism spectra of (ER)i+4 peptide CTA 6.2 and 












Secondly, the β-sheet based RADA16 peptide was synthesized by this same 
method, followed by coupling to PABTC and subsequent cleavage to produce β-
sheet forming CTA (RADA)16-PABTC 6.3 (Figure 6.3A). However, it was 
immediately apparent that 6.3 was not water-soluble, even after heating or 
Scheme 6.4: Synthesis of PABTC functionalzied (ER)i+4 peptide CTA 6.2.  
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sonication. While in theory more polar than CTA 6.2, this peptide is likely to have 
much stronger intermolecular interactions such as hydrogen bonding and ionic 
interactions. Based on literature precedent, it could be forming a β-sheet complex 
without the need for a hydrophobic block.51 To confirm this the peptide was 
dispersed into solutions of guanidine, known to break apart -helix and -sheet 
assemblies.57 When dispersed into 8 M guanidine, solvation of the peptide at 
1 mg/mL was achievable, confirming this hypothesis, and analysis of the 
denatured protein by HPLC confirmed fair purity exhibited by two peaks, as a 
consequence of diastereomer formation (Figure 6.3B), however noise attributable 
to the harsh conditions for solvation is present. As a result, only helical CTA 6.2 











Figure 6.3: A) Structure of PABTC functionalzied RADA16 peptide CTA 6.3. B) 
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5.3.2 Investigating aqueous PISA using a helical 
peptide-based PABTC macro-chain transfer agent  
CTA 6.2 was investigated for aqueous PISA, using a water-soluble initiator, 
VA-044, and heating at 40 C. Polymerizations were conducted at 10 and 15 w% 
solids concentration, targeting a DP of 50 and 100 of the PDDAm block. Solutions 
turned white and cloudy within 2 hours, indicative of polymerization-induced self-
assembly. SEC analysis by DRI in DMF (Figure 6.4) indicated fair control of the 
polymerizations at 10 w% with molecular weight dispersities of 1.28 and 1.39 for 
DP = 50 (P1) and DP = 100 (P2) respectively. At 15 w% and DP = 100 (P3), 
analysis was complicated as SEC indicated a large population at very high 
molecular weight (~80 kDa), suggestive of association in the SEC eluent (DMF) or 
loss of polymerization control.  
 
 
1H NMR spectroscopy in DMSO-d6 indicated that the polymerizations 
proceeded to high conversion overnight (>99% for the 10 w% polymerizations 
Figure 6.4: DMF SEC (DRI) molecular weight distribution of PDAAm polymerized 
using macro-CTA 6.2. 
 
. 



















 10 w%, DP = 50
 10 w%, DP = 100
 15 w%, DP = 100
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Table 6.3: Summary of Dh, PD values and zeta potential values with deviation 
for assemblies formed via aqueous PISA, as determined by DLS analysis and 
micoelectrophoretic analysis respectively. 
. 
and 82% for the 15 w% polymerization). As polymerization appeared to proceed 
well for P1 and P2, DLS was conducted to establish whether stable assemblies 
were forming. However, DLS suggested aggregate formation (Table 6.3) with 
assemblies >1 µm that had poor dispersity (>0.2). Zeta potential was also 
measured to establish whether the peptide was providing charge stability, as 
theoretically each peptide-polymer should have a -1 charge. However, this 
indicated that only the DP = 50 sample exhibited a negative zeta potential (Table 
6.3), suggesting that the peptide was not providing enough charge stability at 
longer PDAAm lengths.   
 
 
Dry-state TEM imaging was conducted on P2, which suggested aggregated 
small spherical nanoparticle formation with diameters much shorter than observed 
by DLS (Figure 6.5). The aggregated nanoparticles observed by the TEM images 
strongly suggest aggregation of the assemblies in solution leading to the poor DLS 





Dh (nm) PD  Zeta Potential 
(mV) 
P1 10 w% 50 1474 ± 85 0.22 ± 
0.15 
-19.03 ± 0.15 
P2 10 w% 100 346 ± 57 0.54 ± 
0.07 
6.32 ± 0.29 




4.80 ± 1.80 
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design to increase charge stabilizing characteristics. This was achieved by 
mimicking work on peptide amphiphiles which are often terminated by a tri-
glutamic acid (EEE) tag. Thus, peptide CTA 6.4 was synthesized as previously, 
bearing a C-terminal EEE motif. Using this macro-CTA DAAm was again 
polymerized, targeting DP = 50 (P4) and DP = 100 (P5) at 10 w%. Both 
polymerizations proceeded to >99% conversion by 1H NMR spectroscopy (DMSO-
d6) when left overnight at 40 ⁰C. Nano-structure formation was observed for both 
samples by DLS in both THF and DMF preventing SEC characterization. DLS of P4 
under aqueous conditions showed aggregate formation, with zeta potential 
measurement of the crude solution indicating positively charged particles (Table 
6.4). Dissolution into a range of buffers suggested that at neutral and basic pH 
the particles were negatively charged, however, aggregation was still observed by 
DLS. It is hypothesized that this may be a cause of chain entanglement. As RAFT 
is poorly suited to basic conditions as a result of CTA hydrolysis,52 it was decided 
to switch to a tri-arginine (RRR) tag for stability under acidic conditions.  
Figure 6.5: Dry-state TEM images of P2, stained with a 1 w% uranyl acetate 
solution on a formvar-carbon coated copper grid. 
 
. 
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5.3.3 Investigating aqueous photo PISA using a random 
coil peptide-based PABTC chain transfer agent 
As a result of unstable assemblies observed with the helical peptide CTA, 
and lack of solubility of the β-sheet peptide, it was decided to switch to a random 
coil peptide (KID-CREB). This was terminated with a trimer of arginine (RRR) 
analogous to the EEE tag but potentially more suitable for low pH conditions that 
suit RAFT mediated PISA (Figure 6.6A). It was also decided to utilize photoinitiation 
by light (405 nm) irradiation, instead of thermal initiation, as there was success 
within the group with this negating the need for initiator.58 RRR capped KID-CREB 
macro-CTA 6.5 was successfully synthesized and used for PISA at 40 C in a pH 2 
sodium phosphate solution (P6), in a photoreactor. A block of DP = 50 PDAAm 
was targeted at 10 w% and a conversion of 88% was reached in 4 hours by 1H 
NMR spectroscopy (DMSO-d6). SEC analysis was possible in THF which showed 
poor dispersity (ĐM = 1.56) and an Mn higher than targeted (33600 g/mol versus 
targeted Mn of 9400 g/mol, Figure 6.6B), however, this is based off a PMMA 
standard.  
 
# Buffer Dh (nm) PD  Zeta 
P4 crude 1666 ± 239 0.72 ± 0.12 14.1 ± 2.42 
P4 pH 4 acetate 4098 ± 158 0.13 ± 0.06 -0.06 ± 0.23 
P4 pH 7 phosphate 1623 ± 45 0.49 ± 0.05 -16.7 ± 0.29 
P4 pH 10 
carbonate 
2011 ± 87 0.50 ± 0.1 -14.4 ± 0.56 
P5 crude 3340 ± 353 0.33 ± 0.07 0.38 ± 2.36 
Table 6.4: Summary of Dh, PD values and zeta potential with deviation for 
P4 in different pH buffers, as determined by DLS analysis and 
microelectrophoresis respectively. 
. 

















DLS of P6 suggested aggregate formation with assemblies over >1 µm. 
Treatment of the samples with a 0.5 M NaCl solution to screen charge interactions, 
did not improve assembly, with aggregates still observed. It is hypothesized that 
the peptide block is not large and hydrophilic enough to stabilize such high DPs of 
hydrophobic monomer. Therefore, CTA 6.5 was used to polymerize DAAm 
targeting 15 DP at 5 w% (P7) using photo-irradiation. Polymerization conversion 
was slower reaching only 75% as determined by 1H NMR spectroscopy (DMSO-
d6), and THF SEC of the polymer suggested a broad (ĐM = 1.70) unimodal 
distribution with a slight low molecular weight shoulder hypothesized to be 
unreacted macro-CTA (Figure 6.7A). 
Figure 6.6: A) Structure of macro-CTA 6.5 B) SEC (dashed = UV 309 nm, line 
































During the polymerization the solution went cloudy indicative of nanoscale 
assembly. DLS confirmed this with fairly large unstable assemblies still observed 
for the 15 DP polymer (Figure 6.7B). Zeta potential did confirm positively charged 
particles which was screened in 0.5 M NaCl, however aggregation was still 
observed in salt solution (Table 6.5). Atomic force microscopy (AFM) was 
conducted on P7 to help confirm morphology. This showed sphere-like particles, 
the size of which were several fold smaller than that observed by DLS, which 
appeared to be clustered - although these observations may be driven by drying 







Figure 6.7: A) Normalized THF SEC Mw distribution of P7 (dashed = 309 nm, line 
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Figure 6.8: Dry state AFM images of P7, and histogram of measured 
particle diameters (bottom right). 
 
. 
Table 6.5: Dh, PD values, zeta potentials and observed size with deviations for 



















Work in the group has pioneered the use of LogPoct/SA to establish the use 
of monomers for aqueous PISA.59,60 We hoped to utilize this technique to establish 
whether the peptide macro-CTAs are polar enough to act as a stabilizing block for 
aqueous PISA. Using the previously reported methodology, the LogPoct/SA was 
  DLS Zeta 
potential 
(mV) 
AFM   
Dh (nm) Dispersity Mean SD Max/Min 
P7 208 ± 6  0.16 ± 
0.04 










1 ± 0 -0.1 ± 1.9 - - - 













Mean = 69 nm
s = 21 nm
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Table 6.6: Atom based octanol-water partition coefficients (ALogP98), calculated 
Connolly solvent accessible surface area (SA) and surface area normalized LogP 
(ALogP98/SA) for CTAs 6.2 and 6.5. 
. 
calculated for both helical CTA 6.2 and coil CTA 6.5, at various ionization states 
(Table 6.6). The calculated LogPoct/SA values are negative and suggest the peptide 
CTAs would have good solubility in water. In fact, they have a lower LogPoct/SA in 
comparison to a DP = 12 PEG; suggesting they theoretically should be a better 






CTA Approx. pH ALogP98 Connolly SA ALogP98/SA 
6.2 2-4 -10.0478 1746.79 -0.0058 
6.2 6-11 -15.943 1729.21 -0.0092 
6.5 2-4 -11.082 1924.08 -0.0058 
6.5 6-11 -14.0306 1924.2 -0.0073 
PEG  
(DP = 12) 
N/A -1.449 754.72 -0.0024 
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5.3.4 Synthesis and aqueous PISA of peptide based 
acrylamide monomers  
As a result of the poor behaviour of the peptide-based macro-CTAs, and 
difficulty in characterization, it was decided to study peptide-based monomers that 
can be grafted through. These can be polymerized with a PEG macro-CTA to give 
a PEG stabilizing block. Towards this aim, the random coil peptide KID-CREB was 
synthesized by SPPS with single couplings, and coupled to acrylic acid by 
OXYMA/DIC coupling on resin. This was then cleaved under standard TFA 
conditions, to give monomer 6.6 (Figure 6.9); HPLC and MS analysis confirmed 
structure and fair purity.  
 
 
This was polymerized to DP = 3, using a PEG2k-CETPA macro-CTA, under 
aqueous photo PISA conditions, to give a PEG-poly(KID-CREB) diblock copolymer, 
with a short peptide block. This was subsequently chain extended with HPMA 
targeting DP = 10 (P8) or 25 (P9) to give a PEG-poly(KID-CREB)-PHPMA triblock 
copolymer. As a control, the same CTA was also used to polymerize HPMA without 
an intermediate peptide block at DP = 10 (P10) and 25 (P11). After 
Figure 6.9: A) Synthesis of peptide side-chain monomer 6.6 B) HPLC of 
monomer 6.6 detetcted at 220 nm. 
 
B A 
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Table 6.7: Summary of Dh and PD values with deviation for P8-11, as 
determined by DLS analysis. *Signal too weak for analysis. 
polymerization, PHPMA-PEG (P10-11) standards were clear, while both P8 and 
P9 had turned slightly turbid, indicative of nanoparticle assembly. DLS of these 
solutions confirmed these observations with no assembly observed for both P10 
and P11, however, assemblies were observed for P8 and P9 (Table 6.7). Also, 
DLS of monomer 6.6 at 5 w% in water showed no assembly. This is highly 
suggestive that peptides are driving assembly during the polymerization and 
indicative that these peptides are not suitable for forming corona blocks as studied 
earlier in this chapter.  
Unfortunately, DLS data for P8 and P9 showed aggregates in both DMF and 
THF, so SEC analysis could not be completed, however, 1H NMR analysis suggested 
good conversion for the PHPMA controls and peptide blocks (>99%). However, 
only fair conversion for the PHPMA chain-extension of the peptide diblock 
copolymers was realized (P8: 67%; P9: 81%), hypothesized to be a result of 
assembly formation in the peptide block step or CTA degradation from photo 








The assembly of such hydrophilic peptides with hydrophilic PEG polymer 
suggests that the assembly is not hydrophobicity driven, which corroborates 
previous LogPoct/SA calculations. It is hypothesized that hydrogen bonding and 







Dh (nm) Dispersity 
P8 3 10 49 ± 0.7 0.15 ± 0.01 
P9 3 25 221 ± 1.3 0.02  ± 0.005 
P10 0 10 * * 
P11 0 25 * * 
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work will investigate the mechanism and formation of therapeutic assemblies via 
peptide-monomer based PISA.  
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5.4 Conclusions 
 
A range of peptide-based macro-CTAs were synthesized via SPPS exhibiting 
different secondary structures. CETPA based CTAs hydrolyzed during solid-phase 
cleavage so PABTC based CTAs were synthesized for polymerization of PISA 
monomer DAAm. While polymerizations with such CTAs proceeded to good 
conversion, aggregation and unstable assemblies were universally encountered, 
some to such a degree that SEC characterization was not possible. LogPoct/SA 
calculation of the CTAs suggested this was not caused by hydrophobicity. As a 
result of these issues, the experimental design was switched from a peptide-CTA 
to a peptide-based monomer for graft through polymerization using a PEG macro-
CTA. Assembly was noted during the graft through polymerization, analyzed by 
DLS, whereas none was observed for the non-peptide controls. This indeed 
confirms that the peptides were not suitable as stabilizing blocks for PISA, and 
thus future work will study the apparent PISA behaviour of various peptide-based 
monomers.  
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5.5 Experimental 
5.5.1 Materials and instrumentation 
 Materials 
Fmoc amino acids were received from Novabiochem or Iris Biotech. All other 
chemicals were obtained from either: Sigma Aldrich, Fisher Chemicals, Acros 
Chemicals, Carbosynth or Alfa Aesar and used as received. CEPTA was kindly 
donated by Mr Zachary Coe, and PEG2k-CETPA was kindly donated by Dr Turgay 
Yildrim.  
 Instrumentation 
1H NMR spectra were recorded on a Bruker Advance 300, a Bruker Advance 
III HD 400 or a Bruker Advance III HD 500 spectrometer at 300, 400 and 500 MHz 
respectively. Shifts are quoted in δ in parts per million (ppm) relative to the 
solvent peak. 
Infrared spectra were recorded on neat samples using a Perkin Elmer 
Spectrum 100 FT-IR Spectrometer. 
Reverse phase high pressure liquid chromatography (HPLC) analysis was 
performed on a modular Shimadzu instrument with the following modules: CBM-
20A system controller, LC-20AD solvent delivery module, SIL-20AC HT 
autosampler, CTO-20AC column oven, SPD-M20A photodiode array UV-Vis 
detector, RF-20A spectrofluorometric detector (not used) and a FRC-10 fraction 
collector (not used). Chromatography was performed on a Shim-pack GISS 5 μm 
C18 (4.6×125mm) reverse phase column heated at 30 °C. Flow rate was set at 
0.8 mL/min and the products were eluted using a gradient of gradient of 18.2 
MΩ·cm water and acetonitrile. A typical elution gradient is shown in Figure 6.10.   
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Figure 6.10: Typical elution gradient for peptide chromatography.  
 
Peptide mass spectra were conducted on either a Thermofischer LCQ fleet 
Ion Trap Mass Spectrometer or a Waters Xevo G2-XS QTof Mass Spectrometer, in 
positive or negative ionization mode respectively.  
Size exclusion chromatography (SEC) in DMF was performed on an Agilent 
1260 Infinity II LC system equipped with a Wyatt DAWN HELEOS II multi-angle 
laser light scattering (MALLS) detector, a Wyatt Optilab T-rEX differential 
refractive index detector, an Agilent 1260 Infinity II WR diode array detector, an 
Agilent guard column (PLGel 5 μM, 50 × 7.5 mm) and two Agilent Mixed-C columns 
(PLGel 5 μM, 300 × 7.5 mm). The mobile phase was DMF (HPLC grade) containing 
5 mM NH4BF4 and was ran at 50 °C at a flow rate of 1.0 mL/min. Number average 
molecular weights (Mn), weight average molecular weights (Mw) and dispersities 
(ĐM = Mw/Mn) were determined using Wyatt ASTRA v7.1.3 software against 
poly(methyl methacrylate) (PMMA) standards (Mw range = 1,160 – 6,025,000). 
SEC in THF was performed on an Agilent 1260 Infinity II LC system equipped 
with an Agilent guard column (PLGel 5 μM, 50 × 7.5 mm) and two Agilent Mixed-
C columns (PLGel 5 μM, 300 × 7.5 mm). The mobile phase used was THF (HPLC 
grade) containing 2% v/v triethylamine at 40 °C at a flow rate of 1.0 mL/min. 
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Number average molecular weights (Mn), weight average molecular weights (Mw) 
and dispersities (ĐM = Mw/Mn) were determined using Agilent SEC software against 
polystyrene (PS) standards used for calibration (Mw range = 925 – 3647000). 
 DLS analysis of the crude PISA solutions was conducted using a Malvern 
Zetasizer Nano S instrument with a 4 mW He-Ne 633 nm laser module at 25 °C 
and at a detection angle of 173°. Samples were diluted with 18.2 MΩ·cm water. 
Z-average hydrodynamic diameters (Dh) were calculated from three repeat 
measurements using Malvern DTS 6.20 software. 
Dry-state stained TEM analysis was performed on a JEOL JEM-1400 
microscope operating at 80 kV. Purified samples were diluted with 18.2 MΩ·cm 
water then deposited onto formvar-coated copper grids. After roughly 1 min, 
excess sample was blotted from the grid and the grid stained with an aqueous 1 
w% uranyl acetate (UA) solution for 1 min prior to blotting, drying and microscopic 
analysis. TEM images were collected by Mr Spyridon Varlas (O’Reilly Group, 
University of Birmingham). 
Atomic Force Microscopy (AFM) was performed on a JPK Nanowizard 4 
system at room temperature in the supplied acoustic enclosure and vibration 
isolation using Nanosensor PPP-NCHAuD tips with a force constant of around 42 
N/m. For data acquisition and handling Nanowizard Control and Data Processing 
Software V.6.1.117 in QI mode with a setpoint of 25 nN was used. Samples were 
prepared on freshly cleaved mica by drop-casting a solution of 0.5 mg/mL crude 
sample, and spin-drying the cast sample.  
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 Photoreactor  
 
The photoreactor set up used included an LED source for the visible-light 
irradiation (TruOpto OSV5X3CAC1E, 4.5 W - purchased from Rapid Electronics), 
and had a radiant flux of 800 mW@400 mA at 12V DC operating at a wavelength 
of 400–410 nm. This was fitted to a custom-built setup equipped with a dimmer 
switch for controlling the output light intensity (Figure 6.11). The vials are 
positioned 19 mm above the LED, giving 76% light intensity at the base perimeter 
of the vial. The base of each vial holder contains a magnetic stirring mechanism 
for sample stirring.  
  
 
Figure 6.11: Photo of photoreactor set-up used for photoinitiated 
polymerizations in this chapter. 
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5.5.2 Small molecule synthesis  
6.5.2.1 PABTC  
 
The synthesis was based off a previously reported protocol.52 Butanethiol 
(5 g, 55 mmol) was added to a stirred suspension of K3PO4 (11.6 g, 55 mmol) 
in acetone (100 mL). Carbon disulfide (3.9 mL, 55 mmol) was added to this 
solution and left to stir for 10 minutes, the solution went bright yellow. After, 
ethyl-2-bromopropionate (8.3 mL, 55 mmol) was added and the precipitation 
of KBr was observed. After stirring for 45 minutes, the solution was filtered 
and the precipitate washed with acetone. The filtrate was taken and the solvent 
removed in vacuo. This crude solid was purified by silica column 
chromatography (50% ethyl acetate in petroleum ether as the eluent) to give a 
white solid (5.4 g, 41%).  
 
1H NMR (CDCl3, 300MHz, ppm) δ = 4.80 (q, 3JHH = 7.4 Hz, 1H, CH), 3.41 – 3.20 
(m, 2H, CH2), 1.70 – 1.59 (m, 2H, CH2), 1.56 (d, 3JHH = 7.4 Hz, 3H, CH3), 1.37 
(dq, JHH = 14.3, 7.3 Hz, 2H, CH2), 0.87 (t, 3JHH = 7.3 Hz, 3H, CH3). 
13C NMR (CDCl3, 300MHz, ppm) δ = 222.0 (CS3), 176.4 (CO), 47.4 (CH), 37.2 
(CH2), 29.9 (CH2), 22.1 (CH2), 16.6 (CH3), 13.6 (CH3). 
MS (ESI) - [M+H]+: calculated m/z 238.0, observed m/z 238.1 
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5.5.3 Peptide synthesis  
 General synthesis  
Peptide synthesis was conducted on a CEM liberty blue  automated 
microwave-assisted peptide synthesizer.  
For coupling steps in DMF, the activator N,N’-diisopropylcarbodiimie 
(DIC) was used in 10 equivalents and oxyma was used in 5 equivalents to 
reduce racemization issues associated with DIC coupling. The Fmoc L-amino 
acids for synthesis were added as a 0.2 M solution in DMF, with the following 
protection chemistry: arginine-Nω-Pbf; aspartic acid-Oε-tBu; glutamic acid-Oε-
tBu; lysine-Nε-Boc; serine-Oγ-tBu; asparagine-Nε-Trt and tyrosine-O-tBu.  
For arginine, coupling steps were conducted at 75 °C for 5 minutes, to 
minimize γ-lactam formation.62 
For deprotection, a solution of 10% piperidine in DMF was utilized. The 
resin was washed with this solution twice for 2 mins at 90 °C under microwave 
irradiation. If aspartate was part of the peptide sequence 0.1 M OXYMA was 
added to the piperidine solution to prevent aspartimide formation.63  
Resin cleavage was conducted after coupling of the CTA. To achieve this 
the resin was first washed thoroughly on a fritted funnel with DMF (10 mL) and 
then methanol (~10 mL) several times. The resin was subsequently dried in 
vacuo to remove residual methanol. This resin was then added to 5 - 10 mL of 
cleavage solution, of 95% v/v trifluroacetic acid (TFA), 2.5% v/v water and 
2.5% v/v triethylsilane.  After 4 hours, the solution was filtered through glass 
wool, and the eluent was concentrated and precipitated into cold diethyl ether. 
The precipitate was isolated through centrifugation and re-washed with diethyl 
ether three times. The final precipitate was dried in vacuo, solubilized in water 
and freeze-dried.  
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 Synthesis of CEPTA functionalized (ER) i+4 peptide (6.1) 
The synthesis was conducted according to the general synthesis outlined 
in 6.5.3.1. A Wang resin (0.6 mmol/g, 0.417 g) was used for synthesis at a 
0.25 mmol scale.  For the final coupling, CEPTA was used instead of amino acid 
at the same 0.2 M concentration. Subsequent cleavage and precipitation was 
conducted to give CTA 6.1. Prep-HPLC was not conducted to ensure enough 
peptide was available for investigation, however purity is fair.  
 
Figure 6.12: HPLC chromatogram of 6.1. 
 
MS (Thermofischer LCQ fleet): (M+Na+) Observed m/z 1997.12, calculated 
m/z 1997.87 
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 Synthesis of PABTC functionalized (ER)i+4 peptide (6.2) 
 
The synthesis was conducted according to the general synthesis outlined 
in 6.5.3.1. A rink amide resin (0.7 mmol/g, 0.357 g) was used for synthesis at 
a 0.25 mmol scale.  For the final coupling, PABTC was used instead of amino 
acid at the same 0.2 M concentration. Subsequent cleavage and precipitation 
was conducted to give CTA 6.2, which was obtained in very good purity without 
further purification (Figure 6.13); it should be noted the product is 
diastereotopic resulting in the two peaks by HPLC.  
 
Figure 6.13: HPLC chromatogram of 6.2. 
MS (Waters):[M+3H+] Observed m/z 697.70, calculated m/z 697.70 
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 Synthesis of PABTC functionalized (RADA)4 peptide (6.3) 
 
 
The synthesis was conducted according to the general synthesis outlined 
in 6.5.3.1. An alanine-Wang resin (0.7 mmol/g, 0.357 g) was used for 
synthesis at a 0.25 mmol scale.  For the final coupling, PABTC was used instead 
of amino acid at the same 0.2 M concentration. Subsequent cleavage and 
precipitation was conducted to give CTA 6.3.  
 
Figure 6.14: HPLC chromatogram of 6.3 (conducted in an 8M 
guanidine solution to ensure solubility). 
LCMS: Not obtained due to high concentration of salt required for 
dissolution  
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6.5.3.5 Synthesis of PABTC functionalized EEE tagged (ER) i+4  peptide 
(6.4) 
The synthesis was conducted according to the general synthesis outlined 
in 6.5.3.1. A Wang resin (0.6 mmol/g, 0.417 g) was used for synthesis at a 
0.25 mmol scale.  For the final coupling, PABTC was used instead of amino acid 
at the same 0.2 M concentration. Subsequent cleavage and precipitation was 
conducted to give 80 mg of CTA 6.4, HPLC indicated significant presence of 
uncapped peptide (~20% by integration).  


















Figure 6.15: HPLC chromatogram of 6.4. 
LC-MS - Thermofischer LCQ fleet: (M+Na+) Observed m/z 1997.12, 
calculated m/z 1997.87  
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The synthesis was conducted according to the general synthesis outlined 
in 6.5.3.1. A rink amide resin (0.7 mmol/g, 0.357 g) was used for synthesis at 
a 0.25 mmol scale.  For the final coupling, PABTC was used instead of amino 
acid at the same 0.2 M concentration. Subsequent cleavage and precipitation 
was conducted to give 121 mg of CTA 6.5 which was obtained in very good 
purity without further purification (Figure 6.16); again the product is 
diastereotopic resulting in the two peaks by HPLC. 
 
Figure 6.16: HPLC chromatogram of 6.5. 
LC-MS - Xevo: (M-H+) Observed m/z 2009.94, calculated m/z 2010.01. 
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The synthesis was conducted according to the general synthesis outlined 
in 6.5.3.1. A rink amide resin (0.7 mmol/g, 0.357 g) was used for synthesis at 
a 0.5 mmol scale.  For the final coupling, acrylic acid was used instead of amino 
acid at the same 0.2 M concentration. Subsequent cleavage and precipitation 
was conducted to give 140 mg of monomer 6.6. The purity was <90% by HPLC 
integration, however, it was determined for initial investigations this was 
sufficient. 
 
Figure 6.17: HPLC chromatogram of 6.6 
MS (ESI) – Observed m/z 1790.1, calculated m/z 1790.0 

















 Chapter 6   318 





















































5.5.4 Aqueous PISA using peptide macro-CTAs  
 CTA 6.2 mediated polymerization of DAAm (P1-3) 
 
CTA 6.2 (1 equiv., 8 mg) and DAAm (P1 and P3: 50 equiv., 35 mg; 
P2:100 equiv., 69 mg) were dissolved in deionized water (P1-2: 0.69 mL; P3: 
0.386 mL) containing VA-044 initiator (0.13 mg), in a 3 mL scintillation vial 
containing a magnetic stirrer. The mixture was degassed by bubbling N2 
through the solution for 10 min. This sealed vial was incubated at 40 C and 
stirred. After leaving overnight, the vial was opened to air and allowed to cool 
to room temperature before the conversion was measured by 1H NMR 
spectroscopy (DMSO-d6) and SEC (DMF) analysis was collected.  
  NMR (DMSO-d6) SEC (DMF) 
Conversion 
(%) 
Mn (theor)  Mn (kDa) Mw (kDa) ĐM 
P1 >99 10.9 21.8 27.7 1.28 
P2 >99 19.3 35.6 49.6 1.39 
P3 82 15.8 23.8 117.6 4.94 
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 CTA 6.4 mediated polymerization of DAAm (P4-5) 
 
CTA 6.4 (1 equiv., 6 mg) and DAAm (P4: 50 equiv., 20.5 mg; P5:100 
equiv., 41 mg) were dissolved in deionized water (0.423 mL) containing VA-
044 initiator (0.08 mg), in a 3 mL scintillation vial containing a magnetic 
stirrer.  The mixture was degassed by bubbling N2 through the solution for 5-
10 min. This sealed vial was incubated at 40 C and stirred. After leaving 
overnight, the vial was opened to air and allowed to cool to room temperature 
before the conversion was measured by 1H NMR spectroscopy (DMSO-d6). SEC 
data could not be collected as aggregation was observed by DLS in DMF, THF 
and water.  





P4 >99 10.4 
P5 >99 18.9 
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6.5.4.3 CTA 6.5 mediated photo-polymerization of DAAm (P6-7) 
CTA 6.5 (1 equiv., 5 mg) and DAAm (P6: 50 equiv., 21 mg; P7: 15 
equiv., 6.3 mg) were dissolved in pH 2 phosphate solution (0.42 mL), in a 3 
mL scintillation vial containing a magnetic stirrer.  The mixture was degassed 
by bubbling N2 through the solution for 5-10 min. This sealed vial was 
incubated in a photoreactor at 40 C and stirred. After leaving overnight, the 
vial was opened to air and allowed to cool to room temperature before the 
conversion was measured by 1H NMR spectroscopy (DMSO-d6) and SEC (THF) 
analysis was collected. 





Mn (kDa) Mw (kDa) ĐM 
P6 88 9,400 33.6 52.3 1.56 
P7 75 3,900 8.6 14.7 1.7 
 
DLS graph for P6-7:  
 
 Aqueous photo-PISA of peptide-monomer using PEG2kCETPA 
macro-CTA 
PEG2k-macro-CTA (1 equiv., 8 mg) and monomer 6.6 (P8-9: 3 equiv., 
20 mg; P10-11: none) were dissolved in deionized water (P8/10: 0.450 mL; 
P9/11: 0.580 mL), in a 3 mL scintillation vial containing a magnetic stirrer.  
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For P8 and P9 the mixture was degassed by bubbling N2 through the solution 
for 5-10 min, and these sealed vials were incubated at 40 C in a photoreactor 
and stirred. After leaving for 4 hours, vials of P8/9 were opened to air and 
allowed to cool to room temperature. To all solutions, HPMA (P8/10: 10 
equiv., 5.1 mg; P9/11: 25 equiv., 12.6 mg) was added, and all solutions were 
degassed again with N2, followed by sealing and incubation at 40 C with 
stirring in the photoreactor. These were left for 4 hours, after which they were 
opened to air and left to cool, before conversion was measured by 1H NMR 
spectroscopy (DMSO-d6) and SEC analysis was collected for P10-11. 





Mn (kDa) Mw 
(kDa) 
ĐM 
P8 >99%, 81% 8.8 n/a n/a n/a 
P9 >99%, 67% 11.0 n/a n/a n/a 
P10 N/A, >99% 3.0 8.8 10.6 1.21 
P11 N/A, >99% 5.6 11.5 13.9 1.21 
 
DLS graph for P8-9:  
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Conclusions and future work 
 
This thesis investigated the use of maleimide fluorophores for use in 
peptide-based applications. Initially, this was investigated through developing 
bromomaleimides for enzyme conjugations to reduced disulfides and lysine 
residues. Poor fluorescence of the conjugates was observed, attributed to poor 
protection of the dye from interactions with water.  
Two routes were then investigated in an attempt to overcome this: through 
developing improved dyes through steric shielding and through the synthesis of 
maleimide derived amino acids for genetic expression in peptides, in solvent 
shielded locations. While synthesis of sterically shielded dyes did realize better 
emission in protic solvents, the increase was small and solubility issues prevented 
aqueous applications. However serendipitously, a novel solid-state emission 
phenomenon was discovered, shown to be different to that seen in an aggregation-
induced emission dye. This compound could provide a better dye for solid-state 
applications where a low weight percentage of dye may be preferential.  
Regarding the fluorescent amino acids, synthesis of activated amino acids 
was successful and studies into the expression of these is ongoing. In particular, 
N- and C-terminal expression of ACM-containing amino acids has been realized, 
and future work will look at the incorporation mid-chain for expression deeper into 
enzymes where solvent interactions should not occur in the native state; 
suggested examples are given in Chapter 4.  Such enzymes could then be 
responsive to denaturing or protein-protein interactions, for example.  
The synthesis of a range of alkyne containing maleimide fluorophores was 
then undertaken for coupling to enzyme intermediate probes. The coupled 
fluorescent probes were successfully realized and initial tests have shown 
successful capture of polyketide intermediates. The stability of the dyes to the 
   327 
expression media used for such experiments was also proven through test 
incubations and extensive chromatographic characterization. Future work will 
focus on using the fluorescence of the dyes to aid identification of off-loaded 
intermediates, and potentially using the dye to measure the kinetics of these 
pathways.  
Finally, the investigation into templation of assembled nanostructures was 
investigated through the synthesis of peptide-functionalized RAFT agents and 
monomers. Universally, peptide-based RAFT agents used for PISA led to 
aggregated assemblies, attributed to hydrogen bonding and ionic interactions. 
However, peptide-based monomers were shown to be PISA active, paving the way 
for a universal one-pot synthesis and encapsulation of peptide-based therapeutics. 
Peptide therapeutics are particularly sensitive to proteolysis and immunogenicity, 
and therefore such encapsulation could be a commercially viable method for 
creating peptide therapeutics without the need for complex, high molecular weight 
separation associated with traditional peptide conjugates.  A greater 
understanding of the driving forces behind this phenomenon are also required to 
aid future project design.   
 
 
 
 
 
